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ABSTRACT 
 Chronic low back pain (CLBP) is a prevalent condition, often involving an inflammatory 
process. Those with CLBP frequently experience behavioral symptoms, including depressed 
mood, fatigue, and sleep disturbance, which may exacerbate pain and reduce quality of life 
(QOL). The purpose of this study was to identify behavioral symptom clusters (depressive mood, 
fatigue, poor sleep) in individuals with CLBP, and to determine whether there are differences in 
pain, QOL and inflammation (plasma IL-6) based on cluster membership. CLBP patients (N=69; 
age = 56±13 years) completed measures of pain, depressive mood, fatigue, sleep, and QOL. 
Blood was obtained for IL-6 measurement. Latent class analysis revealed a two-class model. 
Participants in Class 1 characterized by High Behavioral Symptoms (HBS) had more depressive 
mood, fatigue, and sleep disturbance (including less sleep per night) compared to participants in 
Class 2 characterized by Low Behavioral Symptoms (LBS). Univariate general linear models 
revealed HBS reported worse QOL and pain interference than those in LBS. Pain severity did not 
significantly differ between the classes. Exploratory analysis suggested this was due to a 
moderating effect of IL-6 on pain severity. Levels of IL-6 (controlling for BMI) were trending to 
significantly greater in HBS, compared to LBS, with higher levels of IL-6 correlating with 
greater pain severity and more sleep disturbance. Further, logistic regression revealed higher 
levels of IL-6 predicted HBS membership. In conclusion, behavioral symptoms cluster in 
individuals with CLBP and worsen QOL. Inflammation contributes to the complex relationship 
between behavioral symptoms and pain severity. Clinical recognition of behavioral symptom
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clusters can foster more comprehensive pain assessment and tailored interventions for CLBP 
patients. 
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CHAPTER ONE 
STATEMENT OF THE PROBLEM 
Pain is a complex phenomenon and is listed as the chief complaint of more than 60% of 
all primary care patients and is the number one reason patients consult a healthcare provider in 
the United States (Gaskin & Richard, 2011). More than 250 million Americans and nearly 10% 
of the world’s population are affected by chronic pain. As of 2010, at least 100 million adult 
Americans were estimated to suffer from chronic pain conditions (AAPM, 2010). Most people 
with chronic pain have multiple pain sites according to Center for Disease Control. The cost of 
unmanaged pain ranges from $560 to $635 billion annually in the United States (Gaskin & 
Richard, 2011). 
Common causes of chronic pain include headache (16.1%), low back pain (28.1%), neck 
pain (15.1%), knee pain (19.5%), shoulder pain (9.0%) and hip pain (7.1%). In a 2006 survey, 
59% reported that pain impacts their overall enjoyment of life, with 77% reporting feeling 
depressed, 70% having trouble concentrating, 79% having low energy levels and 86% having 
inability to sleep well (AAPM, 2010).  
Prevalence of Chronic Low Back Pain (CLBP) 
An epidemiological review reported that 55% of adults in the United States had CLBP 
extending beyond one year (Lawrence et al 2008). It is a leading cause of disability word-wide 
and CLBP management is only moderately effective (Murray et al., 2013). CLBP is one of the 
highly prevalent and expensive musculoskeletal conditions (Buchbinder et al., 2013; Dagenais et
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al, 2008). According to the United State Bone and Joint Initiative, back pain accounts for more 
than 264 million lost work days in one year—that’s two work days for every full-time worker in 
the country (2018).  In specific, CLBP has a lifetime prevalence of 40% and point prevalence (at 
any point in time) of 20% (Hoy et al., 2012). Freburger et al (2009) administered a cross 
sectional survey to investigate the prevalence of CLBP in Northern California over a 14-year 
period (1992-2006). Of the 4437 households that were contacted, CLBP (that limited daily 
activities) increased significantly over the 14-year interval from 3.9% in 1992 to 10.2% in 2006.  
This increase occurred across all age groups, both genders, and black and white races. The 
proportion of subjects who sought healthcare for CLBP had also increased from 73% to 84% 
over the 14 year interval (Freburger et al., 2009).  
CLBP patients suffer high economic burden and comorbidity (Gore et al, 2012). Direct 
cost includes health care resources (Physician visits), pharmacological, non-pharmacological and 
invasive therapies (Luo et al, 2004). In the United States, the economic burden including direct 
and indirect costs range from $84% billion to $624.8 billion and out of this, lost work 
productivity is the key contributor of indirect costs ($7.4 to $28 million) (Dagenais etal, 2008). 
Moreover, CLBP is associated with psychological symptoms (i.e., anxiety & depression), and 
these symptoms complicate management (Manchikanit, L et al. 2009). CLBP patients have 
greater burden of comorbidity including depression, anxiety and frequency of musculoskeletal 
and neuropathic pain compared to non –CLBP controls (Gore et al, 2012).  
Definition of CLBP 
CLBP for this study is defined based on the recommendations by the Research Task 
Force (RTF). According to the RTF, CLBP is defined as pain that exists in the space between the 
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lower posterior margin of the posterior rib cage and the horizontal gluteal fold. Additionally, the 
pain had existed beyond three months and for at least half days in the past six months. 
Recommendations by the RTF also include asking two questions to define chronicity.  (1) “How 
long has back pain has been an ongoing problem for you?” (2) “How often has low-back pain 
been an ongoing problem for you over the past 6 months?” (Deyo et al., 2015).  
Scope of the CLBP Problem 
CLBP can cause physical, emotional, and psychosocial problems that impact all aspects 
of daily living. When patients perceive that their contribution to themselves, and their families 
and community are diminished, there can be additional stress and depressed mood that can 
further intensify their pain levels. Additionally, loss of financial status, change in or loss of 
employment or other losses due to CLBP can also increase risk for depressed mood and sleep 
disturbances, thereby affecting quality of life. Few resources are available to address the 
multitude of psychosocial problems and life challenges faced by CLBP patients.  
Findings from studies show that when physical symptoms increase, psychological 
symptoms also increase; with a correlation of 0.5 between physical symptom checklists and 
psychological distress scales (Watson & Pennebaker, 1989). Further, regardless of symptoms 
with or without a diagnosed cause, patients who reported a greater number of physical 
symptoms, also reported greater anxiety or depression and vice versa (Kroenke et al., 1994).   
 There are limited pharmacological and non-pharmacological interventions currently 
available to address the complex combination of symptoms experienced by CLBP patients. For 
instance, if a patient complains of CLBP and sleep disturbances, it is not unusual for 
practitioners to prescribe analgesics that might also have some benefits for improving sleep 
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quality. The anticonvulsants (Pregabalin) and SNRI (Duloxetine) classes of drugs have shown to 
be effective in improving sleep and reducing pain in neuropathic pain (Sabatowski et al., 2004 & 
Boyle et al., 2012). These medications provide symptom relief but not all patients benefit from 
pharmacological interventions. Further opioids are used widely to manage chronic pain; yet, 
increasingly opioid use is associated with serious health risks.  Although there are no placebo-
controlled randomized clinical trials to support use of long-term opioid therapy for chronic non-
cancer pain (Noble, 2008; Eriksen et al., 2006 & Portenoy et al., 2007, the volume of prescribed 
opioids in the United States has increased to 600% from 1997 to 2007 (CDC, 2012). Several 
studies have identified the potentials risks that can affect individuals, patients, families and 
communities at large. In the year 2012, health care providers wrote 259 million prescriptions for 
painkillers, enough for every adult American to have a bottle of pills per the National Vital 
Statistics System Mortality Data (CDC, 2012).  
Scope of Behavioral Symptoms 
Depressive Mood in CLBP 
Depression coexists with chronic pain (Krishnan et al.,1985) and is estimated to cost $83 
billion annually in the United States (Greenberg et al., 2003).Some studies show a 30% to 60% 
co-occurrence rate of pain and depression (Baer, 2003). Othersshow as much as 31% to 100% 
(Miller & Cano, 2009). Meta-analysis has confirmed that depression is a consequence of chronic 
pain and not a predisposing factor (Dworkin & Gitlin, 1991). Further, studies have also 
confirmed that anti-depressants act in chronic pain through analgesic effect rather than through 
effect to improve undiagnosed depression (Blackburn-Munro, 2001).  
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Although depression is known to accompany chronic pain, the nature and extent of the 
relationships between these symptoms is still unclear. Banks and Kerns (1996) argue that 
depression appears to be highest among chronic pain patients as compared to other chronic 
medical conditions. Findings from current studies suggest that there is a bidirectional 
relationship between the chronic pain and depression, but there is lack of evidence on the effect 
of intensity and/or severity of one symptom on the other. Additionally, there is lack of 
conclusive evidence on the predisposition of other conditions that might be a risk for developing 
CLBP. Because symptoms of CLBP and depressive mood present challenges in symptom 
management, and in order to help clinicians to identify and address the psychological distress 
symptoms, it is essential to clarify the relationship between these two symptoms.  
Sleep Disturbances in CLBP 
The impact of CBP on sleep disturbances is recognized worldwide. Sleep disturbance in 
CLBP patients is reported to affect about 50–60% of individuals (Martin, R et al., 2006; Alaadi, 
SM et al. 2012); but others report upwards of 88% of patients with CLBP with sleep disturbance 
(Smith et al, 2000 and Pilowski et al, 1985).  Conversely, more than 40% of patients with 
insomnia also report chronic pain and insomnia has been independently linked to significant 
decrease in quality of life (Zammit et al, 1999; Skevengton et al; 2001; Smith et al; 2000). 
In combination, CLBP and sleep disturbance can cause devastating effects on the well-
being of patients and their families. For example, sleep disturbance is known to increase the 
severity and intensity of CLBP, and vice versa (i.e., the relationship is reciprocal) (Moldofsky, 
1975; 1976). There is lack of evidence, however, to show the extent of the effect of sleep 
disturbance on pain intensity, quality, duration and severity in CLBP patients. There is also a 
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lack of evidence on the extent of the effect of CLBP on specific components of sleep, in 
particular the sleep latency, total sleep time and sleep efficiency. Further, there are limitations in 
the measurement of sleep, with some studies using subjective and others using objective 
measures of sleep in CLBP. Moreover, there is lack of evidence on the mechanisms underlying 
the relation between these disorders.   
Fatigue in CLBP 
Fatigue is a subjective experience, which includes physical and psychological attributes 
(Aaronson et al., 1999). It is defined as tiredness that is extreme and persistent; exhaustion; or 
weakness that can be either mental or physical or a combination of both (Dittner et al., 2004). 
When a symptom of fatigue exists for a long duration (more than six months) without a known 
cause, it is classified as chronic fatigue (Piper, 1989).  It is estimated that about 55% of persons 
with chronic pain may experience fatigue but this is the symptom that often receives the least 
attention in clinical practice (Mota & Pimenta, 2006). Studies are focusing on not only 
identifying the relationship between types of pain (musculoskeletal pain versus neuropathic pain) 
and fatigue, and location of pain and fatigue, but also relationships among fatigue, pain, 
depression and sleep disturbances (Lentz et., 1999; Kwekkebom et al., 2010; Starkweather et al., 
2013& Jaremka et al., 2014). 
Anxiety in CLBP 
Previous research in CLBP and behavioral symptoms has primarily been on depression, 
but recent findings emphasize the importance of anxiety in this population (Reme et al., 2011; 
Newcomer et al., 2010 & Moix et al., 2011). Reme et al., 2010 studied the prevalence of 
psychiatric disorders in 565 patients and assessed with the Mini-International Neuropsychiatric 
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Interview (MINI), a short structured diagnostic interview for DSM-IV and ICD-10 psychiatric 
disorders. The prevalence of psychiatric disorders was 31% and the most common were 
somatoform disorders (18%), anxiety disorders (12%) and major depressive disorders (4%). 
Based on this, the researchers recommended screening CLBP patients for psychiatric 
comorbidity in secondary care due to the serious consequences for prognosis, outcome and 
health care utilization. 
Role of Inflammation as a Potential Common Pathway Linking Pain and Depressive Mood 
Findings from studies demonstrate that depression may increase vulnerability to pain and 
increase circulating levels of inflammatory markers, such as IL-6.  For example, higher IL-6 
levels have been linked with both greater pain and greater chronic medical comorbidity in 
patients with greater depressive symptoms (Poleshuck et al., 2013). Several mechanisms underlie 
the coexistence of pain and depression due to inflammation. They include direct effects of 
proinflammatory cytokines, increased levels of brain extracellular glutamate, and the switching 
of GABA neurotransmission from inhibition to excitation (Jaremka et al., 2014).  Understanding 
neuro- immune mechanisms that underlie depression and pain comorbidity may result in 
interventions that can treat both conditions simultaneously with more than just analgesics and 
antidepressants (Walker et al., 2014). Earlier studies in the past few decades had focused on 
understanding the chronic pain mechanisms in relation to processes of hyperalgesia. Now, it is 
having been recognized that inflammatory mediators can influence both inflammatory pain and 
nerve related pain caused by damage to peripheral nerves or to the CNS (Jaremka et al., 2014).   
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Symptom Clusters in Various Populations 
The study of symptoms clusters has been limited to certain patient populations.   For 
example, in cancer patients, an extensive literature demonstrates the occurrence of symptom 
clusters in a variety of cancer types (Kwekkeboom et al., 2010).  However, most studies have 
focused predominately in lung and breast cancer populations ( Liu et al., 2009; Lengacher et al., 
2012; Ho et al., 2015)  The identified clusters have been grouped into either a general category 
or specific categories. General category symptom clusters include pain, fatigue, disturbed sleep, 
shortness of breath, drowsiness, dry mouth, difficulty remembering, and numbness or tingling 
(Ho et al., 2015; Lengatcher et al., 2012; Kwekkeboom et al., 2010)). Whereas, gastrointestinal 
symptom clusters include nausea and vomiting and clusters under mood problems included 
anxiety and depression (Kim et al., 2005; Liu et al., 2009; Miakowski & Dodd, 2004).  
There is also an extensive literature on symptom clusters in heart failure patients.  Those 
studies identify a correlation between depression and fatigue, depression and anxiety, depression 
and sleep, depression and pain, anxiety and fatigue, and dyspnea and fatigue (Yu et al., 2016; 
Moser et al., 2014; Jurgens et al., 2009). Most researchers’ grouped symptoms in clusters of two 
or three based on physical distress, emotional/cognitive distress, and discomfort (Herr et al., 
2014; Kabban et al., 2015). A cluster placed under physical symptoms included fatigue, pain, 
drowsiness, nausea and reduced appetite. Emotional/ cognitive symptom clusters have been 
identified as anxiety, and depression.  
It is expected that symptom clusters will exist in other chronic conditions; however, there 
is not adequate investigation of symptom clusters across various conditions.  It is possible that 
greater understanding of the presence and type of symptom clusters that exist in other patients 
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with non-cancer chronic pain can lead to targeted interventions addressing more than one 
symptom.   
Summary 
CLBP is a significant health issue that negatively impacts all aspects of quality of life. It 
is difficult to assess, diagnose and manage CLBP; in part, due to the complexity of other 
accompanying symptoms (fatigue, sleep disturbances, anxiety and depression) that co-occur with 
pain.  Further, there is lack of conclusive evidence as to whether some symptoms relate to, or 
cluster with, each other more than other symptoms.  There is also deficit in knowledge on the 
role of inflammation in the etiology and persistence of these symptoms.   
Despite the urgent need to identify the symptoms that might affect health outcomes, there 
has been little inquiry on the symptoms that might coexist with CLBP and thereby affect health 
outcomes. In order to be able to understand the complexities of CLBP and symptoms that coexist 
with CLBP, it is important to determine if symptoms appear in clusters in CLBP and further 
examine the underlying inflammatory process. Identification of phenotypic differences based on 
behavioral symptom clusters might explain some of the variance in pain symptoms and treatment 
response. Such knowledge can be used to tailor an individualized management plan for patients 
in the future. 
Significance 
CLBP is one of the most highly prevalent and expensive musculoskeletal conditions 
(Woolf & Pledger, 2003) (Dagenais et al., 2008). While experts estimate 80% of the population 
will experience back pain at some time in their lives (Rubin, 2007), an epidemiological review 
reported that 55% of adults in the United States had CLBP extending beyond one year 
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(Lawrence et al 2008). CLBP patients incur increased economic burden and comorbidity (Gore 
et al, 2012). In the United States, the economic burden including direct and indirect costs range 
from $84 billion to $624.8 billion and out of this, lost work productivity is the key contributor of 
indirect costs ($7.4 to $28 million) (Dagenais et al., 2008).  Although CLBP is a leading cause of 
disability word-wide, clinical management of CLBP is only moderately effective (Henschke et 
al., 2010).   
This project will evaluate behavioral symptoms as a cluster (both presence and intensity) 
to determine the extent to which identified symptom clusters influence pain and quality of life. 
Additionally, levels of circulating proinflammatory cytokines will be evaluated to determine the 
extent to which inflammation may serve as a common mechanism underlying the associations 
among behavioral symptoms and pain in CLBP patients. Behavioral symptoms (depressive 
mood, sleep disturbance, anxiety and fatigue) commonly accompany CLBP and are a significant 
problem for both patients and caregivers because they assume responsibility to manage these 
symptoms, in addition to dealing with their pain. The literature demonstrates that chronic 
behavioral symptoms negatively impact patient outcomes, including mental and physical 
functional status and overall quality of life (Borsbo et al., 2010; Gormsen et al., 2010; Kroenke et 
al., 2013; Sahin et al., 2017). For the most part, the prevalence and intensity of behavioral 
symptoms are not routinely assessed, nor are they adequately considered as part of the pain 
management plan.  Also, research on behavioral symptoms typically takes a reductionist 
approach, focusing on one symptom; while ignoring the possibility that these symptoms co-occur 
in clusters, interact with each other, and often intensify each other.   
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Although research using a focused approach on individual behavior symptoms in CLBP 
has increased knowledge of the prevalence of fatigue, sleeps disturbance, and depressive mood 
in CLBP patients, and has also added insight as to the importance of assessing these symptoms, a 
new approach is needed to meet the challenges in managing multiple symptoms in this patient 
population. Most clinicians would agree that symptoms do not present in isolation; rather 
multiple symptoms are experienced simultaneously.  Such co-occurrence of symptoms or 
symptom clusters has been investigated in cancer populations, and the findings have led to 
advances in symptom management for cancer care (Garland et al., 2014; Kwekkeboom et al., 
2010; Lengacher et al., 2012; Liu et al., 2009; Miaskowski et al.,2004). Yet in CLBP patients, 
few, if any, studies have investigated behavioral symptoms as a cluster, including how such 
clusters influence the pain experience and quality of life of these patients.  Given this, there is a 
critical need to identify which symptoms cluster together and how these symptoms affect the 
pain experience and overall quality of life in CLBP patients. Such an approach is consistent with 
the holistic view of nursing, and with the National Institute of Nursing’s emphasis on symptom 
management (The NINR Strategic Plan, 2016).   
Ultimately, application of knowledge of symptom clusters in CLBP patients’ can lead to 
improved ways of patient assessment and management. Furthermore, this project is significant in 
that it will examine inflammatory mechanisms posited to underlie behavioral symptom clusters 
in patients with CLBP.  Given that inflammatory processes are implicated in certain types of 
back pain, and that inflammation is associated with each of the behavioral symptoms to be 
addressed (i.e., depressive mood, sleep disturbance, and fatigue); it is possible that increased 
circulating levels of proinflammatory cytokines may be a common underlying mechanistic 
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pathway linking these symptoms to pain.  Understanding potential inflammatory mechanisms in 
CLBP pain has implications for the development of new approaches to manage pain. This 
concept is supported by work in other patient populations, which demonstrate that  both 
pharmacologic and behavioral approaches reduce levels of proinflammatory cytokines (Bower et 
al., 2016; Gallegos et al., 2015; Janusek et al., 2006; Janusek et al., 2008; Reich et al., 2017; 
Rosenkranz et al., 2013). 
Clinical Implications 
Current practice predominately involves assessing and managing a patient with CLBP by 
focusing on a single symptom; that is, chronic pain. The results from this project will allow for 
an appraisal of CLBP not as a unitary symptom, but as a constellation of several interacting 
symptoms with bidirectional linkages to the pain experience. Further, viewing symptoms as 
clusters in CLBP can guide the development of more comprehensive interventions that target 
more than pain per se, but other symptoms that intensify and perpetuate pain. In the end, the  
findings from the proposed study will identify the extent to which  clusters of symptoms impact 
the pain experience and quality of life in CLBP and, secondly the extent to which inflammatory 
processes underlie the complex relationships among pain, depressive mood, and poor sleep.   
It is important to examine the various pain profiles that include behavioral symptoms. 
Understanding differences in pain profiles and their relationship to other symptoms can widen 
the scope of managing pain to be more holistic, which is the essence of nursing.  Moreover, 
knowledge of symptom clusters in CLBP can help identify if there is a sentinel symptom or 
groups of symptoms that can be classified as sentinel symptom cluster.  Evidence for the 
existence of symptom clusters can help shape new ways to identify and manage symptom 
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clusters and to prevent the vicious cycle among these symptoms that amplifies pain and erodes 
quality of life. For instance, this may include more comprehensive assessment tools that allow 
mapping of symptom clusters based on type, quality and intensity; which can inform the 
clinician to more efficiently and effectively manage the symptoms in those with CLBP.  
Implications for Nursing 
Currently, when a CLBP patient is seen in the health care setting, pharmacological 
approaches and nonpharmacological approaches, including pain rehabilitation programs are 
recommended. However, these approaches have not benefited CLBP patients as expected. As a 
result, the pain and suffering caused by this condition continues to challenge not only patients 
but the health care provider as well. The metaparadigm of nursing consists of health, person and 
environment and we nurse are in the forefront when it comes to addressing pain and suffering in 
individuals. The American Nurses Association’s (ANA) (2004) scope and standards of practice 
requires that nurses possess and maintain adequate knowledge and competency in nursing 
practice that obligates knowledge about pain management. Further, the Nursing Social Policy 
statement (2010) and the social responsibility and the Code of Ethics statement (2001) indicate 
that nurses have a moral obligation to advocate on behalf of the patient in managing pain and 
other distressing symptoms. Hence it is essential for nursing to understand the implications of 
CLBP and its impact on patients and the society. Historically, CLBP has caused loss of health, 
decreased functional status, disability, loss of job status and financial losses.  
Although there is evidence on the effectiveness of the non-pharmacological interventions, 
not all patients have access to these modalities. An innovative approach to address the challenges 
of symptom management in CLBP might be to look at the symptom clusters, such as the 
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approach used in cancer patients. In cancer patients, significant advances have been made in 
addressing the interventions that help to improve the three cancer-related symptoms (pain, 
fatigue and sleep disturbance).  
Conceptual Framework 
     The central hypothesis for the proposed study is that behavioral symptoms will exist in 
clusters to influence the pain experience and quality of life in adults with CLBP. It is further 
hypothesized that increased inflammation serves as a common pathway linking behavioral 
symptom clusters with pain. Individuals with CLBP who have certain clusters will experience 
less pain, have lower levels of circulating proinflammatory cytokines, and report better quality of 
life, than other clusters.  
Several theories have been developed to conceptualize the symptom experience in 
humans (Lenz and Pugh 2008; Humphreys et al. 2008; Kim et al. 2005; Goodell and Nail 2005; 
Parker et al. 2005; Armstrong 2003; Haworth and Dluhy 2001; Dodd et al. 2001a; Lenz et al. 
1997; McClement et al. 1997; Teel et al. 1997; Lenz et al. 1995; McDaniel and Rhodes 1995; 
Larson et al. 1994; Rhodes and Watson 1987). These theories have focused upon the complexity 
of the symptom experience itself, how the symptoms manifest, and the outcome of symptoms. 
Some theories have attempted to accommodate the concept of symptom clusters: The Theory of 
Unpleasant Symptoms (Lenz and Pugh 2008), The Theory of Symptom Management 
(Humphreys et al. 2008) and The Symptoms Experience Model (Armstrong 2003). However 
none of the theories have focused on conceptualizing symptom clusters in those with chronic 
pain. Some challenges that arise in developing theories to explain symptom clusters could be 
attributed to:  1) the study of symptom clusters is relatively new, 2) the subjective nature of the 
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symptoms itself, and 3) the complexity in measuring the symptom experiences from an 
individual’s perspective. Hence, this study will be guided by the Theory of Unpleasant 
Symptoms (TOUS), as well as a conceptual model that explicates the relationships among the 
study variables. See Figure 1. 
Theory of Unpleasant Symptoms (TOUS) 
TOUS, is a middle range theory, developed by Lenz and colleagues, and will provide a 
theoretical foundation for the proposed study. The TOUS allows for a different perspective of 
viewing symptoms. It provides researchers with a newer approach to view symptoms as clusters 
and to understand how the symptoms and influencing factors can intensify each other and impact 
an individual’s functional outcomes and quality of life. The TOUS has been used as framework 
to guide studies of symptoms clusters in patients with cancer and in cancer survivors (Chen & 
Tseng, 2005; Fox & Lyon, 2007; Myer, 2009; Lee, 2005); to predict physical activity based on 
symptom cluster in multiple sclerosis (Motl & McAuley, 2009); to measure outcomes in post-
operative tonsillectomy pediatric patients (Huth & Broome, 2007); and to diagnose CHF 
symptoms as a group (Jurgens et al., 2009). Further, studies have been conducted to identify the 
cluster of symptoms and hence accordingly manage treatment options in practice, such as has 
been accomplished with Alzheimer’s patients (Hutchinson & Wilson, 1998).   
Initially, Lenz and colleagues studied three single concepts (fatigue during postpartum, 
fatigue during intrapartum, dyspnea in COPD and asthma) in different clinical populations and 
integrated their findings to identify commonalities across phases and concepts.  This work 
formed the basis for the TOUS theory (Lenz et al, 1995). The two activities a) generating frame 
for the study of fatigue during phases of child bearing and b) identifying similarities between the 
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concepts of fatigue and dyspnea provided the basis of the TOUS theory, as depicted in Figure 1. 
Later, Lenz et al (1997) studied the potential for interaction among the influencing factors and 
generated a new model of the theory as shown in Figure 2.  To facilitate identification of 
similarities in their conceptualizations of two of the three symptoms (dyspnea and fatigue) they 
identified similarities as: a) both are subjective symptoms, b) both can be acute or chronic, c) 
both occur due to anxiety or depression, d) both can occur under normal or illness conditions, 
and e) both can affect function including activities of daily living, and social interaction (Lenz et 
al, 1995).  
Figure 1. Original illustration of the TOUS 
    
 
Note. Adapted from “The middle-range theory of unpleasant symptoms: An update,” by Lenz, E. 
R., Pugh, L. C., Milligan, R. A., Gift, A., & Suppe, F., 1997, Advances in Nursing Science, 
19(3), 14-27. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9055027 
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Figure 2. The updated TOUS.   
                     
 
 
Note. Adapted from “The middle-range theory of unpleasant symptoms: An update,” by Lenz, E. 
R., Pugh, L. C., Milligan, R. A., Gift, A., & Suppe, F., 1997, Advances in Nursing Science, 
19(3), 14-27. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9055027 
 
 
For this study, a framework that integrates existentialism and the TOUS paradigm will be 
used to explore symptom clusters in adult CLBP patients. Within the TOUS, symptoms are 
viewed as occurring in concurrence, affecting ones’ normal functioning and resulting in a 
multiplying effect based on the physiological, psychological and situational factors (Lenz, et al., 
1997). The TOUS incorporates the major concepts of symptoms and performance outcomes, 
along with the interrelated categories of psychological, physiological, and situational factors and 
provide a framework for the metaparadigms of the TOUS (Lenz & Pugh, 2003).  Soren 
Kierkegaard in his words on existentialism raised searching questions of the self; since all 
aspects of life and existence are subjective and ambiguous (Audi, 1999). His quote, “The greatest 
hazard of all, losing one’s self can occur very quietly in the world, as if it were nothing at all. No 
other loss can occur so quietly: any other loss- an arm, a leg, five dollars, a wife etc.- is sure to 
be noticed” (Kierkegaard, 2010). This philosophy can be aptly applied to the patient with CLBP. 
The sufferings faced by CLBP include grief, pain and psychological distress can challenge the 
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existence of the self. In the clinical populations that include symptoms of sleep disorders, chronic 
pain and psychological disorders, there are fewer interventions to alleviate human suffering. It is 
essential for nursing to focus on issues that affect the welfare of CLBP patients in improving 
individual and community health. 
Figure 3.  Conceptual Model for proposed study. 
 
The Conceptual Model for this study is illustrated in Figure 3. The model proposes 
interactive relationships among depressive mood, sleep quality, and fatigue; which through 
inflammation impacts the pain experience and quality of life of the person with CLBP. The 
model explicates the potential linkages and clusters of different combination of symptoms among 
sleep disturbance, depressive mood, anxiety, fatigue, and inflammation in the person with CLBP; 
which ultimately impacts the person’s pain experience and quality of life.  It is hypothesized that 
behavioral symptoms (anxiety, fatigue, poor sleep quality, and depressive mood) exist in 
individuals with CLBP as clusters; which synergistically contribute to worse pain and poorer 
quality of life.  This view is consistent with TOUS, which theorizes that symptoms occur in 
concurrence, affecting a person’s normal functioning and resulting in a multiplying effect on 
outcomes (i.e., physiological, psychological and situational factors (Lenz et al., 1997).  
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Moreover, inflammation is proposed as a common pathway that links symptoms with pain 
outcomes. This is based upon the literature that finds CLBP to be associated with elevated levels 
of proinflammatory cytokines (Risbud & Shapiro, 2014). A Systematic review of articles done to 
assess the magnitude and direction of depression with inflammatory markers published for the 
period between January 1967 and January 2008 identified that the inflammatory markers CRP, 
IL-6, IL-1, and IL-1ra were positively associated with depression (Howren et al., 2009). Thus, 
inflammation may serve as a common biological pathway that links behavioral symptoms to the 
pain experienced by those with CLBP.  Lastly, the model posits that the relationship between 
behavioral symptom clusters and pain is bidirectional.   
Rationale for the Conceptual Model 
Chronic low back pain (CLBP) is a significant and common health issue and is a leading 
cause of disability worldwide (Buchbinder et al., 2013).  The reported estimate of lifetime 
prevalence of CLBP is 40%, and point prevalence (at any point in time) is 20% (Hoy, DG et al., 
2012).  Management of CLBP is only moderately effective (Hoy et al., 2014; Henschke, et al, 
2010).  Moreover, individuals with CLBP experience burdensome behavioral symptoms (i.e., 
depression, fatigue, and poor sleep quality); all of which complicate clinical management 
(Manchikanit, L et al. 2009).   
Depression 
Numerous studies suggest that depression worsens both the severity of pain and disability 
caused by chronic LBP (Carley et al, 2015). A large survey of community dwelling adults found 
that mild to severe depressive symptoms increased the odds of disabling LBP over a period of 
two years by 30–60%. Similarly, baseline disabling low back pain ranging from a little of the 
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time to all of the time increased the odds of depressive symptoms by 27.9–84.2%, respectively.  
Moreover, there is also a bidirectional relationship between depressive mood and LBP intensity; 
and inflammation may mediate such a relationship.  For example, higher IL-6 levels have been 
linked with both greater pain and greater chronic medical comorbidity in patients with greater 
depressive symptoms (Poleshuck et al., 2013).  This was confirmed in a systematic review which 
concluded that inflammatory markers (CRP, IL-6, IL-1, and IL-1ra) are positively associated 
with depression. Moreover, a dose-response relationship between depression and inflammatory 
markers was identified, which was consistent with three causal pathways: depression to 
inflammation, inflammation to depression, and bidirectional relationships (Howren et al., 2009). 
Sleep Disturbance 
It is reported that 50–60% of LBP patients report sleep disturbance (Martin et al., 2006; 
Alaadi et al. 2012).  CLBP patients report increased duration to sleep onset, reduced total sleep 
time, and lower sleep efficiency (Kelly et al., 2011).  Moreover, sleep disturbance is associated 
with psychological distress, physical disability (Van de Water et al., 2011), fatigue and day-time 
sleepiness (McCracken et al., 2002), more severe pain (Alaadi et al., 2012), and more 
hospitalization for their back pain than those without sleep problems (Kaila-Kangas et al., 2006).  
Similar to the relationship between depression and pain, the literature suggests a bidirectional 
relationship between disturbed sleep and pain intensity (i.e., pain may lead to sleep disturbance 
& poor sleep may cause or exacerbate the pain) (O’Brien et al., 2011).  This is confirmed in 
longitudinal studies which have identified a bidirectional relationship between sleep and pain, 
such that a night of poor sleep quality was followed by a day with more severe pain; which 
worsened sleep quality during the subsequent night (Alaadi et al., 2014 ; Jaussent et al., 2017). 
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Anxiety 
The two most common psychological conditions are anxiety and depression (Ansseau et 
al., 2004). In chronic pain, the pain–depression–anxiety relationship is well established. Most 
research has studied the comorbidity of pain with depression than with anxiety (Kroenke et al., 
2013). Anxiety is as prevalent as depression and adversely affects patients functional ability and 
health care costs (Stein et al.,2015). anxiety is also another key behavioral symptoms for which 
there is substantial evidence that there is a bidirectional relationship between CLBP and anxiety. 
Fatigue 
Fatigue is prevalent and problematic for individuals with CLBP (Fishbain et al., 2004; 
Starkweather, 2013; Snekkevik et al., 2014), and fatigue may exacerbate symptoms and 
functional outcomes.  For example, CLBP patients found who have substantial fatigue have more 
pain and depressive symptoms and are at risk for greater disability (Snekkevik et al., 2014). 
Fatigue is related to greater inflammation in those with back pain. Individuals with persistent 
radiculopathy who reported moderate to high fatigue levels, also reported greater psychological 
distress, depressive symptoms and had higher circulating levels of IL-6 and sIL-6R, compared to 
those with low levels of fatigue (Starkweather, 2013).  These findings suggest that inflammatory 
cytokines may influence the manifestation of fatigue and other behavioral symptoms (distress 
and depressive symptoms) in individuals with back pain. 
Inflammation and CLBP 
Chronic LBP is strongly associated with disc degeneration and degenerated discs exhibit 
high tissue levels of proinflammatory cytokines (i.e., inflammation within the disc 
microenvironment) (Risbud & Shapiro, 2014). Recently, CLBP was shown to be associated with 
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persistent elevations of proinflammatory cytokines in the serum (Pedersen et al., 2015)   That 
study prospectively evaluated serum levels of the proinflammatory interleukins (IL-6 and IL-8) 
in patients with lumbar radicular pain due to disc herniation.  The findings revealed that 
chronic lumbar radicular pain was positively associated with a persistent increase of both IL-6 
and IL-8.   
In summary, behavioral symptoms (depression, poor sleep, and fatigue) are associated 
with greater inflammation (Gorth et al., 2015), and worse pain in CLBP 9pegram et al., 2017). It 
is possible that behavioral symptoms may establish and maintain their co-occurrence with pain 
by increasing inflammation.  Moreover, these symptoms may occur in clusters; however, the 
existence of behavioral symptom clusters in CLBP, and whether they alter the experience of pain 
and quality of is unexplored. Such an understanding is significant, as behavioral symptoms 
adversely impact the clinical management of CLBP.  These symptoms not only intensify the pain 
experience, but are likely to hinder exercise performance (part of pain management) and 
consequently lead to poorer treatment outcomes.   In addition, symptoms like poor sleep and 
depressed mood may contribute to progression from acute to chronic pain. Thus, increasing 
knowledge of the relationship between sleep disturbance, depressive mood and inflammation in 
patients with LBP is an important clinical and research question. 
Thus, the present study will use a cross sectional design to identify the presence of 
symptom clusters of fatigue, sleep disturbance, and depressive mood, in CLBP; and to determine 
the extent to which identified clusters predict the pain experience and quality of life.  Further, 
this study will also evaluate the role of proinflammatory cytokines as a common pathway linking 
behavioral symptoms to pain.  
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CHAPTER TWO 
REVIEW OF THE LITERATURE 
Symptoms and Symptom Clusters 
The meaning of the word “symptom” has evolved over the past few centuries. Per the 
Oxford Dictionary, in the Middle Ages until the mid-19
th
 century, symptoms were considered as 
physical or mental phenomena that originated from or accompanied an illness. By the end of the 
19
th
 century, the word had taken on different meanings. Symptoms were considered subjective 
and different from signs, which were considered objective and sensed by the observers (Oxford 
Dictionary, 1992). According to Komaroff, contemporary medical science in the 20
th
 century has 
placed great emphasis on identifying the objective experience using objective pathology which 
has transformed the ability to cure diseases (Komaroff et al., 2001). This transition has benefited 
patients and providers but has come with a price. Sharpe and Carson (2001) and Aronowitz et al., 
2001 contend that there is less emphasis placed on taking a history to assess symptoms and there 
is skepticism when objective methods are used. 
Nurses will agree that the heart of nursing lies in managing pain and discomfort.  This is 
consistent with the philosophical approach of Florence Nightingale who emphasized that the 
focus of nursing was to relieve pain and discomfort (Nightingale, 1946). Nurse scientists have 
more recently focused on symptom management to improve approaches to relieve pain and 
discomfort in patients.  Furthermore, the concept of symptom clusters has gained attention in the 
past few decades. For example, the National Institute of Nursing Research (NINR) has placed
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symptom management and symptom clusters in the top list of goals under the NINR mission and 
strategic plan. 
 The concept of symptom cluster is not new to nursing. In oncology nursing, symptom 
clusters have been extensively investigated as a way to improve symptom management. In order 
to define symptom cluster, Kim et al., 2005, conducted a concept analysis of symptom clusters 
and identified them as a stable group of two or more symptoms that are concurrent and related to 
one another but are not dependent on other symptom clusters. Further, symptom clusters do not 
necessarily share etiologies (Dodd et al., 2004 & Miaskowski et al., 2004). 
Using the Rodgers’ evolutionary method of concept analysis, Kim et al., 2005 identified 
attributes of symptom clusters as relationships of symptoms and relationships of clusters, 
underlying dimensions, stability, occurrence, and common etiology. They defined symptom 
clusters as two or more symptoms related to each other and which occur together. Symptom 
clusters should also have a stronger relationship among symptoms across different clusters. 
Although symptoms within in cluster might not share the same etiology, they should include 
both subjective (self – reported) symptoms and objective (observed) signs. They further 
identified the consequences of symptom clusters to be emotional distress, increased financial 
burden, poorer health status and interference with activities of daily living (Kim et al., 2005). 
Despite the recognition of the potential importance of viewing symptoms as clusters, the 
complex relationships between symptoms have not been well described in the literature, and the 
available research on symptom clusters is limited to a few patient populations. While there is 
need for conceptualization, there is also a need for design, measurement and analysis of the 
symptom clusters across a variety of patient populations. 
25 
 
 
Symptom Clusters in Cancer 
Symptom clusters have been explored most frequently in cancer populations. Over the 
past decade, an abundance of literature has provided level-one evidence supporting the value of 
assessing symptom clusters in cancer patients. These studies can provide direction and depth to 
future studies investigating symptom clusters in non-cancer patients. It is likely that like what 
has been learned in cancer patients; symptom cluster analysis in individuals with non-cancer pain 
will increase understanding of the multi-dimensional nature of pain, as well as predict health 
outcomes, including quality of life. 
In an early review of the literature regarding symptoms in cancer patients, Fan et al 
(2007) identified seven studies which validated the M.D Anderson Symptom Inventory in three 
types of cancer (breast, lung and gastrointestinal).  Findings, however, did not support common 
clusters in those with lung and breast cancer.  This may relate to disparity in assessment tools, 
statistical analyses and unique differences based on type of cancer. However, the authors 
concluded that multiple symptoms affect prognosis, functional status and quality of life in cancer 
patients. Since this review, several studies have provided new evidence supporting the existence 
and importance of symptom clusters in cancer patients; and at least three more recent systematic 
reviews have been published and are described below. 
Harrington et al (2010) conducted a systematic review of studies (2000-2008) examining 
late effects and long-term symptoms grouped as physical limitations, cognitive limitations, 
depression/anxiety, sleep problems, fatigue, pain, and sexual dysfunctions. The authors 
concluded that symptom burden in cancer survivorship was consistent in all the four cancers 
(prostate, breast, gynecological and colorectal) despite different treatment exposure.  Also, the 
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four most common symptoms were depressive symptoms, pain, and fatigue.  In another 
systematic review, Dong et al (2014) examined the composition, consistency and longitudinal 
stability of symptom clusters in advanced cancer patients.  These authors identified 33 studies 
that used various statistical methods (principal component analysis, exploratory factor 
analysis, and hierarchical cluster analysis) to analyze symptom clusters. The four symptom 
clusters identified were: anxiety-depression, nausea-vomiting, nausea-appetite loss, and fatigue-
dyspnea-drowsiness-pain.  From a methodological perspective, it is important to note that all 
four statistical methods tended to reveal different symptom clusters. Hence the authors 
concluded that there was a lack of consistency in identifying symptom clusters and associated 
variables and recommended using the patient’s subjective experience of symptom clusters in 
future studies.  
A recent literature synthesis (Reilly et al., 2013) of symptoms experienced by cancer 
patients receiving active treatment evaluated 21 multinational studies representing a pooled 
sample of 4067 cancer patients.  Across these studies patients reported severity and prevalence of 
individual symptoms based on eighteen instruments that included measuring single symptoms, 
multiple- symptom inventories, from HRQOL or health status measures. Most studies used the 
MD Anderson Inventory. Forty-seven symptoms were identified, which categorized into 17 
groupings.  The researchers concluded that a discrete set of symptoms are common across cancer 
types and may serve as basis for describing a core set of symptoms in cancer. 
Since the publication of the above reviews, Ho et al (2015) published findings from a 
longitudinal study which examined the relationship among depression, fatigue and sleep 
disturbances in premenopausal breast cancer patients compared to postmenopausal women 
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across three-time points.  T1 (i.e., at least two weeks after breast surgery but prior to beginning 
CT), T2 (i.e., within one month after completing a three- to six-month CT regimen, or 
approximately six months after T1 for patients who did not receive CT in Study 1), and T3 (i.e., 
six to eight months after T2). Results revealed that fatigue, depression and sleep disturbances 
manifest as a symptom cluster. Additionally, path analysis within and across-symptom paths 
indicated that all three symptoms correlated within the three-time points. Such a correlation 
between symptoms is important since it can denote that the symptoms manifest as clusters. 
Further, it might also help to identify if one symptom precedes another.  
In summary, within the cancer literature, studies of symptom clusters have included 
mixed-cancer samples; however, some studies have focused on specific cancer types (lung and 
breast predominantly). These studies evaluated symptoms in cancer patients undergoing 
chemotherapy, as well as cancer survivors who had completed treatment. In general, the findings 
identified the symptoms that most commonly make up clusters to be pain, fatigue, and disturbed 
sleep, emotional distress, shortness of breath, drowsiness, dry mouth, sadness, difficulty 
remembering, numbness or tingling during treatment. It is interesting to note that certainly some 
of these symptoms associate more with active cancer treatment; thus, it is important to 
differentiate symptom clusters with respect to timing of treatment. Also, the symptom clusters 
identified were labeled as general, gastrointestinal or mood problems. Clusters placed within the 
general category included pain, fatigue, disturbed sleep, shortness of breath, drowsiness, dry 
mouth, difficulty remembering, and numbness or tingling. Clusters placed under gastrointestinal 
category mostly included nausea and vomiting and clusters under mood problems included 
anxiety and depression. The above studies provide evidence for the existence of distinct 
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symptoms clusters which can be identified, some of which may be common across cancer types 
and the cancer trajectory.  Collectively, these findings can guide testing of interventions to 
address multiple symptoms across cancer types and across the cancer trajectory.  
Symptom Clusters in Heart Failure 
Heart failure patients experience anywhere from about two to nine symptoms (Herr et al., 
2014). Studies have begun to examine the relationships among heart failure symptoms with the 
purpose of determining if such examination can inform clinicians to improve management and, 
thus, benefit these patients’ A recent systematic review conducted by Herr at al., addressed the 
relationships among heart failure symptoms. Out of 1316 studies identified 34 met criteria to be 
included in the systematic review. Results yielded a correlation at moderate level between 
depression and fatigue, depression and anxiety, depression and sleep, depression and pain, 
anxiety and fatigue, and dyspnea and fatigue. The researchers concluded that there is adequate 
support for the presence of heart failure symptom clusters. They also suggested that studies 
defining the phenotype of individual heart failure symptoms might benefit this group of patients 
(Herr et al., 2014). 
A cross sectional study was conducted to identify symptom clusters in individuals with 
heart failure and to identify the relationship between clusters and functional status.  That study 
enrolled a convenience sample of 117 heart failure patients.  Symptom clusters were analyzed 
using factor analysis (principal components method). Additional analysis using regression 
analysis (a backward stepwise model-building approach) to examine the effects of the symptom 
clusters; age and co-morbidity on functional limitations and mobility were conducted. Findings 
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revealed three symptom clusters:  sickness behavior, discomfort of illness and gastrointestinal 
distress (Herr et al., 2015). 
In yet another interesting cross-sectional study conducted in three different regions of the 
world (USA, Asia and Europe), investigators sought to identify and compare symptom clusters 
in heart failure patients across cultures.  Patients with confirmed heart failure (N=720) were 
classified using New York Heart Failure Association Classification. Cluster analysis used 
hierarchical cluster approach and Ward’s method. Findings revealed a core group of symptoms 
that formed two clusters:  physical capacity symptom cluster and emotional/ cognitive symptom 
cluster.  These symptoms clustered similarly among the cultural groups despite the cultural 
diversity (Moser et al., 2014). 
Yu et al., 2016 conducted a secondary data analysis of a cross sectional study which 
interviewed 119 advanced HF patients.  The purpose of that study was to identify symptom 
clusters in heart failure patients and their relationship with quality of life. Exploratory factor 
analysis was used to identify symptom clusters and hierarchical regression analysis was used to 
identify the relationship with quality of life. After adjusting for age, gender and comorbidities 
three distinct symptom clusters were identified. The clusters were distress (shortness of breath, 
anxiety, and depression), decondition (fatigue, drowsiness, nausea, and reduced appetite), and 
discomfort (pain, and sense of generalized discomfort). Based on these findings the researchers 
recommended a need to develop palliative care interventions for symptom cluster control for 
individuals with advanced congestive HF (Yu et al., 2016). 
To summarize, more than one investigator found that there is a correlation between 
depression and fatigue, depression and anxiety, depression and sleep, depression and pain, 
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anxiety and fatigue, and dyspnea and fatigue in HF patients. Most researchers grouped symptoms 
in clusters of two or three based on physical distress, emotional/cognitive distress, and 
discomfort. Clusters placed under physical symptoms include fatigue, pain, drowsiness, nausea 
and reduced appetite. Emotional/ cognitive symptom clusters have been identified as anxiety, 
and depression. There appears to be emerging trends to continue to investigate symptom clusters 
in HF. Collectively these findings provide clear indications that symptom clusters can be 
identified in HF patients, and that this knowledge has potential to improve symptom 
management in HF patients   
Symptom Clusters in Spinal Cord Injury 
Studies on presence of symptom clusters in spinal cord injury (SCI) have gained 
momentum since the early twenty first century. Researchers noted the presence of certain 
symptoms more commonly than the others and with more intensity and severity. The most 
commonly and frequently occurring symptoms in individuals with SCI include chronic pain, 
spasticity and depression. Many studies in the SCI population have revealed the occurrence of 
chronic pain and its effect on functional ability and quality of life.  A link between chronic pain 
and depression has also been identified, such that increased pain related to increased depressive 
symptoms (Barrett et al., 2003; Rintala et al., 1998; Ulrich et al., 2007; Jensen et al., 2007; 
Widerstrom-Noga, Felix, Cruz-Almeida, & Turk, 2007).  
Four studies (Hitzig et al., 2008; Johnson et al., 1998; Noonan et al., 2008) evaluated the 
symptoms of chronic pain, spasticity and depression in SCI patients.  Noonan et al. (2008) 
enrolled 70 individuals who experienced traumatic central cord syndrome; the purpose was to 
study the impact of spasticity, neuropathic pain and sexual dysfunction on quality of life and 
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satisfaction.  Findings revealed spasticity to be reported most often (59%), followed by chronic 
neuropathic pain (39%). Spasticity was not significantly associated with the mental component 
of general health status measure as compared to the physical component score. In a sample of 
216 patients with SCI, Ravenscroft et al (2000) studied the severity and impact of chronic pain in 
spinal cord injury. Results demonstrated that participants with chronic pain had significant 
impairment of daily activities. Muscle spasms were reported in 25% of participants which 
exacerbated pain. Further, pain and depression was reported by 39% of the participants who also 
identified pain as a contributing cause of depression.  
Other studies which examined symptom clusters in SCI individuals, explored the 
experiences of these individuals with respect to chronic neuropathic pain.  Those findings 
identified physical factors including constipation, infections, spasticity and emotional factors 
(anxiety, depression and stress) as contributing to worsening of their pain (Henwood & Ellis., 
2004).  Barrett et al. (2003) studied SCI injury patients admitted to the hospital due to post injury 
complications.  They found that patients with pain had significantly greater levels of 
psychological distress than patients without pain.  A recent meta-analysis found 22.2% of 
individuals had a diagnosis of depression after spinal cord injury, which is greater than the 
prevalence of depression in the general medical population (Williams & Murray 2017). 
Summary 
The review of literature thus far examined symptom clusters in the most commonly 
studied disease conditions. Many conditions such as myocardial infarction, chronic venous 
diseases, and certain respiratory conditions are being studied as well, but are beyond the scope of 
this proposal and will not be considered. However, it is valuable to review the literature and learn 
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how symptom clusters are being studied in various conditions, as these findings can guide 
research of symptom clusters in other health conditions. Researchers continue to investigate the 
existence of symptom clusters and the possible interventions that might benefit individuals who 
have various symptom clusters in different disease conditions. While symptom clusters seem to a 
promising approach to relieve pain and suffering in cancer populations, studies are needed to 
assess the effectiveness of using a symptom cluster approach in non-cancer pain conditions. It is 
not unusual to for patients in many chronic conditions to have more than a few symptoms. The 
limited investigation of symptom clusters across disease conditions is likely since the concept of 
symptom cluster is still relatively new. The next section will review the findings from those 
studies that have examined the relationships between two or more symptoms in individuals with 
CLBP.   
Chronic Pain and Sleep 
Sleep is important for growth, tissue restoration and conservation of energy (Adam & 
Oswald, 1977; Adam & Oswald, 1983). While various sleep disorders including narcolepsy, 
insomnia, and sleep apnea, are described in the pain literature, sleep disturbances and insomnia 
have been most often studied.  Insomnia is defined as a sleep disorder in which a person’s mental 
health and ability to function are reduced by the chronic inability to sleep. About 25% of the 
United States population complain of insomnia (Wittig et al, 1982) and persistent insomnia (i.e., 
greater than 3 years) is present in nearly 50% of this population (Arnett, 1988). The CDC has 
identified insufficient sleep as a public health epidemic (cdc.gov).  Insomnia is associated with 
diminished psychological well-being, including feelings of depression. Moreover, the co-
existence of insomnia with chronic pain makes it more challenging to manage both symptoms. 
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 In contrast to insomnia and sleep deprivation, the term ‘sleep disturbance’ in the chronic 
pain population is characterized by delayed sleep onset, poor sleep quality, reduced sleep 
efficiency and duration, increased activity or movement during sleep, fragmentation of sleep 
architecture and non-restorative sleep (Landis et al, 2004; Lautenbacher et al, 2006). For many 
healthy individuals, sleep disturbance occurs occasionally, such as when one has trouble falling 
asleep or going to back to sleep after waking up during the night. It is natural to expect persistent 
pain will affect sleep, and researchers continue to be intrigued by the relationship between pain 
and sleep. 
There is clear evidence that lack of sleep affects pain in a variety of ways. Early evidence 
found a clear effect of sleep deprivation on pain perception in animals, but data in humans at this 
time was inconclusive (Lautenbacher et al., 2006).  However, there is now evidence of the 
hyperalgesia effect of sleep deprivation in both animals and humans (Ancoli, 2006).  A recent 
study using a mouse model, demonstrated that sleep deprivation exacerbated the physiological 
and behavioral response to musculoskeletal sensitization (Sutton & Opp, 2015).  Further studies 
of experimental sleep deprivation in human subjects demonstrated that sleep deprivation 
enhances pain (Daya & Bentley, 2010; Smith et al, 2007; Kundermann et al., 2004; Lentz et al, 
1999; Onen et al., 2001; Hicks et al, 1978) and sleep loss reduces the threshold for pain 
perception in adult human subjects (Nascimente et al., 2007). Recent meta-analysis to quantify 
the effect of sleep deprivation in healthy human subjects on pain perception revealed a medium 
effect size (SMD =0.62) (Schrimpf et el., 2015). A population based found poor sleep preceded 
new onset of chronic widespread pain (CWP) (Gupta et al., 2006). In another study, sleep loss 
and REM sleep loss were reported to have hyperalgesia effects (Roehrs et al., 2006). A 
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systematic review conducted in 2014 found evidence on the effect of sleep deprivation in animal 
and human models (Karman et al., 2014). Additionally, another review focusing only on 
controlled trials reported conclusive evidence on the increase in bodily complaints or decrease of 
pain thresholds subsequent to sleep deprivation (Finan et al., 2013). Collectively, these findings 
suggest that lack of sleep results in greater sensitization of pain pathways, as well as greater 
perception of pain; yet the precise mechanism remains unclear. 
There is burgeoning research demonstrating a bidirectional relationship between 
disturbed sleep and pain intensity. That is, pain may lead to sleep disturbances and poor sleep 
may cause or exacerbate pain (O’Brien et al., 2011). Longitudinal studies demonstrated that a 
night of poor sleep quality was followed by a day with more severe pain, which consequently 
worsened sleep quality during the subsequent night (Flume et al., 2009). Also, cross sectional 
studies of healthy subjects suggest that pain disturbs sleep quality /continuity and poor sleep 
further exacerbates pain (Smith & Haythornthwaite, 2004). The bidirectional relationship 
between sleep and pain is confirmed by pharmaceutical studies showing that medications used to 
treat insomnia (eszopiclone, triazolan) result in both an improvement in sleep as well as 
reduction of pain (Roth et al., 2009, Walsh, 1996).  Also, clinical trials show improvement in 
pain sensitivity in patients with effective treatment of sleep disorders like restless leg syndrome 
(RLS) and obstructive sleep apnea syndrome (OSAS) (Khalid et al, 2011; Stiasny – Kolster et al, 
2013).  
Several studies have highlighted the effect of sleep disturbance on different bodily 
functions, including cognition, metabolism, emotion and pain regulation, cardiovascular and 
immune function. (MMWR, 2011; Brown et al,, 2012, Hanlon et al., Imeri & Opp 2009).  Sleep 
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disturbance is strongly associated with psychological distress, physical disability (van de Water, 
AT 2011), fatigue and day-time sleepiness (McCracken LM et al., 2002), more severe pain 
(Alsaadi, SM 2012), more hospitalization for low back pain than those without sleep problems 
(Kaila-Kangas, L et al., 2006).  Moreover, sleep disturbance in chronic pain may be attributable 
to pain itself. In contrast to the traditional belief that pain severity can predict severity of sleep 
disturbance, studies show that enhanced pain perception can also be due to sleep disturbance; 
hence, resulting in a vicious cycle.  This is substantial; as 50-88% of patients with chronic pain 
also suffer from sleep disorders (Smith et al, 2000; Gislason & Almquist, 2015; Pilowskyl, 1985) 
and more than 40% patients with insomnia also have a diagnosis of chronic pain (Ohayon, 2005).  
Chronic musculoskeletal pain, including that due to arthritis, low back pain and 
fibromyalgia, are often associated with insomnia (Siversten et al, 2009; Ancoli, 2006; Gureje et 
al, 2009). Epidemiological studies highlight poor sleep quality as an independent risk factor for 
developing chronic pain, especially musculoskeletal pain (Mork & Nilsen, 2011). A few studies 
identified the effects of sleep deprivation (total, selective, show wave and delta wave 
interruption) in healthy subjects on musculoskeletal pain.  Those studies found relationship 
between slow wave sleep (SWS) and sensitivity to pain (Older et al, 1998; Onen et al; 2001& 
Lentz et al; 1999). For example, Lentz et al disrupted SWS for 3 consecutive nights in healthy 
middle aged women and assessed musculoskeletal pain with dolorimetry.  They found decreased 
pain sensitivity in those with disrupted SWS (Lentz et al; 1999). Arima and colleagues 
investigated the effects of SWS deprivation for 3 continuous nights on jaw-muscle activity in 
men without temporomandibular disorders. They reported that out of 10 a subgroup (5 subjects) 
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who showed reduction in SWS during all 3 nights demonstrated a significant trend (p=0.06) for 
decreased pain threshold (Arima et al., 2001).  
Alsaadi et al (2014) evaluated the relationship between intensity of LBP and sleep 
disturbance.  Eighty patients completed a sleep diary and also used an arm band to measure 
sleep.  Findings revealed that a night of poor sleep, difficulty falling asleep, waking after sleep 
onset and low sleep efficiency were followed by a day of higher pain intensity. Additionally, a 
day with higher pain intensity was associated with a decrease in subsequent night’s sleep quality, 
an increase in sleep latency, waking after sleep onset and low sleep efficiency. Similar to the 
findings of Alsaadi and colleagues, Koffel et al (2016) examined changes in pain that might 
predict sleep complaints, in 250 veterans. They identified that changes in sleep complaints at 3 
months predicted changes in pain at 12 months (p< 0,001); and to a lesser extent changes in pain 
predicted changes in sleep (p<0.05).   Other studies have shown that impaired sleep led to new 
onset or worsening of pain (Haack & Mullington, 2005 & Edwards et al; 2008).  
In summary, most studies that researched pain and sleep studied individuals with sleep 
disturbance, as opposed to sleep disorders, such as insomnia. Further, patients with chronic pain 
more often present with symptoms of sleep disturbance, rather than insomnia. Hence for purpose 
of this study, sleep disturbance will be studied in relation to CLBP.  
CLBP and Sleep Disturbance 
In a systematic review, CLBP was reported to contribute to increased duration of sleep 
onset, reduced total sleep time, and lower sleep efficiency (Kelly et al., 2011). These findings are 
confirmed internationally. For example, a study in France investigated subjective sleep quality in 
101 CLBP patients, and found significant alterations in sleep in those with CLBP compared to 
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healthy controls matched for age, sex and height (Marty et al., 2008). Another study conducted 
in Norway on 457 CLBP patients also identified significant sleep problems as compared to 
controls (Hagen et al, 2006). Similarly in the UK a study of 70 CLBP patients found significant 
changes in sleep onset and maintenance when compared to control group matched for age and 
sex (Tang et al, 2007).   
Axen (2015) conducted a case control study to investigate the correlation between pain 
and sleep disturbance and the effect of back pain on sleep disturbance. Among 233 patients with 
acute and persistent LBP, 67% of the sample reported sleep disturbance, which was significantly 
correlated with greater pain.  Also, there was a greater risk of reporting sleep disturbance after 
experiencing pain the previous week (relative risk = 2.1 to 5.8) and a dose response between the 
number of days with pain and the risk of sleep disturbance.  Similarly, another study ( 
O’Donoghue et al., 2009) found that people with CLBP reported poor sleep quality, clinical 
insomnia, longer sleep onset latency, lower sleep efficiency and more awakenings during sleep 
(p<0.05), compared to age and gender matched individuals with chronic pain.  
A prospective cross sectional evaluation of 268 patients with LBP undergoing 
rehabilitation identified a significant relationship between pain and sleep.  Pain was measured 
using the Brief Pain Inventory (BPI), while sleep was measured using the Pittsburgh Sleep 
Quality Index (PSQI).   Findings revealed a 55% increase in the proportion of subjects reporting 
restless/light sleep after pain onset.  Significant direct correlations between SF-MPQ and PSQI; 
between PSQI and VAS; and between overall quality of sleep and VAS were observed. The 
researchers concluded that CLBP significantly reduces quality of sleep (Marin et al, 2006).  
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O’Donoghue and colleagues (2009) compared the sleep quality of 15 CLBP participants 
with healthy age and gender matched controls using subjective and objective measures.  That 
study found that CLBP participants demonstrated significantly poorer overall sleep, as measured 
objectively and subjectively. They also demonstrated lower actigraphy sleep efficiency and 
increased awakenings after sleep onset. Subjectively, they reported increased insomnia, lower 
sleep efficiency (p =< .001) and increased sleep time. Additionally their findings demonstrated a 
significant association between low back pain and physical health, disability levels, and 
subjective sleep quality in the CLBP participants.  
While the above studies detected alterations in sleep onset, quality and efficiency, some 
studies used polysomnography as an additional measure to address sleep disturbance in CLBP.  
For example, a study of CLBP patients (N=51), who completed a self-inventory of sleep 
performance found that half of the participants reported poor sleep, and those with high sleep 
intensity reported less sleep time, more delayed sleep onset, and more nighttime awakenings than 
patients with low intensity. Further, that study revealed decreased or absent stage three and stage 
4 sleep, periodic leg movements and shortened time to onset of rapid eye movement (REM) 
sleep (Atkinson et al., 1988).  
To summarize, evidence to date confirms that CLBP is associated with greater sleep 
disturbance; and that there is a bidirectional relationship between sleep and CLBP (i.e., pain can 
lead to sleep disturbance and sleep disturbance can exacerbate pain). Studies, however, differ 
widely in the measurement of sleep quality, and include a mix of subjective and objective 
measures, making it difficult to compare findings across studies. Most studies were saturated 
with self-report subjective measures of sleep, and discrepancies between subjective and objective 
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measures were identified in three studies (Atkinson et al., 1988; Bulthuis et al, 2004 & Lavie et 
al, 1992). 
It is recognized that there is value in using a combination of subjective and objective 
measures of sleep quality; however, there is a need for more standardization of sleep 
measurement, as well as a need for feasible and valid approaches to measure sleep quality in 
those with CLBP.  In addition, the current literature is unclear as to the influence of ‘sleep 
disturbance’ versus ‘insomnia’ in the CLBP population.  The field is also limited in that most 
studies evaluated Caucasian populations. Hence, there is a need to enroll more diverse 
populations with CLBP to understand the influence of various socio-demographic and cultural 
factors, which can lead to more tailored approaches to manage the challenge of co-occurrence of 
pain with sleep disturbance.  Lastly, there is a need to understand the underlying mechanisms 
linking sleep disturbance to the pain experienced in those burdened by CLBP.   
Mechanisms Linking Sleep to Pain 
The biological mechanism(s) linking sleep and pain are likely complex and remain 
unclear. Yet, scientists are exploring several hypotheses to clarify potential mechanisms that 
might explicate biological processes that underlie the relationship between sleep and pain. For 
example, the neurological hypothesis theorizes that pain and sleep are linked by alpha wave 
intrusion into Non Rapid Eye Movement (NREM) phase of sleep. (Moldofsky, 1975; 1976). 
Other theories invoke dysregulation of neurotransmitter systems, such as the serotonin system 
(Foo and Mason, 2003), the dopaminergic system (Argoff, 2011; Carver et al, 2008; Ursin 2002), 
and the endogenous opioid systems (Sutton & Opp, 2014) (Basbaum & Fields, 1984).  Animal 
data demonstrate opioid injections placed in the nucleus of the solitary tract (NST) (an area that 
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contains the highest concentration of opioid receptors) (Reinoso & Andres 1995) enhanced slow 
wave sleep. More recently, a psychoneuroimmunology approach suggests a role for 
inflammation as one possible mechanism for worsening of chronic pain in those with sleep 
disturbance.  Data supporting a role for inflammation is described below. 
Sleep and Inflammation 
A recent meta-analysis concluded that sleep deprivation is accompanied by increases in 
systemic inflammation (Irwin et al, 2015).  Moreover, systemic inflammation has been found to 
decrease pain threshold in humans who are sleep deprived (De Godin et al, 2013). It is likely that 
sleep and pain are linked through elevations in levels of proinflammatory cytokines (i.e., tumor 
necrosis factor (TNF) and regulation of the hypothalamic-pituitary-adrenocortical (HPA) axis 
(Floam et al, 2015).  However, data is limited in humans who have chronic pain conditions.  
Further, there remains difficulties in arriving at conclusions on the effects of sleep on pain and 
inflammation due to methodological issues related to measuring sleep disturbance and 
differences in characteristics of sleep disturbance).  
Based on evidence to date, insufficient sleep may facilitate and/or exacerbate pain 
through elevations of pro-inflammatory cytokines, like IL-6. Reductions in sleep quality and 
quantity have each been associated with higher circulating levels of IL-6 during the day (Heffner 
et al., 2012). In another study, patients with temporomandibular pain disorders (40 females) who 
were classified as having high disability (Graded Chronic Pain Scale) also had the highest PSQI.  
Moreover, plasma levels of IL-1β, IL-6, IL-10, and TNF-α were significant in the high-disability 
group. Further, the plasma cytokine levels were significantly correlated with increased sleepiness 
(Epworth Sleepiness Scale) and PSQI scores suggestive of sleep disturbance (Park, J. W., & 
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Chung, J. W, 2016). Further, insufficient sleep may establish and maintain its co-occurrence with 
pain and increased inflammation. Additionally, inflammation can signal the brain to engender 
depressive mood (Inflammatory Theory of Depression) and depressive mood can lead to 
increased pain perception (Tang et at., 2008). 
Chronic Pain and Depression 
Depression coexists with chronic pain (Krishnan et al., 1985) and is estimated to cost $83 
billion annually in the United States (Greenberg et al., 2003). Some studies show 30% to 60% 
co-occurrence rate between chronic pain and depression (Baer, 2003). Others show as much as 
31% to 100% (Miller & Cano, 2009). Depression is commonly associated with chronic back pain 
and can also be a risk factor for both low back pain and sciatica (Parreira, P et al., 2018). While 
there is a growing body of literature supporting the link between CLBP and depression, how 
depression relates to other behavioral symptoms, and whether a common biological mechanism 
links these symptoms with pain remains unclear. This section will summarize the evidence on 
the relationship between pain and depression, with emphasis on CLBP.  
Numerous studies suggest that depression worsens both the severity of pain and disability 
caused by pain. A National survey found that subjects with chronic pain due to musculoskeletal 
conditions scored significantly higher than normal on the CES-D. That study also found that 
18% of the population with chronic pain suffers from depression, as compared to 8% of the 
population who did not have chronic pain (Magni et al, 1990). A Canadian Community Health 
Survey (N=118,533) revealed that rates of major depression were at 19.8% for individuals with 
chronic back pain, as compared to 5.9% for pain-free individuals. Moreover, greater pain 
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severity not only predicts greater disability but also is associated with greater severity of 
depression (Currie & Wang, 2004).  
CLBP and Depression 
CLBP can be debilitating due to the pain itself and also due to its impact on psychosocial 
well-being. For example, depression may reduce functional activity in chronic pain by distorting 
one’s perception of their ability to carry out activities.  This was demonstrated by Huanan, et al., 
2010 who found that individuals with chronic pain and depression do not have lower objective 
activity levels (measured by accelerometer) but had lower perception of their ability to carry out 
activities. Acute back pain may differ from chronic back pain, as a recent study found that 
depression in persons with acute back pain was not significantly associated with perceived 
disability (Salt, E et al., 2018).   
Mood disorders, such as anxiety and depression, which accompany CLBP, can 
complicate clinical management. In a large survey of community dwelling adults it was found 
that mild to severe depressive symptoms increased the odds of disabling LBP over a period of 2 
years by 30–60% (Baer, 2003). A systematic review evaluated the effect of depression on acute 
and sub-acute chronic back pain. That review focused on depression or symptoms of depression 
as a prognostic factor on pain-related outcomes, including pain intensity, chronicity (non-
recovery from low back pain), disability, return to work, health-related quality of life, and overall 
patient satisfaction. Eleven of the 17 articles reviewed found that symptoms of depression at 
baseline were related to worse low back pain outcomes at follow-up (effect size ranged from 
1.04 to 2.47). All studies regardless of statistical significance showed that there was a 
relationship between depressive symptoms and low back pain outcomes (Pinheiro et al., 2016). 
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Mood disturbance may also lower pain threshold.  For example, a cross-sectional two-phase 
population based study (N= 424), revealed that high levels of psychological distress, disturbed 
sleep and depression were all associated with having a low pain threshold (Chiu et al., 2005). 
depression is a significant mediator of the relationship between pain and self-perceived disability 
in people with CLBP (Marshall et al., 2017), emphasizing the importance of addressing 
symptoms of depression in those with CLBP.  Further, persons with CLBP who had both anxiety 
and depression had higher pain severity, higher pain-related disability. Further, the interaction 
between anxiety and depression predicted changes in pain interference at one-year follow up 
(Oliviera et al., 2018).   
The relationship between depression and pain is likely bidirectional.  Findings from a 
study of individuals with disabling low back pain showed that pain, ranging from a little of the 
time to all of the time, increased the odds of depressive symptoms by 27.9–84.2%, respectively. 
In contrast, depression may precede the development of CLBP.  Polatin et al were interested in 
studying the psychiatric syndromes in 200 CLBP patients who entered a functional restoration 
program. They found the common diagnoses were major depression, substance abuse, 
personality disorder, and anxiety disorders; with prevalence rates significantly greater than the 
general population. Most interestingly, the study revealed that 54% of those who reported 
depression, 94% of those with substance abuse, and 94% of those with anxiety disorders 
experienced these conditions before the onset of their CLBP (Polatin et al., 1993).  
In another study conducted to identify if depression is an independent risk factor for onset 
of neck and low back pain, a population-based random sample of adults was surveyed and 
followed at 6 and 12 months to measure the time-varying effects of depressive symptoms on two 
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types of pain. After considering possible confounding effects of demographics, socio-economic 
status, health, medical conditions and injuries, it was found that there was an independent and 
robust relationship between depressive symptoms and episode of pain. The authors concluded 
that depression is a strong and independent predictor for onset of neck pain and low back pain 
(Carroll, 2004). 
To summarize, the existing evidence identifies that depression often co-occurs with 
CLBP, and there is a bidirectional relationship between depressive mood and CLBP intensity. 
However, there is insufficient evidence on the nature and severity of the effect of one condition 
on the other. Further knowledge is needed to understand the predisposition of other conditions 
that lead to CLBP and the underlying processes that could attenuate or ameliorate CLBP. Future 
studies are needed to help clinicians address the high rates of emotional distress syndromes in 
CLBP.  
Depression, Inflammation, and Chronic Pain 
Both depression (Howren et al., 2009) and chronic pain are associated with inflammation 
independent of depression (Fasick et al., 2015), suggesting that inflammation may be a common 
pathway whereby these symptoms interact. The following will summarize evidence that supports 
a role for inflammation in depression.  
A large body of work has evaluated levels of inflammatory markers in clinically 
depressed patients.  Overall those studies reveal that depressed patients have activated 
inflammatory pathways, including increased expression of chemokine, adhesion molecules and 
cytokines as compared to individuals without depression (Musselman et al., 2001; Bouhuys et 
al., 2004).  Other studies have shown that patients with major depression have increased serum 
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and/or plasma concentrations of C-reactive protein (Danner et al., 2003; Ford et al., 2004) IL-6 
(Alesci et al., 2005; Sluzewska et al., 1995) and proinflammatory TNF-α (Konsman et al., 2002; 
Mikova et al.,2001). These markers exist in both serum and cerebrospinal fluid in depressed 
patients (Maes, 1999; Irwin, 2002).  Experimental studies in humans have demonstrated 
development of depressive symptoms following infusions of cytokines, such as IFN-α 
(Musselman et al., 2001; Capuron et al., 2004).  Further, elevated levels of cytokines such as IL-
6 and TNF-α predict non-response to treatment for depressive symptoms; and that depressed 
patients with increased inflammatory biomarkers are less likely to respond to conventional 
antidepressant treatments (Lanquillon, 2000).  
To synthesize the literature regarding depression and inflammation, a systematic review 
was conducted to assess the magnitude and direction of depression with inflammatory markers; 
studies published between January 1967 and January 2008 were included. That review concluded 
that inflammatory markers (CRP, IL-6, IL-1, and IL-1ra) are positively associated with 
depression. Associations were strongest in clinically depressed patient samples, but significant 
associations were also identified in community-based samples. Moreover, a dose-response 
relationship between depression and inflammatory markers was identified, which was consistent 
with three causal pathways: depression to inflammation, inflammation to depression, and 
bidirectional relationships (Howren et al., 2009).  Other more recent evidence also confirms that 
inflammation may serve as a common pathway linking depression to chronic pain.  For example, 
higher IL-6 levels have been linked with both greater pain and greater chronic medical 
comorbidity in patients with greater depressive symptoms (Poleshuck et al., 2013). IL-6 was 
unrelated to pain or chronic medical comorbidity among patients without clinically 
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significant depressive symptoms. Hence, the authors concluded that depression may increase 
primary care patients' vulnerability to pain, resulting in elevated levels of inflammatory markers 
such as IL-6 (Poleshuck, 2013). 
 A study of 218 outpatients with rheumatoid arthritis identified depression scores to be 
positively correlated with CRP level; and that. Both the depression score and the CRP level were 
significantly associated with pain, even after adjustment for clinical covariates. Further, logistic 
analysis revealed that the combined effects on the risk of severe pain linearly increased with both 
depression scores and CRP levels. The authors noted that prior studies focused on understanding 
chronic pain mechanisms in relation to processes of hyperalgesia. Now, it is has been recognized 
that inflammatory mediators can influence both inflammatory pain and nerve related pain caused 
by damage to peripheral nerves or to the CNS (Marchand et al., 2005). 
Klyne et al., evaluated circulating pro-inflammatory cytokines and C-reactive protein 
(CRP) to explore the relationship of these inflammatory markers with pain severity and other 
symptomss in acute low back pain (LBP).  That study enrolled ninety-nine individuals who were 
evaluated within two weeks of onset of acute LBP and compared to fifty-five pain-free controls. 
Findings revealed that CRP was higher in LBP patients compared to controls and in those with 
high- than low-pain. In addition, IL-6 was higher in those with high- than low-pain (p<0.05), but 
not controls. The investigators concluded that systemic CRP and IL-6 are important contributors 
to inflammation in the early post-onset phase of LBP and that various factors such as sleep 
quality and psychological status can shape these responses (Klyne etal., 2017). 
Recent findings suggest the possibility of aberrant glial activation in the establishment 
and/or maintenance of central sensitization to pain. Nijs et al. reviewed preclinical 
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neurobiochemistry of animals and found high levels of BDNF, IL-1β, TNF-α, which increase the 
excitability of the central nervous system neurons.  The authors discussed the possibility that 
glial activity in chronic pain may have been triggered by severe stress exposure, and/or sleeping 
disturbances, each of which are established initiating factors for chronic pain development (Nijs 
et al.,2017). 
Currently, studies on the role of inflammation in CLBP are limited. One study, however, 
evaluated 127 patients with disc herniation to determine the association of two cytokines, IL-6 
and IL-8, with long-lasting lumbar radicular pain (N=127).  Findings revealed significantly 
higher levels of serum IL-6 and IL-8 in serum in patients with visual analogue scale (VAS) 
scores >3 at 12 months, than in patients with VAS <3 at 12 months (Weber et el., 2015). The 
authors concluded that their results were the first to show that chronic lumbar radicular pain may 
be associated with a persistent increase of proinflammatory cytokines after disc herniation. 
Given that individuals with CLBP, experience co-occurring behavioral symptoms that are 
also independently associated with inflammation, clusters of these symptoms may underlie 
different pain profiles. The next section describes the extent to which fatigue might act on the 
intensity of the pain experience. 
CLBP and Anxiety 
Several studies have identified a relationship between CLBP and anxiety. Similar to other 
symptoms, there is not enough evidence to support if anxiety worsens in CLBP or if underlying 
anxiety could be a predictor for CLBP. Earlier studies identified preexisting anxiety in patients 
developing CLBP. Polatin et al (1993) assessed 200 CLBP patients in a functional restoration 
program for current and lifetime psychiatric syndromes using a structured psychiatric interview 
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to make DSM-III-R diagnoses. Out of the patients with a positive lifetime history for psychiatric 
syndromes, 54% of those with depression, 94% of those with substance abuse, and 95% of those 
with anxiety disorders had experienced these syndromes before the onset of their back pain. 
Hence it was concluded that that certain psychiatric syndromes appear to precede CLBP 
(substance abuse and anxiety disorders), whereas others (specifically, major depression) develop 
either before or after the onset of chronic low-back pain. 
 Kroenke et al examined the association between anxiety, health-related quality of life 
(HRQL) and functional impairment in primary care patients with chronic musculoskeletal pain. 
Interviews were conducted on 250 primary care patients enrolled in the Stepped Care to 
Optimize Pain care Effectiveness trial. Using validated measures to determine the proportion of 
patients screening positive for five common anxiety disorders: generalized anxiety, panic, social 
anxiety, posttraumatic stress and obsessive-compulsive disorder, it was found that 45% patients 
screened positive for at least one anxiety disorder and hence concluded that nearly half of 
primary care patients with chronic pain screen positive for one or more anxiety disorders, which 
in turn are adversely associated with impairment across multiple domains of HRQL.  
Von Kroff et al., 2005 investigated comorbidity between chronic back and neck pain and 
other physical and mental disorders in the US population. They interviewed a probability sample 
of US adults (n=5692) with chronic spinal pain, other chronic pain conditions and also assessed 
mood, anxiety, and substance use disorders using Composite International Diagnostic Interview 
(CIDI). Results showed that the majority (87.1%) of people with chronic spinal pain reported at 
least one other comorbid condition, including other chronic pain conditions (68.6%), chronic 
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physical conditions (55.3%), and mental disorders (35.0%). Anxiety disorders and mood 
disorders showed a strong association with chronic spinal pain.  
In a controlled trial in an interventional pain setting, evaluating 40 individuals without 
pain or psychotherapeutic drug therapy, Group I, control group; and Group II, chronic low back 
pain group with 40 chronic low back pain patients, there was significant differences were found 
among various clinical syndromes with generalized anxiety disorder, somatoform disorder, and 
depression, with 0% vs 20%, 0% vs 20%, and 5% vs 30% in Group I and Group II consecutively 
(Manchikanti et al., 2002).  
In a recent interesting longitudinal study on 1,269 adult twins (mean age of 53 years), 
investigators studied whether chronic low back pain (LBP) increases the risk of depression or 
anxiety symptoms, after adjusting for shared familial factors. They identified significant 
association between chronic LBP and the risk of depression or anxiety symptoms in the 
unadjusted total sample analysis (odds ratio [OR]: 1.81, 95% confidence interval [CI]: 1.34–
2.44). The researchers concluded that relationship between chronic LBP and the future 
development of depression or anxiety symptoms is not causal and is likely to be explained by 
confounding from shared familial factors Fernandez et al (2017). 
To summarize, anxiety is also another key behavioral symptoms for which there is 
substantial evidence that there is a bidirectional relationship between CLBP and anxiety. 
CLBP and Fatigue 
Findings from several studies demonstrate that fatigue is prevalent and problematic for 
individuals with CLBP (Fishbain et al., 2004; Starkweather 2013; Snekkevik et al., 2014).  For 
example, one study evaluated CLBP patients (N=569) to identify the associations among fatigue, 
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depression, and pain; and to determine if fatigue predicted long-term disability. Findings 
revealed that prevalence of substantial fatigue to be 69.7%; and those with substantial fatigue 
had higher pain intensity, more depressive symptoms, and more disability than those without 
substantial fatigue. Musculoskeletal pain and depression were independently associated with 
substantial fatigue and fatigue predicted long-term disability at 3, 6, and 12 months’ follow-up. 
Further, after pain and depression were controlled for, fatigue remained a significant predictor of 
disability at 6 months’ follow-up. Hence the researchers concluded that the majority of the sick-
listed CLBP patients reported substantial fatigue and those who had substantial fatigue had more 
pain and depressive symptoms and a significant risk of reporting more disability at 3, 6, and 12 
months (Snekkevik et al., 2014) 
Starkweather (2013) conducted an exploratory study of subjects with persistent 
radiculopathy  to determine 1) relationships among fatigue, pain, psychosocial factors, and 
selected biologic markers of immune activation (interleukin [IL] 6 and soluble IL-6 receptor 
[sIL-6R]); and 2) differences in these variables based on fatigue severity. Participants (n = 80) 
were classified according to their level of fatigue as low (27.5%), moderate (32.5%), or high 
(40%). Findings revealed that individuals with moderate to high fatigue levels had greater 
psychological distress, depressive symptoms, IL-6 and sIL-6R, compared to those with low 
levels of fatigue. This study suggests the possibility of immune activation affecting fatigue 
severity and behavioral responses in patients with persistent radiculopathy. 
A prospective cohort study of 120 chronic widespread pain patients (CWP) participating 
in multidisciplinary rehabilitation treatment (baseline, 6 and 18 months of follow-up) revealed 
that higher levels of pain, interference of pain, depression, and negative emotional cognitions, 
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were associated with a higher level of fatigue; while improvement in depression was related to 
improvement in fatigue. The authors concluded that in CWP patients, worse clinical status, and 
dysfunctional pain-related cognitions are associated with a higher level of fatigue. It was 
suggested that improvement in depression might be a mechanism of improvement in fatigue and 
that improvement in fatigue was independent of improvement in pain related cognitions (De 
Rooij et al., 2014). 
Fishbain et al., 2009 analyzed the data from clinical trials of duloxetine [a 
selective serotonin and norepinephrine reuptake inhibitor (SNRI)] to determine whether an 
association between pain, sleep, and vitality exists. Data from 3 double-blind, randomized, 
placebo-controlled, 12-week trials of patients without mood disorder (N = 1,139) was evaluated. 
Of the identified 697 patients, correlations between changes in daily and night pain, and sleep 
interference with vitality changes were -0.34, -0.32, and -0.28, respectively (P < 0.001). The 
direct effect of treatment on change in vitality was statistically significant (68%, P = 0.010).  
Path analyses suggested vitality improvement in patients with chronic pain may be secondary to 
improvement in pain by duloxetine. The researchers concluded that it could not be proved that 
pain causes fatigue; however, there was indication that treatment of pain can improve perception 
of improvement in fatigue.  
The above studies indicate that fatigue is also closely related to pain and there are 
possible relationships between pain, fatigue, depression and sleep disturbances as well. 
CLBP and Quality of Life 
From a clinical and community health perspective, quality of life is an important outcome 
for CLBP patients. Nurses focus on relieving pain and suffering in patients and one of the 
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desired outcomes is to help patients achieve and maintain an optimal quality of life. CLBP 
patients have consistently reported decreased quality of life and multidisciplinary pain 
rehabilitation programs have been shown to improve their quality of life (Waterschoot et al., 
2014; Veehof et al., 2011 & Morley, 1999. In a systematic review and meta-analysis of 12 
studies (N=2961), Lee et al. 2015 identified factors which mediate quality of life in patients with 
back and neck pain. The researchers considered disability as a key indicator of quality of life. 
Results showed that self-efficacy, psychological distress, and fear were significant mediators of 
quality of life. Moreover, path analysis revealed that self-efficacy, psychological distress, and 
fear mediated the relationship between pain and disability, but catastrophizing did not. 
Analysis of factors that contribute to decreased quality of life and how CLBP can affect 
quality of life can help to identify the gaps in literature. Based on this, new strategies to improve 
quality of life can be discovered.  For example, research has shown that multidisciplinary pain 
rehabilitation programs improve daily functioning in patients with chronic back pain.  A 
systematic review of 10 RCTs reporting on 10 multidisciplinary Pain Rehabilitation Programs 
(PRPs) concluded that PRPs that offer more than 100 hours are superior to mono-disciplinary 
treatment and PRPs offering 30 hours of rehabilitation (Waterschoot et al., 2014).  Further, 
studies have shown that integrative approaches for chronic pain improve physical, social, work 
related activities and reduce pain, emotional distress; disability and medication use (Veehof et 
al., 2011).  For example, meta-analysis of 25 RCTs of cognitive Behavioral Therapy (CBT) and 
behavioral therapy concluded that these therapies provide greater changes for cognitive coping, 
pain experience domains and reduced behavioral expression of pain (Morley, 1999). 
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Psychological and social factors also are known to contribute to health related quality of 
life in patients with CLBP. Keeley et al (2006) conducted a prospective study of patients with 
CLBP (N-108) from an orthopedic outpatient clinic. That study assessed demographic 
characteristics, details of back pain and physical aspects of health-related quality of life (SF- 36 
PCS); and recorded the number of healthcare contacts at the 6 month follow up.  Independent 
predictors of SF-36 PCS at 6-month follow-up were duration of pain and back pain related social 
difficulties. Number of healthcare contacts over the 6 months ranged from 1 to 29, and was 
independently predicted by perceived cause of pain, fear avoidance beliefs about work and back 
pain related social difficulties. Based on these results, the investigators concluded that anxiety, 
depression; fear avoidance beliefs relating to work and back pain related stresses predicted the 
impairment in subsequent physical health-related quality of life and number of healthcare 
contacts. 
In a similar study, Horng and colleagues (2005) evaluated factors as predictors of health 
related quality of life (HRQL) in CLBP patients (N=232) enrolled from several ambulatory 
clinics (physical medicine and rehabilitation). Results indicated that there were significant 
correlations of HRQOL with pain intensity, disability scale and days of disability. Significant 
predictors of HRQOL included pain intensity, family income, physical and psychological factors. 
Other changes environmental predictors included disability days, educational level, herb 
medications and physiotherapy. Importantly, the findings from this study also indicated that 
HRQOL of CLBP patients depended on functional status and psychological factors rather than 
simply physical impairment.  
To support this literature, multidisciplinary interventional programs that include cognitive 
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behavioral treatment and physical therapy have also been shown to improve quality of life in 
CLBP patients.  For example, Morone and colleagues (2011) conducted a single blinded RCT 
study to the effect of the multidisciplinary back school program in a rehabilitative center on 
quality of life in 74 patients with chronic non-specific low back pain at three and six months 
follow up. Participants in the treatment group (N=41) received medical assistance, education and 
active back exercises while the control group (N=29) received medical assistance only. The 
treatment group showed significant improvement in quality of life (both physical and mental) 
and significant improvement in disability scores. Moreover, pain perception score (VAS) showed 
a reduction in both groups, but it was significantly lower in BSG at end of treatment and both 
follow-ups.   
In another RCT ( n= 50), Morone et al., 2011 evaluated the effect of the ‘Back School 
Program’ on mental components of quality of life in patients with musculoskeletal pain , mostly 
of the spine with scale elevations of MMPI-II. The control group received medical assistance 
only.  Results indicated that the treated group had significant improvements in quality of life, 
pain and disability. These findings demonstrate that the Back School Program can improve 
quality of life, possibly by reducing pain and disability; yet, no mediation analysis was 
performed. 
A third RCT by Banth and Ardebil (2015), evaluated the effect of mindfulness based 
stress reductions (MBSR) on pain and quality of life of female patients (N=88) with CLBP. 
Participants were randomly assigned to MBSR plus usual medical care, while the control group 
received usual medical care only Findings revealed that MBSR was effective in reducing pain 
severity (McGill Pain Score) and improving physical and mental quality of life. Patients who 
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attended 8 sessions of MBSR reported significantly lower pain than patients who received usual 
medical care.  
Gaps in Knowledge: Symptom Clusters and Inflammation in CLBP 
The above review of literature summarizes the evidence to date as to the most common 
behavioral symptoms (i.e., depressive symptoms, sleep disturbance, and fatigue) associated with 
the pain experience in individuals with CLBP. Further, inflammation levels predicted behavioral 
Class membership. Only a handful of studies have examined symptom clusters in individuals 
with CLBP. One such study identified three clusters of symptoms in a cohort of patients with 
chronic low back pain (n=294).  These clusters were derived from multiple psychological 
questionnaires, with cluster 3 exhibiting the highest scores   across cognitive (eg, kinesiophobia, 
pain catastrophizing, endurance behaviors, low acceptance, low pain self-efficacy) and higher 
scores in affective factors (e.g., depressed mood, anxiety, stress) and significantly greater lumbar 
pressure pain sensitivity, more undiagnosed comorbid symptoms, and more widespread pain than 
other clusters (Rabey et al.,2016).   
There is sufficient evidence that each of these symptoms might coexist with one or more 
but there are also several gaps in knowledge. For instance, existing evidence identifies that 
depression often co-occurs with CLBP, and there is a bidirectional relationship between 
depressive mood and CLBP intensity. However, there is not sufficient evidence on the nature and 
severity of the effect of one condition on the other. Additionally, it is not clear if there are 
underlying processes in CLBP and depression that could attenuate or ameliorate CLBP. 
Secondly, evidence to date confirms that CLBP is associated with greater sleep disturbance; and 
that there is a bidirectional relationship between sleep and CLBP (i.e., pain can lead to sleep 
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disturbance and sleep disturbance can exacerbate pain). However studies differ widely in the 
measurement of sleep quality, and include a mix of subjective and objective measures, making it 
difficult to compare findings across studies to arrive at a definitive conclusion. There are also 
design issues that limit the validity and generalizability of prior studies in examining relationship 
of sleep to CLBP. The value of subjective measures is recognized; however, there is need for 
studies that measure both subjective and objective measures, as each type of measure can 
provide valuable insight.    
Finally, although evidence on relationship between CLBP and behavioral symptoms 
fatigue is evolving, there is need for further studies that address clusters of symptoms.  It is 
notable that there are several gaps in the area of symptom cluster research in non-cancer pain. 
Only three studies have thus far studied symptom clusters in non-cancer pain; however, these 
studies did not focus on CLBP.  Rather, those studies focused on the relationship between 
symptoms, in heterogeneous pain populations (headache, neck pain, fibromyalgia) and very few 
focused on CLBP in particular. Henceforth there is not only a dearth in knowledge on 
relationship between symptoms in CLBP but also as to what symptoms could occur in clusters in 
this population. 
Although there is burgeoning evidence as the existence of depressive symptoms, sleep 
disturbance, and fatigue in CLBP, no studies have evaluated these symptoms as clusters, and this 
remains a gap in knowledge.  Evaluating these symptoms as a cluster will advance knowledge of 
interactions among co-occurring symptoms, which can support the development of interventions 
that target more than one symptom.  It is clear that the co-occurrence of symptoms adversely 
impacts the pain experience and quality of life in individuals with CLBP.  Hence, there is a need 
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for future investigations to advance knowledge of the relationships among these behavioral 
symptoms as a cluster and to determine how they influence pain and quality of life in CLBP 
patients.  Further, it is possible that these co-occurring symptoms are mediated through a 
common psycho-biological mechanism.  Hence, there is a need to understand potential 
mechanisms, such as inflammation, which may serve as a common pathway linking these 
distressing symptoms to pain.  
Implications and Future Direction 
Findings from this study will increase understanding of the role of depressive mood, 
fatigue, and poor sleep, as a symptom cluster, on inflammatory biomarkers, pain, and quality of 
life in patients with CLBP.  This knowledge can inform the development of specific symptom 
profiles to be used clinically to develop individualized and mechanism-oriented treatment 
strategies for CLBP patients in the future. Moreover, it is important to understand whether a 
common pathway mediates these symptoms.  One such pathway is inflammation.  Each of these 
symptoms (i.e., depressive mood, sleep disturbance and fatigue) has been associated with excess 
production of inflammatory mediators. For example, insufficient sleep may facilitate and/or 
exacerbate pain through elevations of pro-inflammatory cytokines, like IL-6. Both, reductions in 
sleep quality and quantity have each been associated with higher circulating levels of IL-6 during 
the day. Insufficient sleep may establish and maintain its co-occurrence with pain and increased 
inflammation. Similarly fatigue can cause increased inflammation. Inflammation can signal the 
brain to engender depressive mood (Inflammatory Theory of Depression); Depressive mood can 
lead to increased pain perception. Thus, an examination of key inflammatory molecules (e.g., IL-
58 
 
 
6) as a common pathway linking these behavioral symptoms can provide initial mechanistic 
evidence. 
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CHAPTER THREE 
DISCUSSION OF PROPOSED RESEARCH METHODOLOGY 
Examination of Symptom Clusters and Underlying Inflammation in Patients with CLBP 
Chronic low back pain (CLBP) has been identified as one of the most common 
complaints of patients with musculoskeletal disorders (Andersson, 1999). CLBP is defined as 
presence of pain in the lumbar region that lasts more than 7-12 weeks (Currie & Wang, 2004). 
Further, CLBP can cause restricted work capacity, social activities limitations, emotional 
problems, and reduced quality of life (Bentsen et al., 2008). The overall purpose of this proposal 
is to determine the extent to which behavioral symptoms, independently or as a cluster, predict 
pain quality and intensity and quality of life in patients with CLBP.  Additionally, the 
relationship of these symptoms as clusters and underlying inflammation will be determined.  
Thus, the following specific aims and hypotheses will be addressed in individuals with CLBP:  
Specific Aims and Hypotheses 
Aim 1: To identify behavioral symptom clusters in individuals with CLBP. 
Hypothesis 1:  Behavioral symptom clusters will be identified in individuals with CLBP. 
Aim 2: To determine differences in pain experience (pain severity and interference) and 
quality of life among identified clusters.  
Hypothesis 2: Pain experience and quality of life will differ among identified clusters. 
Aim 3: Determine differences in inflammatory biomarkers based on symptom clusters 
and pain experience.
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Hypothesis 3: Inflammation will differ with the pain experience, quality of life, and 
symptom cluster.  
Aim 4: Explore regression models to determine predictors of the pain experience and 
quality of life in individuals with CLBP. 
Research Design and Methods 
Overview of design.  This chapter delineates how the proposed conceptual model was 
verified. Overview of design, setting, samples, study procedures and variables used in the 
analysis for applying the Model among CLBP are also included. 
This cross-sectional design identified behavioral symptom clusters and determined 
differences in pain profiles and quality of life among the identified symptom clusters.  In 
addition, differences in key inflammatory proinflammatory cytokines (i.e., IL-6 ) among clusters 
were examined.  Individuals (N=69) who had experienced low back pain for at least 6 months 
were recruited from the chronic pain clinic at Loyola University medical Center. Participants 
completed psychometric instruments measuring; pain quality and intensity, depressive mood, 
fatigue, sleep as well as demographic forms.  Health history was obtained by self-report and 
review of medical records. Blood amount of 10 ml was obtained by venipuncture for 
measurement of pro-inflammatory cytokines known to be associated with CLBP. Latent class 
analysis was used to identify symptom clusters, and differences in pain and quality of life among 
symptom clusters by analysis of variance.  
Sample. Eligible participants (N=86) were identified by providers (Physicians and 
Nurses).  The subjects were selected from the outpatient clinics of the Loyola University Medical 
Center.  Inclusion criteria for the study were: a convenience sample of men and women, who 
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have been diagnosed with CLBP and are between the ages of 21 to 70 years.  In addition, 
participants were alert and oriented, able to write, read and speak English at the fifth-grade level, 
and were able to consent to participate in the study. Exclusion criteria included no history of 
spinal or orthopedic surgeries in past 6 months, no lower extremity weakness or neurological 
signs of brain or nerve injury (eg.,seizures, cerebral palsy, spinal tumor/ trauma or infection), no 
steroid therapy, no immune altering drugs,  no chronic illnesses with immunological 
complications (eg., rheumatoid Arthritis, cancer in  the past 5 years), no psychiatric disorders, no 
major immune-based disease, no drug or alcohol abuse, no heavy smoking ( no more than 15 
cigarettes a day). 
Sample size. An a priori power analysis conducted using Dziak et al., approach (Dziak et 
al., 2014) (for Aim 1) and the G*Power 3 (Faul, Erdfelder, Lang, & Buchner, 2007)  software 
(for Aims 2 and 3) to estimate the number of participants.  To avoid missing an effect and 
accepting the null hypothesis, a higher power and alpha is the recommendation in pilot studies 
than in traditional studies (Schoenfeld, 1980). Therefore, instead of using an alpha of 5% (i.e. a 
two-tailed 5% type 1 error rate) and power of 80%, an α=10% and power of 85% were used in 
the subsequent calculations of the sample size. For Latent Class Analysis, a sample size of 98 
would able to detect an effect size of 0.45 with a 3-class LCA model (Dziak, Lanza, & Tan, 
2014).  
For Aims 2 and 3, the effect size was derived from three meta-analysis articles by 
Hoffman et al (34 articles) and Morley et al., 1999 (33 articles), Astin et al (25 articles). The 
effect size for depression in the above studies was large at 0.81 and effect size of pro-
inflammatory markers derived from meta-analysis article by Howren et al (2009) (51 articles) 
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was 0.35.  G*Power calculations for F-tests, indicated that a sample of 98 were adequately detect 
an effect size of f
2
=0.45 using 3 classes and alpha level of 0.10 two-sided level of significance.  
To preserve statistical power, multiple imputations were used for data missing at random.   
Study procedure. Once IRB approval was granted, the principle investigator (PI) 
communicated with the Physician at the pain clinic and research committee team members to 
understand the detailed recruitment process, findings, and difficulties while conducting the study. 
Potential CLBP participants were then identified by the nurses and the physician and then 
approached by the principal investigator in the pain clinic. Potential participants were given a 
description of the purpose and nature of the study and their role, including risks and benefits 
before enrollment. Participants were screened and consents obtained. Eligible participants who 
met the inclusion criteria were enrolled and blood samples drawn.  Study participants were 
provided with questionnaires and ACTi watch to take home. The study consisted of one-time 
point for data collection. After completion of the informed consent document, the participants 
were provided a packet of self-report questionnaires.  They also were requested to provide blood 
sample of 10 ml during venipuncture. Participants completed the following self-reported 
measures: The Center for Epidemiologic Studies Depression Scale (CES-D), Pittsburgh Sleep 
Quality Index (PSQI), Brief Pain Inventory (BPI), Brief Fatigue Inventory (BFI), Quality of life 
(Carol Ferrans HRQoL), Social Provisions Scale analgesic use, demographics form, and survey 
of health behaviors. Participants who completed the study were given a $25 gift card for their 
time and transportation.  
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Study variables. The variables used in the study were operationalized by using valid and 
reliable instruments.  In the following section, each measure is explained briefly and the 
reliability and validity is provided.  Full copies of each instrument are included in Appendix A.  
The independent variables evaluated for this study are sleep quality, depressive mood, 
fatigue, and proinflammatory cytokines (IL-6). Dependent variables are pain intensity and 
quality of life.  Table 1 (below) lists study variables. Each instrument is included in Appendix A.  
Table 1. Study Variables 
Independent Variables  Dependent Variables 
 
Covariates 
Sleep 
Disturbance 
Depressive 
Mood 
Fatigue Inflammation Pain (Severity 
and Interference) 
Quality 
of life 
outcome 
Social Support Health 
Behaviors 
PSQI 
Sleep Diary 
ACTi watch 
Depression 
(CES-D) 
Brief 
Fatigue 
Inventory 
Proinflammatory 
Cytokines (IL-6) 
Brief Pain 
Inventory 
Carol & 
Ferran -s 
HrQol 
Social 
Provisions 
Scale (SPS) 
Medications 
(Analgesics 
use) 
Demographics 
 
Sleep Quality Measures 
Measurement of sleep quality. For the purposes of this study, subjective and objective 
measures were used to measure sleep disturbance. Subjective measures included sleep diary, 
self-report questionnaires, while the objective measure was wrist actigraphy. It is recognized that 
polysomnography (PSG) is the gold standard to measure sleep quality but is not frequently used 
in research due to its complexity and expense. Most studies that report sleep quality in CLBP 
have used self-report questionnaires. However, self- report measures do not always correlate 
with PSG studies and, as such, have limitations (Silva et al., 2007). Alternative to the 
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polysomnography studies are newly developed portable devices that can provide less expensive, 
more accurate objective measures of sleep as compared to self-report scales (van de Water et al., 
2011). While some studies have investigated the accuracy of actigraphy to evaluate parameters 
of sleep compared to PSG in the general population, only one study has studied accuracy of these 
devices in the CLBP (Van de Water et al., 2011).  
Pittsburgh Sleep Quality Index (PSQI). The Pittsburgh Sleep Quality Index (PSQI) 
was used in this study as an index of subjective perception of sleep quality. The PSQI includes 
19 questions segregated into seven components: subjective sleep quality, sleep latency, sleep 
duration, habitual sleep efficiency, sleep disorders, use of hypnotics, and daytime dysfunction. 
Sleep latency were assessed using two questions rated according to time to fall asleep. Sleep 
duration was be assessed by one question rated 4 on a Likert scale from >7 to <5 hours, and 
sleep efficiency by hours asleep divided by total of hours in bed. Use of hypnotics and poor 
daytime functioning are rated by a 4-point Likert scale (not during the past month, less than once 
per week, once or twice per week, 3 or more times per week). Sleep disorders was assessed with 
nine questions focused on waking up in the middle of the night or early in the morning, getting 
up to go to the toilet, difficulty breathing properly, coughing or snoring loudly, being too cold, 
being too hot, having nightmares, experiencing pain, or other reasons for disturbed sleep. Each 
question is rated with a 4-point Likert scale (not during the past month, less than once per week, 
once or twice per week, 3 or more times per week). Subjective sleep was evaluated with one 
question rated by a 4-point Likert scale from very good to very bad. The seven components were 
each be scored from 0 (no difficulty) to 3 (severe difficulty), and summed, to give an overall 
score ranging from 0 to 21. The PSQI has demonstrated good validity and reliability, with 
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studies reporting a Cronbach alpha of 0.83 for its seven components (Buysse et al., 1989). The 
validity of PSQI was determined among older adults by examining sleep quality for 78 adults 
aged 55+ in the community and compared PSQI with actigraphy and concluded that although 
PSQI can be a valuable tool for adults, it should not be used as substitute for actigraphy. 
Sleep diary. The sleep diary is a subjective tool that was completed by participants upon 
waking for seven nights consecutively in addition to the actigraphy and PSQI. Participants were 
asked to record the time they went to bed, the time it took to fall asleep, time they woke up, 
amount of time awake after falling asleep, number of awakenings during night, time they woke 
up and total amount of sleep obtained. Participants were also asked how they would rate their 
quality of sleep on a scale of 1 to 9 (1=terrible, 9=great). Finally, they were also asked how 
rested they felt after waking up in the morning on a scale of 0 to 4 (0 – Not at all, 4 – Extremely) 
Extent of exercise, medications taken, and any illness were also be obtained to identify causes of 
sleep disturbances. 
Actigraphy. Alsaadi et al (2014) investigated the criterion validity of Armband and 
Actiwatch for assessing sleep disturbances in LBP. Fifty LBP patients underwent overnight sleep 
recordings at the same time and were assessed using both the PSG and Armband. Among the 50 
patients, 33 wore an Actiwatch. Criterion validity was calculated using epoch-by-epoch 
agreement, sensitivity, specificity and prevalence and bias- adjusted kappa (PABAK) for sleep 
versus wake between each device and PSG. The relationship between PSG and the two devices 
were assessed using intraclass correlation coefficients (ICC 2, 1). The study participants showed 
symptoms of sub-threshold insomnia (mean ISI=13.2, 95% CI=6.36) and poor sleep quality 
(mean PSQI=9.20, 95% CI=4.27). Observed agreement with PSG was 85% and 88% for the 
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Armband and Actiwatch. Sensitivity was 0.90 for both devices and specificity was 0.54 and 0.67 
and PABAK of 0.69 and 0.77 for the Armband and Actiwatch respectively. The ICC (95%CI) 
was 0.76 (0.61 to 0.86) and 0.80 (0.46 to 0.92) for total sleep time, 0.52 (0.29 to 0.70) and 0.55 
(0.14 to 0.77) for sleep efficiency, 0.64 (0.45 to 0.78) and 0.52 (0.23 to 0.73) for wake after sleep 
onset and 0.13 (20.15 to 0.39) and 0.33 (20.05 to 0.63) for sleep onset latency, for the Armband 
and Actiwatch, respectively. These results showed that both devices have varied criterion 
validity across the sleep parameters. Researchers (Lavie et al., 1992, Long et al., 2017, Kravitz et 
al., 2015 & Connaughton et al., 2014) have also noted excellent validity for measures (by using 
the Respironics Actigraphy) for total sleep time, good validity for measures of sleep efficiency 
and wake after onset to poor validity for sleep onset latency. 
Proinflammatory cytokines.  IL-6 is considered a key inflammatory response mediator 
(Hirano et al., 2005).  IL-6 is chosen as representative of an exemplary proinflammatory 
cytokine, as it is more dependable detected and evaluated than the other classic pro-inflammatory 
cytokines (TNF alpha and IL-1 beta) (Fernandez-Botran, 2010).  These cytokines are 
multifunctional components of the pro-inflammatory response that are absent under normal 
circumstances but produced at enhanced levels as a result of environmental and psychosocial 
stress. All samples were assessed in duplicate. Sensitivity is < 0.7 pg/ml for IL-6 and <3.9 pg/ml 
for TNF-alpha. Intra assay variability is <7 % for these cytokines.  Blood amount of 10 ml were 
collected by venipuncture and plasma were frozen to -20 degrees Celsius for batch analysis. 
Plasma cytokines were measured using an enzyme linked immunosorbent assay (ELISA). 
Depressive mood. Depressive mood was measured by the Center for Epidemiologic 
Studies Depression Scale (CES-D). This is a 20-item tool used to assess frequency and duration 
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of depressive symptoms. The CES-D has good construct validity in clinical and community 
samples, good test-retest reliability and internal consistency alpha of 0.86 (Radloff, 1977). The 
CES-D asks respondents to rate the frequency with which each symptom or feeling occurred 
during the previous 7 days. Item content is rated on a 4-point scale ranging from 0 (rarely or less 
than one day) to 3 (most or all of the time, 5-7 days), so that total scores range from 0 to 60. 
Higher scores indicate greater depression. A score >16 indicates risk for depression and a score 
of greater than 19 is used to assess clinically relevant depressive symptoms. 
Pain. The Brief Pain Inventory is a self-reporting/interview tool is used patients with pain 
from chronic diseases or conditions such as cancer, osteoarthritis and low back pain and to assess the 
severity of pain and the impact of pain on daily functions. It is used to severity of pain, impact of pain 
on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or 
the past week. It takes five minutes to complete the short form, used in this study. It can be used as 
measures of pain severity and pain interference and Cronbach alpha reliability ranges from 0.77 
to 0.91 (Cleeland et al., 1989). 
Quality of life.  The Quality of Life Index (QLI) developed by Ferrans and Powers was 
used in this study to measure quality of life in terms of satisfaction with life (Ferrans & Powers, 
1985). This tool consists of two parts.  The first part measures satisfaction in different aspects of 
life and the second part measures the importance of those same aspects. Scores are based on four 
categories including health and functioning, psychological/ spiritual, social and economic, and 
family (Ferrans, 1996; Ferrans & Powers, 1985; Ferrans & Powers, 1992; Ferrans, 1990; 
Warnecke, Ferrans, Johnson, & et al., 1996). 
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Social support. The Social Provisions Scale (SPS) assesses 6 relational provisions: 
attachment, social integration, reassurance of worth, reliable alliance, guidance,  and  nurturance 
(Cutrona, CE 1984). The degree to which social relationships currently support each provision is 
rated. Cronbach α for the SPS is reported to be 0.84, and the reliability  is reported to be 0.55 
(Russell, D. et al., 1984).  Subjective Social Status is defined as a person’s sense of place within 
a hierarchy, which does not always agree with objective status 
(http://www.macses.ucsf.edu/research/psychosocial/subjective.php).  
Of note, people who place themselves lower on the social ladder mount larger IL-6 
responses to the acute stress challenge, than those who place themselves higher on the ladder. 
The MacArthur Scale of Subjective Social Status were administered to capture the participant’s 
perception of their place on the social ladder, taking into account standing on multiple aspects of 
SES and social position. Respondents marked where they would place themselves on a ladder 
representing where people stand in the USA. 
Health behaviors.  Health behaviors can be altered by pain and, in turn, can influence 
the inflammatory and behavior responses to pain.  Health behaviors were considered as 
covariates and were include: smoking, alcohol & caffeine intake, physical activity and 
medication use.  (See Appendix for Health Assessment Survey.)  Physical activity items were 
adapted from the Kaiser Physical Activity Survey and address 4 domains of physical activity in 
women: household and care giving, occupational, sport and exercise, and active living habits 
{Ainsworth, 2000}.  Items to measure food habits were adapted from the Food Habits 
Questionnaire {Kristal, 1990}.  Use of prescription medications and supplements (vitamins, 
minerals, nutritionals, herbals, soy products, and naturopathic remedies) are also included in the 
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Health Assessment Survey. 
Analgesic use. To record the frequency and potency of use of analgesic medications, the 
participants were requested to log medications taken on a 4-point scale in terms of frequency of 
use and potency of analgesics. This were scored on a scale of 0 to 4 points (0 indicating no 
analgesic use, 1 indicating less than daily non-opioid analgesic use, 2 indicating daily non-opioid 
analgesic use, 3 indicating less than daily opioid use, and 4 indicating daily opioid use) (Esmer et 
al., 2010). Participants were asked to complete the instruments listed in Appendix A (Table 2). 
Table 2. Study Instruments 
 
 Sleep 
(PSQI) 
Depression 
(CES-D) 
Brief Pain 
Inventory (BPI) 
Brief Fatigue Inventory 
(BFI) 
Description 
 
Measures 
and patterns 
of sleep 
Assesses 
frequency 
and duration 
of depression 
symptoms 
Measures 
severity of pain 
and impact on 
daily functions 
Measures fatigue 
 
No of Items 7  20  9 9 
Method  Self-admin Self-admin Self - admin Self-admin 
Scoring 0-3 scale 
3 negative  
0-60,16 and 
above signs 
of depression 
No scoring 
algorithm. 
Worst pain can 
be used to 
measure pain 
severity 
0 -10 numeric rating scale 
where 0 is no fatigue or 
does not interfere and 10 
is bad fatigue or 
completely interferes with 
activity/ work. 
Reliability 
 
High 
reliability 
(internal) 
α=0.83 for 7 
components 
Good test–
retest 
reliability 
and internal 
consistency 
α=0.86 
Cronbach alpha 
0.77 to 0.91 
 
Validity High validity 
in cancer 
patients 
Good 
construct 
validity in 
clinic and 
commission 
samples 
 Excellent correlation with 
the fatigue component of 
the Function Assessment 
of Cancer Therapy (r = -
0.88) 
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 Discrepancies from the original data collection plan. A total of 69 participants were 
enrolled in the study and participated by providing data and blood samples. There were two ways 
that the sample of participants in the study differed from the planned sample. First, this final 
sample fell short of the planned sample size (N = 98), which was determined based on an a priori 
power analysis. A sample size of at least 98 participants would have ensured that this study had 
adequate power to accurately identify any significant effects. With a sample size that does not 
meet this minimum threshold, in this study there is a chance that with some of the analyses 
described throughout this section, that a true effect may be missed and instead the null 
hypothesis may erroneously be accepted (Schoenfeld, 1980).  
Second, this sample differed from the planned sample in terms of the age range of 
participants. The original study plan called for participants between the ages of 35 and 75 years. 
Several participants’ ages fell outside of this range, which allowed us to include more 
participants to get closer to the planned sample size (though we still fell short, as outlined 
above). Specifically, four participants were below the planned age of 35 (these participants 
reported their ages as 22, 24, 30, and 32) and 1 was above the planned maximum age of 75 (this 
participant reported his/her age as 77). The limitations that result from this study based on these 
discrepancies between the planned and actual sample size will be discussed further in the 
Discussion section. 
Study Limitations 
There are several potential study limitations.  First, a cross sectional study design does 
not permit a determination of causal relationships. However, a cross sectional study can identify 
associations and guide the development of future hypothesis testing (Cohen et al., 2007). The 
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second challenge is validity. Internal validity refers to the strength of the inferences from the 
study. In this study, internal validity might be compromised since there is no control group that is 
compared with the study participants. External validity is the extent to which the study can be 
generalized to a universal population across time, place and persons (Carlson & Morrison, 2009). 
In this study, the sample is small and participants are recruited from a single facility. This will 
limit the generalizability of the study results.  In addition, the proposed study will use convenient 
sampling, which increases the possibility of selection bias. It is also possible that those 
individuals with more intense pain or poorer quality of life may choose not to participate, further 
increasing the chance of selection bias (Heffner, 2011). 
A variety of potential confounders need to be considered in investigations of individuals 
with CLBP. Important factors include: age, gender, race, education, marital status, employment, 
SES, drug use (prescription, over-the-counter, illicit drug use), smoking, alcohol and caffeine 
intake, co-morbidities, (prior depression, and psychological disorders), and general health 
behavior (diet, exercise, BMI).  
Protection of Human Subjects 
IRB approval was obtained from the Loyola University Health System (LUHS). 
Extensive efforts were taken to protect data information and personal data of the study 
participants. Informed consent was being obtained from all study participants prior to study 
participation by the primary investigator. Study materials were is printed in English and at the 
fifth grade level of literacy.  
According to the Department of Health and Human Services, risk should be justified by 
anticipatory benefits to research subjects or society as stated in all research ethics codes. Benefits 
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are the advantages from participating in the study and minimal risk refers to the probability of 
injury or harm as a result of participating in the study can vary from minimal to significant 
(2012). In this study, participants encountered minimal risk.  This risk was primarily due to 
physical discomfort related to venipuncture, psychological or emotional distress resulting from 
sharing their personal information in relation to sleep disturbance, depression and chronic pain. 
Other potential risks included the loss of time due to travel time and loss of money. Further, 
some may interpret this as being observed in some manner. The participants were hence 
compensated for their time and travel expenses to the amount of $25 after completion of the 
study. Efforts were being taken to minimize injury caused by venipuncture.  
To protect participants against any potential risks, the investigator described in detail the 
study and the contents of the informed consent to the participants and then obtained consent. 
Participants were also being explained that they have the right to withdraw from the study at any 
time and their withdrawal will not affect the care provided to them otherwise.  
Although this study might not provide benefits to the participants, it was explained to 
participants that it was hoped that results from this study will help in identifying how various 
symptoms can affect chronic low back pain patients and therefore interventions can be looked in 
to provide better quality of care.  
Potential Risks 
Psychological Risks 
Completing the written instruments concerning psychological health may contribute to an 
increase in feelings of anxiety or depression. The CES-D wwas be used to screen for depressive 
symptoms. It is important to emphasize that the CES-D is a screening tool used in population 
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studies—it is not a diagnostic depression tool.  The recommended cutoff score for depression on 
the CES-D is 27.  Each participant’s score on the CES-D were evaluated prior to completion of 
the study appointment. If the participant scored 27 or greater on the CES-D, they were 
immediately notified of the score and encouraged to contact their primary care or mental health 
provider.  If the participant chooses, the study staff will contact the participant’s health care 
provider or, if they do not have a provider, the subject will be referred to Loyola University 
Mood Disorder Clinic.   Any participant expressing thoughts of harming their self or others will 
be followed up immediately by accompanying the participant to the Loyola University 
Emergency Department, or nearest Emergency Department, or calling 911 as appropriate.  
Blood Collection 
The collection of blood was performed by a registered nurse experienced in venipuncture. 
Efforts were made to make the participant comfortable during venipuncture and blood collection.   
Adverse Events 
No adverse events were noted. 
Confidentiality 
To maintain confidentiality and anonymity of study participants, unique code numbers 
were used for subject identification and the data files stored at Loyola University Chicago.  Paper 
copies of data (only with unique codes) were stored in compliance with Loyola University 
Chicago requirements, including but not limited to a locked file cabinet in a locked room 
specifically designated for data storage for this project.  The Master file of participant names and 
medical record numbers are stored only in a computerized encrypted file stored on a memory 
drive of a password protected computer that is located in a locked file cabinet within an office 
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having limited access.  Only study personnel, as appropriate, will have access to participant 
identification (i.e., for purposes of enrollment, follow-up, medical record review). 
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CHAPTER FOUR 
RESULTS 
Introduction 
 Research suggests that chronic lower back pain (CLBP) is the chief complaint of primary 
care patients and is the number one reason that physicians choose to consult with health care 
providers. The cost of treating CLBP for the 100 million adult Americans who suffer from this 
type of pain is $560 to $635 million annually(Gaskin & Richards, 2011). Given the high 
prevalence and societal cost of CLBP, it is important to identify potential psychosocial factors 
that may contribute to the pain experience. The overall objective of this study was to understand 
of the extent to which sleep disturbance, depressive mood, and inflammatory processes interact 
to influence not only the experience of pain but also the quality of life of individuals with CLPB. 
To accomplish this objective, latent class analysis was used to identify CLPB behavioral 
symptom clusters and as well to evaluate the interactive relationships among depression, sleep 
disturbance, and fatigue in these patients.  Further, the impact of inflammation on both pain and 
behavioral symptoms was explored. The following Aims and Hypotheses were addressed: 
Aim 1: To identify behavioral symptom clusters in individuals with CLBP. 
Hypothesis 1:  Behavioral symptom clusters will be identified in individuals with CLBP. 
Aim 2: To determine differences in pain experience (pain severity and interference) and 
quality of life among identified clusters. 
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Hypothesis 2: Pain experience and quality of life will differ among identified clusters. 
Aim 3: Determine differences in inflammatory biomarkers based on symptom clusters 
and pain experience. 
Hypothesis 3: Inflammation will differ with the pain experience, quality of life, and 
symptom cluster.  
Aim 4: Explore regression models to determine predictors of the pain experience and 
quality of life in individuals with CLBP. 
Sample Descriptive and Demographic Characteristics 
 The sixty-nine participants in this study ranged between ages 22 and 77 years, with a 
mean age of 55.8 years (standard deviation [SD] = 12.9 years) and a median age of 57.0. 
Eighteen participants were male (26.1%) and 51 were female (73.9%). Forty participants 
identified as Caucasian (58.0%), fourteen identified as Hispanic or Latino (20.3%), 11 identified 
as African American (15.9%), and 4 identified as Asian or Pacific Islander (5.8%). Participants 
were diagnosed with a range of etiologies for their back pain by their medical provider and 
confirmed through medical record, including lumbar radiculitis, lumbar stenosis, lumbar facet 
arthropathy, lumbar disc herniation, and unspecified back pain. Twenty-five participants (38.5%) 
identified additional pain in the neck or knee area as coexisting medical conditions per medical 
record. Table 3 summarizes sample demographic characteristics and back pain diagnoses. 
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Table 3. Demographic Characteristics of the Sample (N=69) 
Gender Frequency 
%(SD) 
Female 51 (73.9) 
Male 18 (26.1) 
                     Ethnicity  
Caucasian 40 (58) 
Hispanic/Latino 14 (20.3) 
African American 11 (15.9) 
Asian/ 
Pacific Islander 
4 (5.8) 
          Diagnosed Conditions  
Lumbar radiculitis/disc herniation 26 
Spinal stenosis/Lumbar 7 
Lumbar facet arthropathy 17 
Sacroiliac joint pain 5 
Unspecified back pain 14 
SD = Standard deviation. 
 Statistical analysis. Descriptive statistics for each of the study variables were computed 
(see Table 4) and assessed for normality and outliers. All variables were within expected ranges. 
The skewness and kurtosis values were normally distributed (-3 to 3), indicating no for 
transformation of these variables. Hence, parametric analyses were used to address study 
hypotheses. Analgesic use was recoded to a dichotomous variable where non-opioid use was 0 
and opioid use is 1.  
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Table 4. Descriptive Statistics for Study Variables  
 Sample Mean (SD) 
(N=69)                              
Cluster 1 Mean (SD) 
(N=34) 
Cluster 2 Mean (SD) 
(N=35) 
Average Hours Slept 6.32 (1.61) 5.43 (1.10) 7.70 (1.33) 
Sleep Disturbance (PSQI) 9.30 (4.49) 12.44 (2.32) 6.12 (2.79) 
Depressive (CESD) 18.29 (12.33) 26.15 (11.56) 11.52 (5.24) 
Fatigue (BFI) 5.68 (2.35) 6.76 (1.72) 4.34 (2.41) 
Quality of Life 19.21 (0.90) 18.72 (0.73) 19.66 (0.81) 
Inflammation (IL-6) 2.78 (1.87) 3.15 (2.17) 2.23 (1.21) 
Pain Severity (BPI) 5.90 (1.77) 6.10 (1.92) 5.29 (1.44) 
Pain Interference (BPI) 6.30 (2.23) 6.97 (1.87) 5.61 (2.57) 
Social Support (SPS) 2.55 (0.48) 2.62 (0.39) 2.43 (0.62) 
 Frequency (%) Frequency (%) Frequency (%) 
Analgesic Use 18 (26) 11 (32) 6 (17) 
Abbreviations: QoL⸺Quality of life, CES-D⸺Center for Epidemiology Studies Depression Scale, BPI-S⸺Brief Pain 
Inventory (Severity), BPI⸺Brief Pain Inventory (Interference), SPS⸺Social Provisions Scale, BFI⸺Brief Fatigue 
Inventory, PSQI⸺The Pittsburgh Sleep Quality Index, IL-6⸺Interleukin-6. 
 
 Preliminary results. Preliminary results revealed that based on established cut off 
scores, 67% of sample reported CESD > 16 (elevated risk for depression) and 85% of the sample 
reported PSQI > 5 (increased sleep disturbance) per Table 5. 
  
79 
 
 
Table 5. Bivariate Correlations Between All Study Variables 
 QoL CESD BPI-S BPI-I SPS BFI Analgesic IL6 Hours 
sleep 
CESD -.54
**
         
BPI-S -.11 .19        
BPI-I -.34
*
 .41
**
 .63
**
       
SPS .01 .05 .02 .02      
BFI -.41
**
 .47
**
 .47
**
 .69
**
 .06     
Analgesic -.35
*
 .35
**
 .40
**
 .40
**
 -.21 .37
**
    
IL6 -.11 .20 .34
**
 .27 -.05 .20 .1325   
Hours sleep .20 -.31
*
 -.29
*
 -.15 -.10 -.25 .05 -.20  
Sleep Dist.  -.23 .42
**
 .26
*
 .17 -.20 .38
**
 .21 .18 -.24 
 
*. Correlation is significant at the 0.05 level (2-tailed).  **. Correlation is significant at the 0.01 level (2-tailed).  
Abbreviations: QoL⸺Quality of life, CES-D⸺Center for Epidemiology Studies Depression Scale, BPI-S⸺Brief Pain 
Inventory (Severity), BPI-I⸺Brief Pain Inventory (Interference), SPS⸺Social Provisions Scale, BFI⸺Brief Fatigue 
Inventory, PSQI⸺The Pittsburgh Sleep Quality Index. 
 
As a part of the preliminary analyses, a correlation analysis was conducted, and Pearson’s 
correlation coefficients were examined between each pair of study variables. As shown in Table 
4, quality of life was negatively correlated with depressive mood (r = - 0.54, p = 0.01), pain 
interference (r = -.34, p = p = 0.05, fatigue (r = -41, p = 0.01), and analgesic use (r = -35, p = 
0.05). Depressive mood was significantly positively related to pain interference (r = .41, p = 
0.01), fatigue (r = .47, p = 0.01), analgesic use (r = .35, p = 0.01), and sleep disturbance (r = 
.42, p = 0.01) and negatively correlated with average amount of sleep per night (r = .31, p = 
0.01). Pain severity was positively related with pain interference (r = .63, p = 0.01, fatigue (r = 
.47, p = 0.01, analgesic use (r = .40, p = 0.01), inflammation (r = .34, p = 0.01), and sleep 
disturbance (r = .26, p = 0.05), and negatively related with average amount of sleep per night (r 
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= .29, p = 0.05). Pain interference was positively related to fatigue (r = .69, p = 0.01),  and 
analgesic use (r = .40, p = 0.01). Fatigue was positively related to sleep disturbances (r = .38, p = 
0.01) and analgesic use (r = .37, p = 0.01). IL-6 was positively correlated with sleep disturbances 
(r = .33, p = 0.01). These preliminary analyses provide support for the hypothesis that these 
variables are related. 
 Differences between clusters. A series of univariate analyses were conducted to 
determine whether there were any subgroup differences (age, gender, race/ethnicity, coexisting 
pain) in any of the main study variables. In this manner, the inclusion of demographic 
characteristics as covariates for the main study analysis was determined. Given that all study 
variables were continuous in nature, univariate analyses relied on a technique that tested for any 
significant mean difference in scores for each measure by subgroup.  
To test for gender differences, independent samples t-tests were conducted to determine 
if there were any significant differences in mean scores for males and females. Independent 
samples t-tests are appropriate for use when evaluating mean differences in continuous variables 
between two subgroups. Results indicated that there were no significant difference between male 
and female participants in quality of life (t(59) = 0.77, p = .45), depressive mood (t(59) = 0.73, p 
= .47), pain severity (t(59) = 1.21, p = .23), pain interference (t(59) = 0.89, p = .38), social 
support (t(59) = 0.61, p = .55), fatigue (t(59) = 1.00, p = .32), number of hours of sleep (t(59) = 
0.79, p = .43), sleep disturbance (t(59) = 1.35, p = .18), analgesic use (t(59) = 1.54, p = .13), or 
inflammation (t(59) = 0.89, p = .38). 
To examine whether age was significantly associated with any of these continuous study 
variables, correlation analyses were conducted and Pearson’s correlation coefficients (r) were 
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examined. Correlation analyses are appropriate for use when comparing the association between 
two continuous variables. In this study, age was a continuous variable and so were each of the 
study variables. Results of these correlation analyses indicated that age was not significantly 
associated with any of the study variables (r’s = -.18 - .14, p’s > .05). 
 To test for race/ethnicity differences in the study variables, analyses of variance 
(ANOVAs) were conducted to determine if there were any significant differences in mean scores 
based on race/ethnicity. ANOVA is appropriate for use when comparing mean scores between 
more than two groups – in this case, we compared mean scores between Caucasian, 
Hispanic/Latino, African American, and Asian/Pacific Islander participants. Results of these 
ANOVAs indicated that none of the study variables that differed significantly by racial/ethnic 
group. Other study variables were planned for inclusion as covariates in the main study analysis: 
social support and use of analgesics. Variables should only be included as covariates if they are 
found to be significantly associated with the outcomes of interest. In this case, preliminary 
analyses were conducted to examine whether these covariates were significantly associated with 
pain severity, pain interference, and quality of life, as these are the dependent variables in this 
study. Given that all these covariates and dependent variables are continuous in nature, bivariate 
correlation analyses were conducted, and Pearson’s r values were assessed to determine whether 
there was a significant association between each covariate-dependent variable pair. Table 2 
earlier in this section provides support for including analgesic use as a covariate in the main 
study analyses, given that this variable was significantly associated with all of the outcome 
variables (quality of life, pain severity, and pain interference). In contrast, social support was not 
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significantly associated with any of the outcome variables, so this variable was not included as a 
covariate in any of the main analyses.  
 Aim 1: To identify behavioral symptom clusters in individuals with CLBP.  To 
address this first aim and examine whether the first hypothesis – that behavioral symptom 
clusters would be identifiable in individuals with CLBP – a latent class analysis (LCA) was 
conducted using the mixture modeling technique within Mplus. First a two-class model was 
tested using the following variables: average amount of average amount of sleep per night, sleep 
disturbance, depressive mood, and fatigue. Results from this analysis (shown in Table 6) indicate 
that this two-class model provided a good fit for the data. Next, a three-class model was tested 
using the same variables with the same Mplus technique. This model also indicated a good fit for 
the data.  
Table 6. Results of the Two-Class Latent Class Analysis Model 
 HBS  LBS 
 Estimate S.E. p  Estimate S.E. p 
Average Nightly Sleep 5.43 0.18 <.001  7.7 0.27 <.001 
Sleep Disturbance 12.44 0.40 <.001  6.12 0.56 <.001 
Depressive Mood 26.15 1.98 <.001  11.52 1.05 <.001 
Fatigue 6.68 0.30 <.001  4.35 0.49 <.001 
 
To identify which of these models provided the better fit (two-class vs. three-class), a 
Vuong-Lo-Mendell-Rubin (VLMR) likelihood ratio test was conducted with the three-class 
model. This post hoc statistical test compares the model with K classes (in this case, three 
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classes) with a model with K-1 classes (two classes). A significant VLMR test is an indication 
that the current model provides a significantly better fit to a set of data than the model testing one 
less class. The results of this post hoc analysis indicated that the three-class model did not 
provide a significantly better fit over the two-class model (p = .41), therefore the two-class 
model was preferable and was used in all follow-up analyses for this study. 
Based on the findings from LCA and post hoc VLMR likelihood ratio test, a new cluster 
variable was created and each participant in the sample was assigned a ‘1’ or ‘2’ to represent 
which cluster they fell into based on their scores for the measures of average amount of sleep per 
night, sleep disturbance, depressive mood, and fatigue. Based on LCA two behavioral symptom 
clusters were identified, Class 1 or "High Behavioral Symptoms” (HBS) characterized by more 
depressive symptoms, more fatigue, fewer average hours of sleep per night, and more sleep 
disturbance than participants who were assigned to Class 2, or "Low Behavioral Symptoms” 
(LBS). Participants who were assigned to HBS or LBS. (Shown in Table 7 and Figure 4). 
Table 7. Relative Levels of Behavioral Symptoms  
Cluster Depressive 
Symptoms 
Fatigue Average 
Hours Sleep 
Sleep 
Disturbance 
IL-6 
HBS 
(n=34) 
↑ ↑ ↓ ↑ ↑ 
LBS 
(n=35) 
↓ ↓ ↑ ↓ ↓ 
 
Average latent class probabilities for most likely class membership by latent class assignment 
showed strong confidence in class assignment, with a 93.8% match for participants in HBS and a 
96.9% match for participants in LBS.  
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Figure 4. Means of scaled measures (z scores)  
  
The sample was split relatively evenly between these two clusters, with 34 participants in 
HBS (49.3%) and 35 participants in LBS (50.7%). No participants were excluded from 
assignment, making this a 100% match. Chi-square analyses were conducted to examine whether 
the gender or racial/ethnic breakdown of these groups was proportionally different. Participants 
in HBS were 74% female and 72% of participants in LBS were male; this difference was not 
significant (χ2 = 0.73, p = .39). Approximately 58% of each cluster identified as Caucasian, 20% 
as Hispanic/Latino, 15% as African American, and 5% as Asian/Pacific Islander; which by chi-
square test was not significant (χ2 = 0.25, p = .62). An independent samples t-test was conducted 
to examine whether the mean age of participants in each cluster was significantly different. The 
mean age of participants in HBS was 54.12 years and the mean age of those in LBS was 56.76 
years. This difference was not statistically significant (t = 0.72, p = .47) (Table 8). 
85 
 
 
Table 8. Demographic Characteristics by Cluster Membership 
Cluster Male Female Caucasian Hispanic African 
American 
Asian/Pacific 
Islander 
Age 
HBS 74% 72% 58%                 20%              15%             5% 54.12 
LBS 26% 28% 56.76 
 χ2 = 0.73, p = .39                            χ2 = 0.25, p = .62 t = 0.72, 
p = .47 
 
Aim 2: To determine differences in the pain experience (pain severity and 
interference) and quality of life among identified clusters. To address this second aim and 
examine whether the second hypothesis – that there would be differences in the pain experience 
and quality of life among identified clusters – a series of univariate general linear models were 
run (one model for each dependent variable). Cluster was the categorical independent variable, 
the three continuous dependent variables were quality of life, pain severity, and pain 
interference.   
The first model examined quality of life. Participants in HBS reported lower quality of 
life scores than participants in LBS (Means = 115.8 vs. 140.9). This difference was significant (F 
(1,57) = 8.38, p < .05, η2 = .16). The second model examined pain severity. Participants in HBS 
reported higher pain severity than those in LBS (Means = 6.10 vs. 5.29). This difference was not 
significant (F (1,57) = 3.11, p = 0.08, η2 = .06). The third model examined pain interference, and 
again, participants in HBS reported higher pain interference than those in LBS (means = 6.67 vs. 
5.61). This difference was  significant (F (1,57) = 4.68, p = 0.04, η2 = 0.10). The statistical 
results of these analyses are presented in Table 9. 
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Table 9. Analysis Results for HBS and LBS 
 Sum of Squares df Mean Square F p η2 
Quality of Life 13.37 1 13.37 22.476 0.00001 0.38 
Pain Severity 9.30 1 9.30 3.11 0.08 0.06 
Pain Interference 22.75 1 22.75 4.68 0.04 0.10 
 
 Aim 3: Determine differences in inflammatory biomarkers based on symptom 
clusters and pain experience. A univariate general model was used to address the third aim and 
to examine whether the third hypothesis – that there would be differences in inflammatory 
biomarkers based on symptom cluster– was supported. In this model, inflammation was entered 
as the continuous dependent variable, cluster was entered as the categorical independent variable, 
and BMI was entered as continuous covariates. This time, analgesic use was not included as a 
covariate, as earlier correlation analyses did not identify a significant association between 
analgesic use and inflammation. Participants in LBS had trend towards significantly lower 
inflammation levels than participants in HBS when controlling for BMI (F (1, 66) = 3.38, p = 
.07, η2 = .06).  
Table 10. Differences in IL-6 Between Clusters 
 Sum of Squares df Mean Square F p η2 
Cluster 11.26 1 11.26 3.38 0.07 0.06 
BMI 5.80 1 5.80 1.74 0.19 0.03 
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Exploratory models were evaluated to predict quality of life, pain severity, and pain interference 
by group; IL-6, and group by IL-6 interaction while controlling for BMI. Findings revealed that 
LBS has marginally significantly higher quality of life compared to HBS, even controlling for 
the interaction between IL-6 and Cluster membership. This model also shows that IL-6 is related 
to QoL when controlling for cluster and that the relationship between IL-6 and QoL differs by 
cluster. The model predicting pain severity changed substantially with the inclusion of the cluster 
by IL-6 interaction. Here, the findings showed that LBS had lower pain severity (t (49)= -2.61, p 
= 0.01) and that the relationship between pain severity and IL-6 was significantly higher in LBS 
compared with HBS (t (49) = 2.61, p = 0.01). The results for pain interference were effectively 
unchanged; pain interference was not significantly related to any of the independent variables (ps 
> .011). These results appear in Table 11. 
Figure 5. Interaction effects of IL-6 between pain severity, interference, and quality of life 
among identified clusters  
 
 
88 
 
 
Table 11. Differences in the Pain Sseverity, Interference, and Quality of Life Among Clusters  
 
 B S.E. β t p 
QoL      
Intercept 55.97 24.10 - 2.01 0.05 
Cluster 2 53.75 16.82 0.52 1.80 0.08 
IL6 14.99 7.64 0.82 1.96 0.05 
BMI 0.003 0.02 0.03 0.13 0.89 
Cluster 2:IL6 -12.97 6.23 -0.71 2.083 0.04 
Pain Severity      
Intercept 17.29 2.67 - 6.47 0.81 
Cluster 2 -4.53 1.89 0.03 -2.40 0.02 
IL6 -1.59 0.85 -0.79 -1.87 0.07 
BMI -0.003 0.002 -0.26 -1.66 0.10 
Cluster 2:IL6 1.68 0.69 0.84 2.43 0.02 
Pain 
Interference 
     
Intercept 72.87 17.53 - 4.16 0.00 
Cluster 2 -20.06 12.38 -0.33 -1.62 0.11 
IL6 -2.48 5.61 -0.19 -0.44 0.66 
BMI 0.004 0.01 0.04 0.28 0.78 
Cluster 2:IL6 4.33 4.55 0.34 0.95 0.35 
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Aim 4: To explore regression models to determine predictors of behavioral clusters 
and quality of life in individuals with CLBP. To address Aim 4, which was exploratory in 
nature and therefore was not paired with a hypothesis, two regression models were conducted, 
which examined whether specific behavioral factors and inflammation (IL-6 levels) are 
predictive of the behavioral clusters or quality of life identified by LCA.  
In the first model, which was a logistic regression model, analgesic use, BMI, and IL-6 
levels were included as the continuous independent variables and the LCA-based behavioral 
cluster (HBS or LBS) was entered as the categorical dependent variable. The results of this 
analysis suggested that only IL-6 predicted Cluster membership  (t (45) =2.02, p = .04), such that 
higher IL-6 levels predict a higher probability of belonging to HBS (see results in Table 12). 
Table 12. Predictor of Clusters 
 B S.E. Wald df p Odds Ratio 
(Intercept) 1.21 0.73 1.65 1 0.10 3.34 
Analgesic -0.96 0.72 -1.34 1 0.18 0.38 
IL6 -0.57 0.28 -2.02 1 0.04 0.57 
BMI 0.002 0.001 1.93 1 0.05 1.002 
 
In the second model, which was a linear regression model, analgesic use, BMI, and IL-6 
levels were included as the continuous independent variables and quality of life was entered as 
the continuous dependent variable. This model indicated that analgesic use significantly 
predicted quality of life, such that great analgesic use was related to lower quality of life. In 
contrast, neither inflammation (IL-6) nor BMI predicted quality of life. 
90 
 
 
Table 13. Predictor of Quality of Life 
 B S.E. β t p 
(Intercept) 139.94 8.13 -- 17.22 0.00 
Analgesic -21.44 10.10 -.34 -2.12 0.04 
IL6 -1.62 2.41 -.04 -0.67 0.51 
BMI 0.02 0.02 .14 0.71 0.48 
 
Summary 
 This study examined whether sleep disturbance, depressive mood, fatigue, and 
inflammation interact to impact the experience of pain and quality of life among patients 
suffering from CLBP. Table 14 shows the study aims and hypotheses and addresses whether 
support was identified for each hypothesis or whether the null hypothesis was accepted.  
Table 14. Summary of Study Findings 
 Aim Hypothesis Finding 
1 To identify behavioral 
symptom clusters in 
individuals with CLBP 
 
Behavioral symptom 
clusters will be identifiable 
in individuals with CLBP 
Fully  
supported 
2 To determine differences in 
the pain experience (pain 
severity and interference) and 
quality of life among 
identified clusters 
 
There will be differences in 
the pain experience and 
quality of life among 
identified clusters 
Partially  
supported 
3 Determine differences in 
inflammatory biomarkers 
based on symptom clusters  
 
There will be differences in 
inflammatory biomarkers 
based on symptom clusters 
Partially 
supported 
4 Explore regression models to 
determine predictors of 
behavioral symptom clusters 
and quality of life in 
individuals with CLBP 
Behavioral and 
inflammatory predictors will 
be related to clusters 
identified and quality of life 
Partially  
supported 
91 
 
 
Regarding Aim 1, the latent class analysis that was conducted identified two distinct 
classes of study participants. Participants in HBS reported less sleep on average per night, more 
sleep disturbance, more depressive moods, and more fatigue compared to participants in LBS. 2. 
Regarding Aim 2, univariate general linear models found that there was a significant difference 
in quality of life and pain interference between the two cluster of participants, with those in HBS 
reported experiencinglower  quality of life and pain interference than those in LBS. There was no 
significant difference, however, in pain severity between the two clusters of participants. 
Regarding Aim 3, there was no significant difference in inflammatory biomarkers (IL-6) 
between the two clusters when controlling for BMI. Finally, regarding Aim 4, in which 
exploratory regression analyses examined whether behavioral factors and inflammatory levels 
predicted behavioral profile and quality of life, inflammation levels predicted behavioral cluster 
membership and analgesic use predicted quality of life. 
Overall the findings of this study provide important contributions to the understanding of 
the differential effects that CLBP can have on patient’s quality of life and pain experience, based 
on other factors, including sleep disturbance, depressive mood, fatigue, and inflammation levels. 
In the next section, these results are summarized and paired with a discussion of the implications 
associated with the findings from this study. In addition, strengths of this study, limitations to the 
generalizability of the findings will be discussed, considering the reduced sample size that was 
utilized based on difficulties with participant recruitment. Finally, the next section will end with 
a conclusion that suggests future directions for research that may build off this study’s findings 
and will discuss this research team’s future work in this area. 
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CHAPTER FIVE: DISCUSSION 
SUMMARY OF FINDINGS 
Introduction 
The overall purpose of this study was to identify behavioral symptom clusters (i.e., based 
on measures of  sleep disturbance, depressive mood, and fatigue) and to determine the 
relationship among identified clusters, inflammation (i.e., plasma IL-6), pain and quality of life 
in patients with CLBP. LCA revealed a two-class model. Participants in Class 1 characterized by 
High Behavioral Symptoms (HBS) had more depressive mood, fatigue, and sleep disturbance 
(including less sleep per night) compared to participants in Class 2 characterized by Low 
behavioral Symptoms (LBS). Univariate general linear models revealed HBS participants 
reported worse QOL than those in LBS. Pain severity was not significantly different between the 
classes,  but pain interference was significantly different. (though exploratory analysis suggested 
this may be due to a moderating effect of IL-6 on pain severity). Levels of IL-6 (controlling for 
BMI) were trending towards significantly greater in HBS participants, compared to LBS, with 
higher levels of IL-6 correlating with greater pain severity and more sleep disturbance. Further, 
logistic regression analysis revealed higher levels of IL-6 predicted HBS membership.  To the 
author’s knowledge, these findings are the first to evaluate behavioral symptom clusters with 
respect to inflammation, pain, and quality of life.  
These findings suggest that behavioral symptom clusters in those with CLBP contribute 
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to worse QOL. Moreover, inflammation contributes to the complex relationship between 
behavioral symptoms and pain severity. Clinical recognition of behavioral symptom clusters can 
foster more comprehensive pain assessment and tailored interventions for CLBP patients. The 
following will discuss these findings in comparison to similar studies evaluating depressive 
mood, sleep disturbance, fatigue and inflammation on the pain experience and QoL of those with 
CLBP.  Clinical implications are identified and future directions for research are derived.  
CLBP, Depression and Inflammation 
Depression is commonly associated with chronic back pain and can also be a risk factor 
for both low back pain and sciatica (Parreira P et al., 2018). In our study, depressive mood was 
measured using the CES-D, a tool designed to screen populations for risk for depression 
(Radloff, L. S. et al., 1977) and revealed a mean depression scores of 21, with 67% of the sample 
reporting CES-D scores that were above the cut score (i.e., >16), indicating risk for depression.  
Poleshuck et al reported a mean CES-D score of 29.3 for persons with CLBP (Poleshuck 
et al., 2013). In comparison, our study showed lower mean depression scores (21) but still above 
the cut-score of 16. Systematic reviews (Howren et al., 2009; Pinheiro et al., 2016) confirm the 
high prevalence of depressive mood in persons with acute and chronic back pain.  For example, 
among seventeen articles reviewed, eleven reported depressive symptoms at baseline related to 
worse low back pain outcomes (presence of CLBP, medical care seeking associated with CLBP, 
and activity-limiting CLBP) in follow-up. All studies regardless of statistical significance 
showed that there was a positive relationship between depressive symptoms and low back pain 
(Pinheiro et al., 2015).   
Depression can also affect functionality of persons with CLBP.  For example, depression 
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is a significant mediator of the relationship between pain and self-perceived disability in people 
with CLBP (Marshall et al., 2017), emphasizing the importance of addressing symptoms of 
depression in those with CLBP.  Further, persons with CLBP who had both anxiety and 
depression had higher pain severity, and higher pain-related disability. Further, the interaction 
between anxiety and depression predicted changes in pain interference at one-year follow up 
(Oliviera et al., 2018).  The present study found that those reporting greater depressive mood had 
poorer QOL, greater pain interference with activities, more fatigue, sleep disturbance, fewer 
hours of sleep per night, and greater analgesic use. Of note, acute back pain may differ from 
chronic back pain, as a recent study found that depression in persons with acute back pain was 
not significantly associated with perceived disability (Salt, E et al., 2018).  These findings 
suggest that duration of back pain influences the extent to which depressive symptoms modify 
pain perception, as well as perception of disability.  
Inflammation is a common pathway linking depression and pain. For example, persons 
with major depression exhibit increased serum and/or plasma concentrations of IL-6 (Alesci et 
al., 2005; Sluzewska et al., 1995), and this may potentiate pain particularly in pain conditions 
involving inflammatory proceses. In another study, higher IL-6 levels have been associated with 
both greater pain and greater chronic medical comorbidity in patients with greater depressive 
symptoms; whereas, IL-6 was unrelated to pain among patients without clinically 
significant depressive symptoms (Poleshuck et al. 2013).  Hence, the authors concluded that 
depression may increase vulnerability to pain, perhaps through elevated levels of inflammatory 
markers, such as IL-6. Findings from our study, revealed that IL-6 predicted cluster membership, 
such that higher IL-6 levels predict a higher probability of belonging to HBS.  
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Klyne et al., evaluated circulating pro-inflammatory cytokines and C-reactive protein 
(CRP) to explore the relationship of these inflammatory markers with pain severity and other 
symptomss in acute low back pain (LBP).  That study enrolled ninety-nine individuals who were 
evaluated within two weeks of onset of acute LBP and compared to fifty-five pain-free controls. 
Findings revealed that CRP was higher in LBP patients compared to controls and in those with 
high- than low-pain. In addition, IL-6 was higher in those with high than low-pain (p<0.05), but 
not compared to controls. The investigators concluded that systemic CRP and IL-6 are important 
contributors to inflammation in the early post-onset phase of LBP and that various factors such 
as sleep quality and psychological status can shape these responses (Klyne etal., 2017). Similar 
to this study, our study participants with HBS were trending towards significantly higher IL-6 
levels than participants in the LBS cluster when controlling for BMI. Although participants had 
chronic but not acute back pain, there is a similarity in the findings with respect to behavioral 
symptoms and sleep associating with the pro-inflammatory cytokines. 
CLBP, Fatigue and Inflammation      
Findings from several studies demonstrate that fatigue is prevalent and problematic for 
individuals with CLBP, and that a complex relationship exists among fatigue, depression, and 
other symptoms common in those with CLBP (De Rooij et al., 2014; Fishbain et al., 2004; 
Starkweather 2013; Snekkevik et al., 2014).  For instance, De Rooij et al. prospectively 
evaluated 120 chronic widespread pain patients (CWP), participating in a multidisciplinary 
rehabilitation treatment. The results revealed that higher levels of pain, interference of pain, 
depression, and negative emotional cognitions, were associated with a higher level of fatigue; 
while improvement in depression was related to improvement in fatigue (De Rooij et al., 2014).  
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The present findings confirm the findings of this group, as persons with an HPS profile reported 
increased sleep disturbance, increased fatigue, and more pain severity, pain interference, and 
fatigue scores. Starkweather et al (2013), in a study of individuals with persistent radiculopathy, 
showed relationships among fatigue, pain, psychosocial factors, and selected biologic markers of 
immune activation, IL-6 and soluble IL-6 receptor (sIL-6R). Specifically, findings from that 
study revealed that individuals with moderate to high fatigue levels had greater psychological 
distress, depressive symptoms, IL-6 and sIL-6R, compared to those with low levels of fatigue.  
The present study links fatigue to not only more intense behavioral symptoms, but also 
higher levels of IL-6. Findings revealed that those with greater fatigue had worse QOL, more 
depressed mood, more sleep disturbance, increased pain severitiy and greater pain interference. 
Additionally, fatigue was also significantly positively associated with sleep disturbances and 
analgesic use.   
Differences in instruments used to measure fatigue across studies, makes it difficult to 
compare levels of fatigue. In this study, fatigue was measured using the BFI, a tool used to 
measure fatigue in cancer populations.  In another study, Starkweather assessed fatigue in 
patients with persistent radiculopathy using the Profile of Mood States Fatigue/Inertia (POMS-
F/I), a seven-item subscale that contains seven adjectives suggesting weariness, inertia, and low 
energy level and identified fatigue to be significantly correlated with psychologic distress, 
depressive symptoms, IL-6, and sIL-6R (Starkweather 2013).  However, the level of fatigue was 
not correlated with pain intensity (Starkweather 2013), which is similar to that of other studies 
(Snekkevik et al., 2014; Fishbain et al., 2004; Fishbain et al., 2005). 
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CLBP, Sleep and Inflammation 
Indiviudals suffering from CLBP report increased duration of sleep onset, reduced total 
sleep time, and lower sleep efficiency (Kelly et al., 2011), consistent with our findings. Using the 
PSQI we demonstrated that 85% of the sample reported PSQI > 5 (over the established cut-score, 
indicating sleep disturbance), and that greater sleep disturbance was associated with greater pain 
severity and pain interference, and, not surprisingly, greater daytime fatigue.  Also, those 
individuals who reported more sleep disturbance and also used more analgesics. On the other 
hand, those who reported more social support had better sleep quality. IL-6 was positively 
correlated with sleep disturbance. Further, participants with HBS reported less sleep on average 
per night and more sleep disturbance, compared to those with LBS.  
Several studies have evaluated sleep quality and its influence on facilitating and/or 
exacerbating pain through elevations of pro-inflammatory cytokines, like IL-6. Similar to the 
present results, reductions in sleep quality and quantity have each been associated with higher 
daytime circulating levels of IL-6 (Heffner et al., 2012). Recent meta-analysis concluded that 
sleep deprivation is accompanied by increases in systemic inflammation (Irwin et al, 2015) and 
systemic inflammation has been found to decrease pain threshold in humans who are sleep 
deprived (De Godin et al, 2013). In another study, patients with temporomandibular pain 
disorders (40 females) who were classified as having high disability (Graded Chronic Pain Scale) 
also had the highest PSQI.  Moreover, plasma levels of IL-1β, IL-6, IL-10, and TNF-α were 
significantly increased in the high-disability group. Further, the plasma cytokine levels were 
significantly correlated with increased sleepiness (Epworth Sleepiness Scale) and PSQI scores 
suggestive of sleep disturbance (Park, J. W., & Chung, J. W, 2016). While conclusive data is still 
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limited for human subjects, the findings of this study are consistent with the above studies in that 
greater sleep disturbance associated with greater levels of IL-6. 
Recent findings suggest the possibility of aberrant glial activation in the establishment 
and/or maintenance of central sensitization to pain. Nijs et al. reviewed preclinical 
neurobiochemistry of animals and found high levels of BDNF, IL-1β, TNF-α increase the 
excitability of the central nervous system neurons.  The authors discussed the possibility that 
glial activity in chronic pain may have been triggered by severe stress exposure, and/or sleeping 
disturbances, each of which are established initiating factors for chronic pain development (Nijs 
et al.,2017). Results from this study also indicate the potential for sleep disturbance, as a 
behavioral factor, to contribute to increased inflammatory cytokine levels. Thus, investigation of 
the relationship of behavioral symptoms and glial activation is warranted.  
Symptom Clusters and Chronic Illness  
Findings from this study revealed two distinct behavioral symptom clusters, named HBS 
and LBS. Participants in HBS reported less sleep on average per night, more sleep disturbance, 
more depressive mood, and more fatigue compared to participants in LBS. There was a 
significant difference in pain interference and quality of life between the two participant Classes, 
with those in LBS experiencing a significantly higher quality of life than those in HBS. Although 
there was no significant difference, in pain severity  there was a trend towards higher levels of 
circutlating IL-6 in HBS compared to LBS, when controlling for BMI. Further, inflammation 
levels predicted behavioral Class membership. Only a handful of studies have examined 
symptom clusters in individuals with CLBP. One such study identified three clusters of 
symptoms in a cohort of patients with chronic low back pain (n=294).  These clusters were 
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derived from multiple psychological questionnaires, with cluster 3 exhibiting the highest scores   
across cognitive (eg, kinesiophobia, pain catastrophizing, endurance behaviors, low acceptance, 
low pain self-efficacy) and higher scores in affective factors (e.g., depressed mood, anxiety, 
stress) and significantly greater lumbar pressure pain sensitivity, more undiagnosed comorbid 
symptoms, and more widespread pain than other clusters (Rabey et al.,2016).  Although the 
present study only identified two behavioral symptom clusters, it is possible that other cluster 
phenotypes might be identified when a greater range of symptoms are measured.  Nevertheless, 
the findings from the present study add to the emerging work regarding symptom clusters in 
CLBP, and whether unique clusters predict worse pain and/or QOL. 
There is a more robust litertature describing symptom clusters in other patient 
populations, such as patients with heart failure and cancer. In heart failure patients, two domains 
of  symptom clusters have been identified, clusters of physical symptoms (fatigue, pain, 
drowsiness, nausea and reduced appetite) and clusters of emotional/cognitive symptoms (anxiety, 
and depression). Unlike the present study, studies of heart failure patients have not included 
sleep disturbance in cluster analysis, nor has this area of symptom cluster research included the 
relationship of clusters to inflammatory cytokines.   
Other studies have focused on spinal cord injury (SCI) patients, in an attempt to 
understand chronic pain and its effect on functional ability and quality of life.  A cluster analysis 
study on SCI patients revealed 3 subgroups: (1) dysfunctional (34.6% of all participants), (2) 
interpersonally supported (33.0% of participants), and  (3) adaptive copers (32.4% of 
participants), based on pain severity, life interference, affective distress scores, life control, and 
activities scores (Widerstrom-Noga, Felix, Cruz-Almeida, & Turk, 2007). 
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The literature evaluating symptom clusters in cancer patients is very robust and quickly 
translated with impact on patient care. Researchers have even started looking at additional 
studies to test intervention designed to manage a specific cancer symptom cluster. Such studies 
have been conducted in cancer patients undergoing chemotherapy, as well as cancer survivors 
who had completed treatment. Harrington et al (2010) conducted a systematic review of studies 
(2000-2008) examining late and long-term effects of cancer treatment, and concluded that 
symptom burden in cancer survivorship was consistent in four cancers (prostate, breast, 
gynecological and colorectal), with the most common symptoms being depressive symptoms, 
pain, and fatigue. Dong et al. (2014) identified 33 studies that analyzed symptom clusters in 
cancer patients that used various statistical methods (principal component analysis, exploratory 
factor analysis, and hierarchical cluster analysis) to analyze symptom clusters. The four symptom 
clusters identified were: anxiety-depression, nausea-vomiting, nausea-appetite loss, and fatigue-
dyspnea-drowsiness-pain. In another  literature synthesis of 21 multinational studies (sample of 
4067 cancer patients), revealed that there was a discrete set of symptoms experienced by cancer 
patients receiving active treatment (Reilly et al., 2013). Ho et al (2015) in a longitudinal study 
examined the relationships among depression, fatigue and sleep disturbances in premenopausal 
breast cancer patients compared to postmenopausal women across three-time points. Results 
revealed that fatigue, depression and sleep disturbances manifest as a symptom cluster. These 
findings in cancer pateints closely mirrors the behavioral symptom clusters identified by the 
present study evaluating patients with CLBP.  
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Implications for Research, Practice, and Theory 
The findings from the present study identified two clusters of behavioral symptoms in 
patients with CLBP, with a cluster of high levels of symptoms associating with worse QOL. 
Moreover, higher IL-6 contributed to the complex relationship between behavioral symptoms 
and pain severity. Clinical recognition of behavioral symptom clusters can foster more 
comprehensive pain assessment and tailored interventions for CLBP patients.  The implications 
of this study on furthering nursing research, practice, theory and education are discussed below. 
Research    
An important area of research in low back pain is to investigate factors that contribute to 
the progression of acute pain to chronic pain. It is possible that unique symptom profiles may 
increase vulnerability for acute pain syndromes to become chronic. In contrast, reducing such 
symptoms and/or fostering health promoting activities, may counter such pain progression.  
Health promotion may include environmental and lifestyle (nutrition and physical activity) 
factors, which may reduce intensity of behavioral symptom and stem the progression of acute to 
chronic CLBP. Biological mechanisms that might underlie symptom clusters can also help to 
identify factors for transition of acute to chronic pain. There is a possibility that HBS cluster 
participants might have increased risk for acute pain persistence that becomes chronic pain. The 
findings from this study are a first step for examination of inflammatory markers as possible 
underlying mechanisms for symptom cluster profiles. The extent of other inflammatory 
processes that underlie the complex relationships among pain, depressive mood, and poor sleep 
if clarified can build the ability to help manage symptom clusters in CLBP patients. While IL-6 
was the only marker tested, further research could analyze other inflammatory markers that may 
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play a role in CLBP. Another direction of research would be to develop valid instruments to 
measure symptom clusters. Improved measurement tools can equip nurse scientists to better 
measure cluster of symptoms in CLBP patients and predict health outcomes.  
Behavioral symptom clusters may be reduced by complemetary approaches that target 
unique clusters or symptom phenotypes.  Emerging work suggests mindfulness or cognitive 
behavioral therapy may be beneficial for patients with CLBP.  For example, Day et al., 
conducted a pilot randomized trial to compare the feasibility, tolerability, acceptability, and 
effects of group-delivered mindfulness meditation (MM), cognitive therapy (CT), and 
mindfulness-based cognitive therapy (MBCT) for CLBP. For the (Intent- To – Treat) ITT 
sample, large improvements in post-treatment scores for pain interference, pain intensity, 
physical function, and depression were found, with no significant between-group differences. 
Analysis of the follow-up data, however, revealed that MBCT participants improved 
significantly more than MM participants on pain interference, physical function, and depression 
(Day et al., 2019).  Future studies that test mind-body interventions designed to target symptom 
clusters might prove to be a more efficient clinical approach that could be used to treat patients 
in outpatient or community settings.  
Practice 
Nurses are at the forefront in providing direct patient care. The role of nurses in care of 
CLBP patients is well documented. In addition to educating patients on prescribed medications, 
nurses assist patients in referral  to non-pharmacological modalities including cognitive 
behavioral approaches, acupuncture, yoga, meditation, and biofeedback. As noted above, such 
modalities may reduce emotional and behavioral responses to chronic pain conditions, and 
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improve quality of life. As a result, it is important to include assessment of a patient’s emotions 
and behavioral symptoms in addition to assessment of pain, and to prescribe complementary 
approaches to assist the patient in dealing with a chronic pain condition. 
Current trends in a comprehensive pain management program include a generic approach 
to identify risk. Using various symptom cluster profiles in CLBP patients can help nurses 
identify patients who might benefit more from one type of treatment option versus another. 
Additionally, the duration of the treatments can also be targeted based on the symptom profile. 
For example, if a patient reports increased sleep disturbance, and depression and underlying high 
levels of inflammation, a need for treatment with longer duration to target these symptoms might 
be beneficial versus a patient with a different profile. 
The metaparadigm of nursing focuses on the health, person and environment. 
Approaching symptoms as clusters brings to practice the essence of nursing where a patient is 
viewed as a person with coexisting symptoms versus the objective approach of focusing  only on 
pain. The identification of a cluster of behavioral symptoms that associate with poorer quality of 
life and which interact with inflammation as shown in this study, can serve as a first step to bring 
symptom cluster awareness to the forefront of clinical management of those with CLBP.  In the 
future, studies can evaluate the clinical impact of interventions that target clusters of symptoms 
to determine their efficacy and ablility to improve quality of life for those with CLBP.  
Further, nurses are taking a lead in identifying health promotion activities in various 
populations. One of the most significant area that nurses can help CLBP patients in practice 
might be to identify environmental and life style factors that might be contributing to their pain 
severity and poor quality of life. For instance, offering classes targeting nutrition, exercise and 
104 
 
 
early counseling to high risk patients might be a good beginning. Measures to assist in health 
promotion teaching activities can alleviate symptoms and might contribute to reducing opioid 
overdose and death, thereby increasing life expectancy. 
Theory 
 The philosophical underpinning of existentialism and the theory of TOUS were used to 
arrive at the conceptual model for the study. The model proposed interactive relationships among 
depressive mood, sleep quality, and fatigue; which through inflammation impacts the pain 
experience and quality of life of the person with CLBP which have been tested using regression 
model. For the future, the model can be further developed for use in the CLBP population after 
incorporating symptoms and any other variable that might fit in this model. The primary goal of 
the study was to determine whether symptom clusters are recognizable within the myriad of 
symptoms that the CLBP participants reported, which was verified and confirmed using LCA. It 
might be beneficial to create a theoretical model for symptom clusters in CLBP by nurse 
theorists that can be used to guide future research and education. 
Study Limitations 
Several study limitations were identified, including limitations related to the design, 
sample and confounding variables.  The following identifies limitations in each of those areas.  
Design. A cross sectional study design was used in this investigation, and although this 
design allows more rapid data collection, it has several limitations.  One limitation is that the 
data collected is limited to one point in time, which may not be representative.  Cross sectional 
studies provide only a ‘snapshot’ of the person’s situation, which will be affected by many 
individual and environmental factors; this may confound outcome measures.  Another limitation 
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is that a cross sectional design does not permit a determination of cause and effect. On the other 
hand, a cross sectional study can identify associations and generate hypotheses that can be tested 
in longitudinal studies (Cohen et al., 2007). Random sampling and random assignment, selecting 
samples from other populations conducted over longer periods of time can decrease the threat 
due to external validity. There is also the possibility of threat due to statistical regression 
(Heffner, 2011). This study used several instruments to measure study variables, and may have 
proved burdensome to some participants. External validity is the extent to which the study can be 
generalized to a universal population across time, place and persons (Carlson & Morrison, 2009). 
In this study only one pain clinic was used for recruitment. Study particpants were mostly 
women, above 50 years old and Caucasian; thus, generalizability to a more racially/ethnically 
and male population is limited. 
Sample. In this study, the small sample size limits the generalizability and the use of 
convenience sampling can increase possibility of selection bias. It is also possible that those 
individuals with more intense pain or poorer quality of life may choose not to participate, further 
increasing the chance of selection bias (Heffner, 2011). On the other hand, the sample was 
heterogeneous in terms of type and duration of pain. Etiology of pain ranged from lumbar 
radiculitis, lumbar stenosis, facet arthropathy to herniated disc. Some participants also had 
coexisting neck or knee pain. Due to a small sample size, some  significant relationships may not 
have been identified. Out of the 86 participants, six participants withdrew, and eleven 
participants had missing data, hence restricting the sample size to 69. Lack of time to complete 
the several questionnaires was one of the reasons given for incomplete data. Participants had to 
maintain daily sleep diary recordings for a week and complete several questionnaires. Some 
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participants indicated that the compensation provided for blood draw and the questionnaires was 
not adequate. Since this study did not have funding support, it limited the compensation offered 
to participants for their time. Future research can focus on identifying instruments that can 
measure symptom clusters more efficiently thereby reducing participant burden. 
Covariates. A variety of potential confounders need to be considered in investigations of 
individuals with CLBP. Important factors include: age, gender, race, education, marital status, 
employment, SES, drug use (prescription, over-the-counter, illicit drug use), smoking, alcohol 
and caffeine intake, co-morbidities, (prior depression, and psychological disorders), and general 
health behavior (diet, exercise, BMI). For purpose of the study some of these variables were 
controlled but due to extent of data collected, it was not possible to control for all confounders. 
Measures. The study used Actigraphy as objective measure for sleep. Data from 
Actigraphy was collected form only 20 participants in the study due to financial and time 
constraints, hence data collected were not used in data analysis. Future studies targeting 
objective measures of sleep can help quantify the hours of sleep even if the sleep quality might 
be difficult to correlate with any objective measure. The sleep diary and the PSQI were used to 
measure sleep and only PSQI used to analyze sleep disturbances. The data available from the 
sleep diary might also be examined for further research on sleep and its implications in CLBP. 
Future researchers can focus on measuring pain using a more multidimensional mesaure of the 
pain experience to better capture the full nature of pain. All data gathered in the study were self- 
reported except the inflammatory markers. Self-reported data can rarely be verified 
independently verified and can also carry potential bias. One way to identify congruency of data 
is the use of objective measures, for instance actigraph and/ or PSG. 
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Strengths of the Study 
The study was designed as a small cross sectional study, which provided results more 
quickly than a longitudinal design.  However, due to design limitations, it requires careful 
interpretation and confirmation of results in larger longitudinal studies (Hackshaw, A., 2008). 
Nevertheless, findings from this study can be used as a first step toward understanding how 
symptom clusters impact quality of life and the pain experience in CLBP. Additionally, the study 
might be a starting point to understand the role of inflammatory markers from a biological and 
behavioral perspective of symptoms. Another strength of the study is that it can guide the 
development and testing of new interventions to improve quality of life and health outcomes 
based on these results. Lastly, the study findings may enhance interest in the field of 
psychoneuroimmunology and lead to development and implementation of programs for early 
interventions with this group of patients. Ultimately the goal is to reduce pain, reduce analgesic 
use, and decrease behavioral symptoms (i.e., sleep disturbance, depression, and fatigue), all of 
which will improve QOL. 
Future Directions 
According to the strategic plan of NINR, the priorities for research in nursing include 
four areas of scientific focus: symptom science, wellness, self-management and end- of- life 
care. Promoting innovation and emphasizing innovative strategies for research careers have also 
been identified as cross- cutting areas to the advancement of nursing science (National Institute 
of Nursing Research, 2016). Under the profile of symptom science, NINR emphasizes the need 
to understand symptoms such as pain, fatigue and sleep disturbance. Further, understanding the 
biological and behavioral aspects of symptoms with the goal of developing and testing new 
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interventions to improve quality of life and health outcomes have been highlighted (National 
Institute of Nursing Research, 2016). This purpose and nature of the present study is clearly 
aligned with the research agenda set by NINR.  
Appraisal of CLBP not as a unitary symptom but as a constellation of several interacting 
symptoms is an important first step toward advancing quality of life in the CLBP population. 
This study aimed to determine if symptoms in CLBP presented as clusters, which can be a 
foundational step to assist future researchers to curtail the vicious cycle between various 
symptoms and pain from a different perspective. When symptoms are examined as clusters there 
might be a possibility of targeting individuals with unique interventions based on the symptom 
cluster profile. Overall the findings show that behavioral symptoms cluster in those with CLBP 
and worsen QOL. Inflammation contributes to the complex relationship between behavioral 
symptoms and pain severity. Clinical recognition of behavioral symptom clusters can foster more 
comprehensive pain assessment and tailored interventions for CLBP patients.   
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Demographic Information Form 
 
Sociodemographic Questionnaire  
 
The MacArthur Network on SES and Health has developed a sociodemographic questionnaire which is 
currently being used in a number of network sponsored projects. The instrument begins with subjective 
social status questions developed by the network; (see MacArthur Subjective Social Status Scale in the 
Psychosocial Notebook). The remaining questions assess educational attainment, occupational status, 
income and assets. Ideally, all questions would be used; if a subset must be selected, items 1, 2, 3, 4, 6b 
and 6c, 7 and 9 are recommended.  
 
Question 1 
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Question 2 
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Question 3. What is the highest grade )or year) of regular school you have complete? 
(Check one.) 
Check 
box 
Elementary  High 
School 
 College  Graduate School 
 01  09  13  17 
 02  10  14  18 
 03  11  15  19 
 04  12  16  20+ 
 05       
 06       
 07       
 08       
 
Question 4. What is the highest degree you earned? 
Check Box  
 High school diploma or equivalency (GED) 
 Associate Degree (Junior College 
 Bachelor’s Degree 
 Master’s Degree 
 Doctorate 
 Professional (MD,JD,DDS,etc) 
 Other (please specify) 
 None of the above (less than High School) 
  
Question 5. Which of the following best describes your current main daily activities and/or 
responsibilities? 
Check Box  
 Working full-time 
 Working part-time 
 Unemployed or laid off 
 Looking for work 
 Keeping house or raising children full-time 
 Retired 
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Question 6. With regard to your current or most recent job activity: 
 
In what kind of business or industry do (did) you work? 
(For example: hospital, newspaper publishing, mail order house, auto engine manufacturing, 
breakfast cereal manufacturing.) 
 
What kind of work do (did) you do? (Job Title) 
(For example: registered nurse, personnel manager, supervisor of order department, gasoline 
engine assembler, grinder operator.) 
 
How much did you earn, before taxes and other deductions, during the past 12 months? 
 
Check box  
 Less than $5,000 
 $5,000 through $11,999 
 $12,000 through $15,999 
 $16,000 through $24,999 
 $25,000 through $34,999 
 $35,000 through $49,999 
 $50,000 through $74,999 
 $75,000 through $99,999 
 $100,000 and greater 
 Don’t know 
 No response 
 
Question 7. How many people are currently living household, including yourself? 
 
 Number of people in household? 
 Of these people, how many are children? 
 Of these people, how many are adults? 
 Of the adults, how many bring income into household? 
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Question 8. Is the home where you live: 
 
Check 
Box 
 
 Owned or being bought by you (or someone in the household)? 
 Rented for money? 
 Occupied without payment of money or rent? 
 Other (specify) 
 
[Some might try to get a “market value” estimate of the value of owned homes and an estimate 
of how much principal was outstanding on the mortgage.] 
Question 9. Which of these categories best describe your total combined income for the 
past 12 months? 
This should include income (before taxes) form all sources, wages, rent from properties, 
social security, disability and or veteran’s benefits, unemployment benefits, workman’s 
compensation, help from relatives (including child payments and alimony), and so on. 
Check Box  
 Less than $5,000 
 $5,000 through $11,999 
 $12,000 through $15,999 
 $16,000 through $24,999 
 $25,000 through $34,999 
 $35,000 through $49,999 
 $50,000 through $74,999 
 $75,000 through $99,999 
 $100,000 or greater 
 Don’t know 
 No response 
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Question 10. If you lost all your current source(s) of household income(your paycheck, 
public assistance, or other forms of income), how long could you continue to live at your 
current address and standard of living.   
 
Check box  
 Less than 1 month 
 1 to 2 months 
 3 to 6 months 
 7 to 12 months 
 More than 1 year 
 
Question 11. Suppose you needed money quickly, and you cashed in all of your (and your 
spouse’s) checking and savings accounts, and any stocks and bonds.  If you added up what 
you would get, about how much would this amount to? 
 
Check box  
 Less than $500 
 $500 to $4,999 
 $5,000 to $9.999 
 $10,000 to $19,999 
 $20,000 to $49,999 
 $50,000 to $99,000 
 $100,000 to $199,999 
 $200,000 to $499,999 
 $500,000 and greater 
 Don’t know 
 No response 
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If you now subtracted out any debt that you have (credit card debt, unpaid loans including 
car loans, home mortgage), about how much would you have left? 
 
Check box  
 Less than $500 
 $500 to $4,999 
 $5,000 to $9.999 
 $10,000 to $19,999 
 $20,000 to $49,999 
 $50,000 to $99,000 
 $100,000 to $199,999 
 $200,000 to $499,999 
 $500,000 and greater 
 Don’t know 
 No response 
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DATA COLLECTION TOOLS: PAIN AND QUALITY OF LIFE TOOL
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Ferrans and Powers  
QUALITY OF LIFE INDEX 
 GENERIC VERSION - III 
PART 1. For each of the following, please choose the answer that best describes howsatisfied you are 
with that area of your life. Please mark your answer by circling the number. There are no right or wrong 
answers. HOW SATISFIED ARE YOU WITH: 
____________________________________________________________________________________ 
1. Your health? 1 2 3 4 5 6 
____________________________________________________________________________________ 
2. Your health care? 1 2 3 4 5 6 
____________________________________________________________________________________ 
3. The amount of pain that you have? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
4. The amount of energy you have for everyday activities? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
5. Your ability to take care of yourself without help? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
6. The amount of control you have over your life? 1 2 3 4 5 6 
____________________________________________________________________________________ 
7. Your chances of living as long as you would like? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
8. Your family’s health? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
9. Your children? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
10. Your family’s happiness? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
11. Your sex life? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
12. Your spouse, lover, or partner? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
13. Your friends? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
14. The emotional support you get from your family? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
15. The emotional support you get from people other than your family? 1 2 3 4 5 6 
____________________________________________________________________________________  
Page 2 HOW SATISFIED ARE YOU WITH: Very Dissatisfied Moderately Dissatisfied Slightly Dissatisfied 
Slightly Satisfied Moderately Satisfied Very Satisfied 
___________________________________________________________________________________ 
16. Your ability to take care of family responsibilities? 1 2 3 4 5 6 
___________________________________________________________________________________ 
17. How useful you are to others? 1 2 3 4 5 6 
___________________________________________________________________________________ 
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18. The amount of worries in your life? 1 2 3 4 5 6 
___________________________________________________________________________________ 
19. Your neighborhood? 1 2 3 4 5 6 
___________________________________________________________________________________ 
20. Your home, apartment, or place where you live? 1 2 3 4 5 6 
___________________________________________________________________________________ 
21. Your job (if employed)? 1 2 3 4 5 6 
___________________________________________________________________________________ 
22. Not having a job (if unemployed, retired, or disabled)? 1 2 3 4 5 6 
___________________________________________________________________________________ 
23. Your education? 1 2 3 4 5 6 
___________________________________________________________________________________ 
24. How well you can take care of your financial needs? 1 2 3 4 5 6 
___________________________________________________________________________________ 
25. The things you do for fun? 1 2 3 4 5 6 
___________________________________________________________________________________ 
26. Your chances for a happy future? 1 2 3 4 5 6 
___________________________________________________________________________________ 
27. Your peace of mind? 1 2 3 4 5 6 
___________________________________________________________________________________ 
28. Your faith in God? 1 2 3 4 5 6 
___________________________________________________________________________________ 
29. Your achievement of personal goals? 1 2 3 4 5 6 
___________________________________________________________________________________ 
30. Your happiness in general? 1 2 3 4 5 6 
___________________________________________________________________________________ 
31. Your life in general? 1 2 3 4 5 6 
___________________________________________________________________________________ 
32. Your personal appearance? 1 2 3 4 5 6 
___________________________________________________________________________________ 
33. Yourself in general? 1 2 3 4 5 6 
___________________________________________________________________________________  
PART 2. For each of the following, please choose the answer that best describes how important that 
area of your life is to you. Please mark your answer by circling the number. There are no right or wrong 
answers. HOW IMPORTANT TO YOU IS: 
_____________________________________________________________________________________ 
1. Your health? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
2. Your health care? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 3. Having no pain? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 4. Having enough energy for everyday activities? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 5. Taking care of yourself without help? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 6. Having control over your life? 1 2 3 4 5 6 
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_____________________________________________________________________________________
_ 7. Living as long as you would like? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 8. Your family’s health? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 9. Your children? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 10. Your family’s happiness? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 11. Your sex life? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 12. Your spouse, lover, or partner? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 13. Your friends? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 14. The emotional support you get from your family? 1 2 3 4 5 6 
_____________________________________________________________________________________
_ 15. The emotional support you get from people other than your family? 1 2 3 4 5 6 
_____________________________________________________________________________________ 
 Page 4 HOW IMPORTANT TO YOU IS: Very Unimportant Moderately Unimportant Slightly Unimportant 
Slightly Important Moderately Important Very Important 
_____________________________________________________________________________________
__ 16. Taking care of family responsibilities? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 17. Being useful to others? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 18. Having no worries? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 19. Your neighborhood? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 20. Your home, apartment, or place where you live? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 21. Your job (if employed)? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 22. Having a job (if unemployed, retired, or disabled)? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 23. Your education? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 24. Being able to take care of your financial needs? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 25. Doing things for fun? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 26. Having a happy future? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 27. Peace of mind? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 28. Your faith in God? 1 2 3 4 5 6 
121 
 
 
_____________________________________________________________________________________
__ 29. Achieving your personal goals? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 30. Your happiness in general? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 31. Being satisfied with life? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 32. Your personal appearance? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ 33. Are you to yourself? 1 2 3 4 5 6 
_____________________________________________________________________________________
__ © Copyright 1984 & 1998 Carol Estwing Ferrans and Marjorie J. Powers 
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Social Provisions Scale 
Instructions: Using the scale below, please circle the number after each statement that indicates 
how much each statement describes your situation.  If you feel a statement is VERY TRUE, you 
would circle STRONGLY AGREE.  If you feel a statement CLEARLY does not describe your 
relationships, you would answer STRONGLY DISAGREE. 
1=STRONGLY DISAGREE 
2= DISAGREE 
3= AGREE 
4=STRONGLY DISAGREE 
1 There are people I know who will help me if I really need it 1 2 3 4 
2 I do not have close relationships with others 1 2 3 4 
3 There is no one I can turn to in times of stress 1 2 3 4 
4 There are people who call on me to help them 1 2 3 4 
5 There are people who like the same social activities I do 1 2 3 4 
6 Other people do not think I am good at what I do 1 2 3 4 
7 I feel responsible for taking care of someone else 1 2 3 4 
8 I am with a group of people who think the same way I do about things 1 2 3 4 
9 I do not think that other people respect what I do 1 2 3 4 
10 If something went wrong, no one would help me 1 2 3 4 
11 I have close relationships that make me feel good 1 2 3 4 
12 I have someone to talk to about decisions in my life 1 2 3 4 
13 There are people who value my skills and abilities 1 2 3 4 
14 There is no one who have the same interested and concerns as me 1 2 3 4 
15 There is no one who needs me to take care of them 1 2 3 4 
16 I have a trustworthy person to turn to if I have problems 1 2 3 4 
17 I feel a strong emotional tie with at least one other person 1 2 3 4 
18 There is no one I can count on for help if I really need it 1 2 3 4 
19 There is no one I feel comfortable talking about problems with 1 2 3 4 
20 There are people who admire my talents and abilities 1 2 3 4 
21 I do not have a feeling of closeness with anyone 1 2 3 4 
22 There is no one who likes to do the things I do 1 2 3 4 
23 There are people I can count on in an emergency 1 2 3 4 
24 No one needs me to take care of them 1 2 3 4 
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Analgesics Use 
 
 
Dear Participant, 
Please circle the number that indicates use of analgesics in the past week. 
0 - No analgesic use  
1 - Less than daily non-opioid analgesic use 
2- Daily non-opioid analgesic use 
3- Less than daily opioid use 
4- Daily opioid use 
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ID: _________________ Start Date: _____/_____/______ 
Sleep Diary 
Please keep this booklet by your bed, and fill it out last thing at night and first 
thing in the morning everyday of this study protocol.  Please fill out the sheet 
marked BEDTIME just before you go to sleep at night.  Fill out the sheet marked 
WAKETIME the first thing the following morning.  We realize that estimates of 
time to falling asleep and time awake during the night are not going to be exact, 
just do the best you can. 
When filling out the Bedtime Diary, we would like to know about the 
exercise you did closest to your bedtime.  The table below contains 
examples of different exercise levels. 
Level of Exercise 
 
Light (walk) 
 Walking, shopping, light work 
at home, carrying light items. 
Medium (jog) 
 Jogging, heavy work at home, 
moderate exercise 
Heavy (run) 
 Running, tennis, stair climbing, 
strenuous exercise. 
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BEDTIME     
 
          Keep by Your  Bedside–Please fill this out LAST thing at night 
 
Today is:   Sun  M  T  W  Th  F  Sat Today’s date is: _____________ 
 
Today, I napped for a total of………………………………………. _______ minutes 
 
Today, I was ill (e.g., cold, fever, nausea)……………………………  1  =  Yes    2  =  No 
 
Today I exercised for a total of…………………………………………   _______minutes 
 
Today, the level of my exercise was  ……. 0  =  none    1  =  light    2  =  medium    3  =  
heavy 
     
 If you exercised, check the time you exercised? 
_____morning_____afternoon______evening     
 
You have told us what medications you take regularly.  Did you take any other 
medications today?       
 If so, what were those medications?  
_________________________________________________________________ 
______________________________________________________________________
____ 
 
 
 
Today, I took off my ActiWatch.         1  =  Yes     2  =  No  
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WAKETIME  
     
 
Keep by Your Bedside–Please fill this out FIRST thing in the morning 
 
Today is:   Sun  M  T  W  Th  F  Sat   Today’s date is: ____________ 
  Last night I got into bed at…    ____:____ AM    PM 
  I actually tried to go to sleep at…    ____:____ AM    PM 
  I think it took me about…    _________minutes to fall asleep 
  This morning I finally woke at…    ____:____ AM    PM 
 I actually got out of bed to start my day at…  ____:____ AM    PM 
  
Last night after I finally fell asleep, I remember waking up this many times during the 
night  
 (Circle one):      0  1 2 3 4 5        or            more 
Altogether, these awakenings lasted about ______ minutes.  
The overall quality of your night’s sleep:  (Circle one; 1=terrible, 9=great) 
  1 2 3 4 5 6 7 8 9 
 
 
Please circle the appropriate number to indicate how you feel this morning, after waking up. 
This morning I feel: not at all a little moderately quite a bit extremely 
    Rested 0 1 2 3 4 
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PROMIS Item Bank v1.0-Emotional Distress-Anxiety⸺Short Form 4a 
Emotional Distress-Anxiety – Short Form 4a 
Please respond to each question or statement by marking one box per row.  
In the past 7 days… Never Rarely Sometimes Often Always  
I felt fearful................................................  1  2  3  4  5  
I found it hard to focus on anything other than my anxiety......................  1  2  3  4  5  
My worries overwhelmed me.....................  1  2  3  4  5  
I felt uneasy ................................................  1  2  3  4  5  
 
2 June 2016 © 2008-2016 PROMIS Health Organization and PROMIS Cooperative Group Page 1 of 1 
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5/29/2017 PSQI Request Saravanan, 
Anitha 
https://outlook.luc.edu/owa/#viewmodel=ReadMessageItem&ItemID=AAMkADMyNDk3ZDhjLTNhYzUtNDhiMC05NmFkLWZjMzk5Z
GQ1NzY0MABGAAAAA… 1/2 
PSQI Request 
Sent on behalf of Dr. Buysse 
Dear Anitha, 
You have my permission to use the PSQI for your research study. You can find the 
instrument, scoring instructions, the original article, links to available translations, and 
other useful information at www.sleep.pi艘.edu under the Research/Instruments tab. 
Please ensure that the PSQI is accurately reproduced in any on‑line version (including 
copyright information). We request that you do cite the 1989 paper in any publications 
that result. Note that Question 10 is not used in scoring the PSQI. This question is for 
informational purposes only, and may be omi艘ed during data collection per 
requirements of the particular study. This copyright in this form is owned by the 
University of Pi艘sburgh and may be reprinted without charge only for 
non‑commercial research and educational purposes. You may not make changes or 
modifications of this form without prior wri艘en permission from the University of Pi艘
sburgh. If you would like to use this instrument for commercial purposes or for 
commercially sponsored research, please contact the Office of Technology Management 
at the University of Pi艘sburgh at 412‑648‑2206 for licensing information. 
Good luck with your research. 
Sincerely, 
Daniel J. Buysse, M.D. 
Professor of Psychiatry and Clinical and Translational Science 
University of Pi艘sburgh School of Medicine 
E‑1123 WPIC 
3811 OʹHara St. 
Pi艘sburgh, PA 15213 
T: (412) 246‑6413 
F: (412) 246‑5300 
buyssedj@upmc.edu 
This e‑mail may contain confidential information of UPMC or the University of Pi艘sburgh. Any unauthorized or improper 
disclosure, copying, 
distribution, or use of the contents of this e‑mail and a艘ached document(s) is prohibited. The information contained in this 
e‑mail and a艘ached 
Gasiorowski, Mary <GasiorowskiMJ@upmc.edu> 
Fri 5/26/2017 11:24 AM 
To:Saravanan, Anitha <asaravanan@luc.edu>;  
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HealthMeasures Terms of Use 
Definitions: 
• HealthMeasures: a resource encompassing four measurement systems: PROMIS®, NIH 
Toolbox®, Neuro-QoL, and ASCQ-MESM 
• Measurement System: a collection of health measurement instruments under one brand, 
such as PROMIS or NIH Toolbox 
• Provider: the Department of Medical Social Sciences at Northwestern University Feinberg 
School of Medicine 
• User: anyone who employs a HealthMeasures Measurement System or Instrument in a 
research, clinical, educational, or other setting 
• Publicly Available: HealthMeasures Instruments which are available for download at 
healthmeasures.net 
Thank you for your interest in HealthMeasures. Please read our Terms of Use carefully as we 
include information which applies universally to all of our measurement systems as well as 
information specific to individual measurement systems. 
You understand and agree that the Provider gives access to HealthMeasures Instruments (e.g., 
item banks, short forms, profile measures) subject to these Terms of Use. Provider reserves the 
right to update the Terms of Use at any time. Changes to the Terms of Use will apply to new 
users, new instruments, and to new projects created by existing users after these changes are 
posted. 
Use of HealthMeasures Measurement Systems, instruments, related materials, and services 
requires acceptance of all terms and conditions stated herein. You agree to abide by all of the 
HealthMeasures Terms of Use as a condition of using HealthMeasures. No modifications or 
additions to these Terms of Use are binding upon Provider unless previously agreed to in 
writing by an authorized representative of Provider. 
Single Use, Reproducibility, and Distribution 
• All HealthMeasures Instruments are copyrighted. All English and Spanish versions of PROMIS 
and Neuro-QoL and some NIH Toolbox self- and parent-proxy report instruments (NIH Toolbox 
Emotion and select Sensation) are publicly available for use without licensing or royalty fees for 
individual research or individual clinical use. Such use of HealthMeasures Measurement 
Systems and Instruments is “single use,” meaning solely for User’s research, clinical, 
educational, or other application. 
• User shall not reproduce HealthMeasures Instruments except as needed to conduct the 
authorized single use research, clinical, educational, or other activity. User shall not distribute, 
publish, sell, license, or provide HealthMeasures products, by any means whatsoever, to third 
parties not involved with the authorized single use as stated above, 
2 
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without the prior written agreement of the Provider. Users must request permission to reprint 
HealthMeasures Instruments for reasons not included in the single use case. 
• Commercial Users must seek permission to use, reproduce, or distribute any HealthMeasures 
Measurement Systems and Instruments, regardless of purpose, at all times. 
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• Users wishing to integrate instruments into proprietary technological systems, including in the 
Single Use case, must seek written approval. Proprietary technological systems include, but are 
not limited to, computerized adaptive tests, apps, and web portals used for data collection. 
Provider may incur costs in providing the permission to integrate, and those costs may be 
passed along to the User. 
• Users who secure license agreements to deliver HealthMeasures instruments through 
technological systems owned and supported by Provider do not need additional licenses to use 
the HealthMeasures instruments provided with the technological system to which User has 
been granted license. If the license agreement for the technology owned and supported by 
Provider includes reproduction and distribution rights, the license agreement itself is sufficient 
permission for reproduction and distribution and covers all requirements to seek permissions 
or consent required herein. 
• User agrees not to adapt, alter, amend, abridge, modify, condense, make derivative works, or 
translate HealthMeasures Instruments without prior written permission from the Provider. In 
cases where permission is granted, User will be expected to evaluate the impact of approved 
modifications. 
• User agrees and undertakes not to sell or incorporate HealthMeasures Measurement Systems 
and Instruments into materials that could be sold without prior written consent from the 
Provider. 
• To inquire about permissions, email help@healthmeasures.net. 
Indemnification 
• User agrees and undertakes to indemnify and hold Provider harmless against any and all 
claims, loss or damage, including fees, penalties or fines and third party claims, and attorneys’ 
fees arising from User’s use of any HealthMeasures Measurement System or Instrument. 
Further, User shall be obliged to indemnify, defend and/or hold harmless Provider and its 
agents, trustees, officers, medical affiliates, employees, and their respective successors, heirs, 
and assignees against any liability, damage, loss or expense incurred in connection with User’s 
use of any HealthMeasures Measurement System or Instrument. 
• Consent to User’s use of HealthMeasures Measurement System or Instrument is given ‘AS IS’, 
without any accompanying services or improvements. Provider does not accept any liability 
resulting from User’s use of any HealthMeasures Measurement System or Instrument. All 
HealthMeasures Measurement Systems and Instruments are supplied to User with no 
warranties or representations of any kind as to the accuracy, currency, or the 
3 
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merchantability or fitness of the HealthMeasures Measurement Systems or Instruments for a 
particular purpose. 
• Neither Provider nor any party involved in creating, producing, or delivering any 
HealthMeasures Measurement System or Instrument shall be liable for any damages, including 
without limitation, direct, incidental, consequential, indirect, or punitive damages arising out of 
access to, use of, alterations of, or inability to use any HealthMeasures Measurement System or 
Instrument, or any errors or omissions in the content thereof. 
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Trademarks 
• User will include Provider’s trademark ownership statement on all printed copies of any 
HealthMeasures Measurement System or Instrument in the same form as it appears on the 
document that User is downloading from this website. 
• User agrees and undertakes not to remove the trademark notices which appear on any 
printed HealthMeasures Measurement System or Instrument. Use of HealthMeasures 
Measurement Systems and Instruments does not and will not create any right, title or interest 
thereof for User, other than the right to use HealthMeasures Measurement Systems and 
Instruments under these Terms of Use. 
Publications and Presentations 
• Any publication or presentation created from research, clinical, educational, or other 
applicable use of any HealthMeasures Instruments should include a statement that indicates 
which instruments (including version number) were used and provide an appropriate citation. 
• For precise copyright citation, see the measurement system of interest below. 
Furthering Research 
• Use of HealthMeasures Instruments in clinical research is encouraged, with the understanding 
that data collected from that use will contribute to knowledge about the validity of 
HealthMeasures measures. USERS OF HealthMeasures TOOLS ARE STRONGLY ENCOURAGED TO 
SUBMIT A BRIEF REPORT INCLUDING SAMPLE DEMOGRAPHIC INFORMATION, CLINICAL DATA 
SUFFICIENT TO characterize THE SAMPLE, AND SCORE DISTRIBUTIONS (E.G., BASELINE MEAN 
AND STANDARD DEVIATIONS OR CHANGE SCORES). This brief report should be submitted to 
help@healthmeasures.net for internal review. None of this submitted information will be 
published without the written consent and participation of the submitter. In addition to the 
brief report, clinical researchers are encouraged to submit de-identified data for collaborative 
analysis and reporting. Data ownership would remain with the submitter. Clinical researchers 
are strongly encouraged to collaborate with HealthMeasures investigators when applying these 
items and banks to their research. 
4 
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Additional Terms and Conditions of Use for PROMIS 
The PROMIS Terms and Conditions contained in this document serve as an agreement between 
Provider and Users of any and all aspects or components of PROMIS. 
COPYRIGHT NOTICE AND CLAIMS OF COPYRIGHT INFRINGEMENT 
PROMIS tests, test protocols, test items, norms, norms tables, scoring programs, 
scoring keys (including scoring algorithms, scale definitions, scale membership, 
and scoring directions), score reports, software, and other PROMIS-related 
materials are ©2006-2017 PROMIS Health Organization or other individuals/entities that have 
contributed information and materials, and are being used with the permission of the copyright 
holders. For a table of PROMIS copyright holders and the copyrighted information and 
materials employed by the copyright holders, see Appendix A. 
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Additional Terms and Conditions of Use for NIH Toolbox 
NIH Toolbox Terms and Conditions 
The NIH Toolbox Terms and Conditions contained in this document (hereinafter referred to as 
“NTAC”) serve as an agreement between Provider and Users of any and all aspects or 
components of the NIH Toolbox. 
COPYRIGHT NOTICE 
NIH Toolbox tests, test protocols, test items, norms, norms tables, scoring programs, scoring 
keys (including scoring algorithms, scale definitions, scale membership, and scoring directions), 
score reports, software, and other NIH Toolbox-related materials are ©2017 Northwestern 
University and the National Institutes of Health. Information and materials contributed to the 
NIH Toolbox by other individuals/entities are being used with the permission of the copyright 
holders. 
CONFIDENTIALITY. 
User acknowledges and agrees that the contents of the NIH Toolbox may constitute trade 
secrets, which include confidential and proprietary material, information, and procedures. User 
will not resell or otherwise distribute materials, or authorize or allow disclosure of the contents 
of a test instrument protocol, including test questions and answers, or normative data, except 
under the limited circumstances described in the section titled, "Maintenance of Test Security 
and Test Use," or as otherwise contemplated in the published manual associated with the test. 
User acknowledges and agrees that the use or disclosure of trade secrets in a manner 
inconsistent with the provisions of this Agreement may cause Provider irreparable damage, for 
which remedies other than injunctive relief may be inadequate. Accordingly, User agrees that in 
any request by Provider to a court of competent jurisdiction for injunctive or other equitable 
relief seeking to restrain such use or disclosure, User will not maintain that such remedy is not 
appropriate under the circumstances. 
5 
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PERMISSIONS AND LICENSING POLICY 
Reproduction of any NIH Toolbox materials, except for authorized single use of publicly 
available NIH Toolbox measures, requires the prior written consent of Provider. Questions and 
answers, including practice questions and answers, may not be reproduced without written 
permission, regardless of the number of lines or items involved. Test copies may not be bound 
in theses or reports placed in libraries, generally circulated, or accessible to the public, or in any 
article or text of any kind. 
PERMISSION TO USE COPYRIGHTED TEST NORMS 
Provider has the sole right to authorize reproductions of any portion of their published tests, 
including test norms. Copying of test norms without authorization is a violation of federal 
copyright law. The term "copying" includes, but is not limited to, entry of NIH Toolbox test 
norms into a computer's memory for purposes of test processing, scoring, or reporting. Any 
person or organization wanting to use NIH Toolbox test norms outside of official NIH Toolbox 
software must submit a written request to help@healthmeasures.net. If permission is granted, 
a fee may be charged. For the avoidance of doubt, permission from Provider for use of test 
norms does not imply endorsement of, or responsibility for, the accuracy or adequacy of any 
test processing, scoring, or reporting service. 
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MODIFICATION OF NIH TOOLBOX COMPONENTS 
Provider recognizes the importance of continued scientific development of the NIH Toolbox 
measures to meet the needs of researchers, but emphasizes the importance of maintaining 
rigorous measurement standards. Therefore, User may make modifications to NIH Toolbox 
Cognition, Motor, Emotion and Sensation tests and test items if, and only if, the following 
conditions are met: 
1. Specific modification plans must be enumerated and submitted in writing to Provider for 
approval. This request must include the specific changes to be made and the rationale for the 
changes. This written request must be signed by the lead researcher. 
2. User may not make modifications to any component of NIH Toolbox without written consent 
of Provider. 
3. All modifications should be fully validated against the existing NIH Toolbox measure(s) on 
which they were based. Plans for a concurrent validation study should be included in the 
written request for modifications. If no validation study is planned, this must be noted in the 
written request, along with an explanation. 
4. User must send validation study results to Provider for review prior to publication citing any 
results of said study or any results citing use of NIH Toolbox. 
5. Provider will review validation study data and will inform User if modification to NIH Toolbox 
measure(s) constitute an “Approved Adaptation” or a “Non-Validated Adaptation” of NIH 
Toolbox. Provider will update HealthMeasures.net accordingly to inform other users and 
prospective users of these modifications, along with contact information for the lead 
researcher. 
6. User must cite NIH Toolbox in any and all presentations, publications, or other third-party 
sharing of research data, indicating whether any measures used constitute Approved 
Adaptations or Non-Validated Adaptations. 
7. Provider maintains all rights to Approved Adaptations as well as Non-Validated 
Adaptations of NIH Toolbox tests and test items made by User. User may under 
no circumstances license, 
6 
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distribute, or share any components of NIH Toolbox with third parties, regardless 
of the extent of modifications, without official, written consent of PROVIDER. 
User is entitled to no ownership claim of intellectual property as a result of 
making any NIH Toolbox modifications, and is hereby enjoined from 
communicating or stating any such claims. 
MAINTENANCE OF NIH TOOLBOX TEST SECURITY AND TEST USE 
• Each person or institution using the NIH Toolbox Measures must agree to comply with these 
basic principles of test security. 
• Test takers must not receive test answers before beginning the test. Test questions are not to 
be reproduced or paraphrased in any way. 
• Access to test materials must be limited to qualified persons with a responsible, professional 
interest who agree to safeguard their use. 
• Test materials and scores may be released only to persons qualified to interpret and use them 
properly. 
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• If a test taker or the parent of a child who has taken a test wishes to examine test responses 
or results, the parent or test taker may be permitted to review the test and the test answers in 
the presence of a representative of the school, college, or institution that administered the test. 
Such review should not be permitted in those jurisdictions where applicable laws require the 
institution to provide a photocopy of the test subsequent to review. If User is not certain of the 
effect of the laws in User’s jurisdiction, the User should contact their jurisdiction's professional 
organization. 
USER QUALIFICATIONS 
Test users must have the appropriate knowledge, skills, training and experience to responsibly 
use NIH Toolbox measures. “Test users” are those persons responsible for the selection, 
administration, scoring and interpretation of tests and the communication of results. Provider 
reserves the right to ask individuals requesting access to NIH Toolbox Cognition measures to 
provide documentation that they have the experience and training necessary to use those 
measures, or are working under the supervision of someone qualified to use those measures. 
NIH Toolbox Cognition measures are classified as “C-Level.” C-Level tests require a high degree 
of expertise in test interpretation, and thus can only be requested by a User with state licensure 
or certification to practice in a field related to the request, or a doctorate degree in psychology, 
education, or a closely related field, with formal training in the ethical administration, scoring, 
and interpretation of clinical assessments related to the intended use of the assessment. Any 
users of C-Level assessments must be supervised by one or more users with C-Level 
qualifications, which must have been provided in advance to Provider per this process. 
RULES GOVERNING USE OF THE NIH TOOLBOX BY VARIOUS CATEGORIES OF 
USERS 
Universities, schools, organizations, businesses, clinics, and hospitals are subject to the 
guidelines set forth above and must have appropriately qualified individuals on staff in order to 
use the NIH Toolbox tests. 
PROTECTIVE ORDERS. User agrees to seek a protective order safeguarding the 
confidentiality of 
7 
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test materials classified by Provider as “C-level” assessments if User is required to produce such 
materials in court or administrative proceedings. 
NO WARRANTY. Provider makes no warranties, expressed or implied, including warranties 
of merchantability or fitness for a particular purpose. Provider will not, under any 
circumstances, be liable for User's expense for delays, for costs of substitute materials, or for 
possible lost income, grants, profits, or any other special or consequential damages that may 
result from using the NIH Toolbox. 
Additional Terms and Conditions of Use for Neuro-QoL 
People using Neuro-QoL should include the following copyright notice. 
COPYRIGHT NOTICE 
©2008-2017 David Cella on behalf of the National Institute for Neurological 
Disorders and Stroke (NINDS). Some content used with permission of the 
PROMIS Health Organization. 
8 
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Appendix A 
PROMIS Copyright Holders and Their Copyrighted Information and Materials 
The table set forth below identifies individuals and entities who have contributed items in 
support of building PROMIS item banks and the copyrighted information and materials 
employed by such persons. As a user of PROMIS you are entirely responsible for respecting the 
proprietary rights of such persons, and for complying strictly with the requirements set forth 
herein. If you have questions about these requirements and your legal obligations, you may 
wish to consult an attorney. 
Thomas M. Achenbach, PhD 
Child Behavior Checklist for Youth 
Torbjörn Åkerstedt Karolinska Sleep Diary 
Stanley E. Althof 
Center for Marital and Sexual Health Sexual Functioning Questionnaire 
Julie Barroso, PhD 
HIV-Related Fatigue Scale 
Dorcas Beaton 
Disabilities of the Arm, Shoulder and Hand (DASH) 
Basia Belza 
Multidimensional Assessment of Fatigue 
Smita Bhatia 
Minneapolis-Manchester Quality of Life Instrument – Adolescent Version 
Jill Binkley, PT 
Lower Extremity Functional Scale 
Thomas Borkovec 
Penn State Worry Questionnaire 
Ron Borland 
Perceived dependence items from International Tobacco Control Policy Evaluation Study (ITC) 
Lynn Breau 
Non-communicating Children's Pain Checklist 
Bengt Brorsson 
Swedish Health Related Quality of Life Survey 
Richard Brown, PhD Parkinson Fatigue Scale 
Elly Budiman-Mak, MD Foot Function Scale 
Arnold Buss 
Buss-Durkee Hostility Inventory 
Daniel J. Buysse 
Pittsburgh Sleep Quality Index 
Andrei Calin, MD 
Bath Ankylosing Spondylitis Function Index (BASFI) 
9 
Approved Version 1.12-2017 
David Cella, PhD 
Functional Assessment of Chronic Illness Therapy (FACIT) Center on Outcomes, Research, and Education 
Item Banks 
Larry Chambers, PhD 
McMaster Health Index Questionnaire 
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Trudie Chadler 
14-Item fatigue scale 
Amy Copeland 
Smoking Consequences Questionnaire 
Ann Coscarelli 
Cancer Rehabilitation Evaluation System (CARES) 
Kimberly A. Cote 
Brock Sleep and Insomnia Questionnaire 
Laura Creti 
Sexual History Form 
Peter Dent, MD 
Juvenile Arthritis Self-Report Index (JASI) 
Ed Diener 
Satisfaction with Life Scale 
Joe DiFranza 
Autonomy over smoking scale 
Dr. Colleen Dilorio Epilepsy Self-Efficacy Scale 
George Domino Assessment of Sleep Sleep Questionnaire 
Maxime Dougados, MD Dougados Functional Index (DFI) 
Alan B. Douglass 
Sleep Disorders Questionnaire 
David Drobes 
Questionnaire of Smoking Urges - Long Form 
M Tuncay Duruoz, MD Duruoz Hand Index 
Jack D. Edinger, Professional Resource Exchange Edinger’s Sleep History Questionnaire 
Colin A. Espie 
Beliefs and Attitudes about Sleep Scale 
Dysfunctional Beliefs and Attitudes about Sleep Scale - 10 Glasgow Content of Thoughts Inventory 
Insomnia Impact Scale 
Sleep Disturbance Questionnaire 
JF Etter 
The Cigarette Dependence Scale, English-language version 
Sydney Ey 
Youth Life Orientation Test 
10 
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Jeremy Fairbank, MD 
Oswestry Low Back Pain Disability Questionnaire (OLBPDQ) 
Catherine S. Fichten Sleep Diary 
Sleep Questionnaire 
Robert Ficke 
Performance Outcomes Measures Project 
J.D. Fisk 
Fatigue Impact Scale 
Ross Flett Affectometer-2 
James F Fries, MD 
Health Assessment Questionnaire (HAQ) 
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Marie Gage 
Self-Efficacy Gauge (SEG) 
Richard Gracely 
Descriptor Differential Scale of Pain Affect (DDS - Pain Affect item) 
Johanna CJM de Haes, PhD Rotterdam Symptom Checklist 
Stephen Haley, PhD 
Late Life Function and Disability Instrument: Function Component 
Danete Hann, PhD and Paul Jacobsen, PhD Fatigue Symptom Inventory 
Todd Heatherton 
Fagerstrom Test for Nicotine Dependence 
Vicki Helgeson Benefit Finding Scale 
Philip S Helliwell, MD, PhD 
Revised Leeds Disability Questionnaire 
Sarah Hewlett MD 
Rheumatoid Arthritis Self-Efficacy Scale (RASE) 
Ian Hindmarch 
Quality of Life of Insomniacs 
Leeds Sleep Evaluation Questionnaire (LESQ) 
Mark Hlatky, MD 
Duke Activity Status Index (DASI) 
Timothy J. Hoelscher Insomnia Impact Scale 
William L. Holzemer PPBL 
E. Scott Huebner, PhD 
Multidimensional Students’ Life Satisfaction Scale (MSLSS) Student’s Life Satisfaction Scale 
Paul Jacobsen 
Fatigue Symptom Inventory 
Alan Jette AMPAC 
11 
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Jeffrey G. Johnson, PhD 
Patient Health Questionnaire for Adolescents (PHQ-A) 
Robert Kerns WHYMOI 
Dinesh Khanna 
UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (SCTC GIT) 2.0 
Dr Sunil Kripalani 
Self-efficacy for Appropriate Medication Adherence Scale (SEAMS) 
Lauren Krupp 
Fatigue Severity Scale 
Sleep Symptom Questionnaire 
Jin-Shei Lai, PhD 
Pediatric Fatigue Item Bank 
Kathryn A. Lee 
Numerical Rating Scale for Fatigue 
Stephen J. Lepore Social Constraint Scale 
Debra Lerner, PhD 
Work Limitations Questionnaire 
Kenneth Lichstein Sleep Questionnaire 
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Mark S. Litwin 
UCLA Prostate Cancer Index 
Daniel Lovell, MD 
Juvenile Arthritis Functional Assessment Scale 
Juvenile Arthritis Functional Assessment Report for Children (JAFAR-C) 
Anne Lynch-Jordan (S. Kashikar-Zuck, & K. Goldschneider) Adolescent Pain Behavior Questionnaire 
Ayala Malach-Pines Burnout Measure 
Ralph Marino, MD 
Capabilities of Upper Extremity (CUE) 
Sherry McKee 
The 39-Item Perceived Risk and Benefits Questionnaire 
John Mayer 
Brief Mood Introspection Scale 
Robert Meenan, MD 
Arthritis Impact Measurement Scales 2 (AIMS2) 
Tito Mendoza, Charles Cleeland MD Anderson Symptom Inventory 
Charles M. Morin 
Insomnia Interview Schedule Sleep Diary 
Douglas E. Moul 
Pittsburgh Insomnia Rating Scale 
Nikolaus Netzer Berlin Questionnaire 
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Olugbenga Ogedegbe 
Medication Adherence Self-Efficacy Scale 
Geraldine Padilla 
Quality of Life Scale – Cancer 
Tonya M. Palermo, PhD 
Child Activity Limitations Interview (CALI) 
George Parkerson, MD Duke Health Profile 
Donald Patrick, PhD WHOQOL-100 US Version 
Pfizer, Inc. 
International Index of Erectile Function, Erection Harness Scale 
Megan Piper 
Wisconsin Inventory of Smoking Dependence Motives 
Ovide Pomerleau 
Michigan Nicotine Reinforcement Questionnaire 
Arnold L. Potosky 
Prostate Cancer Outcomes Study 
Quentin R. Regestein Hyperarousal Scale 
Graham J. Reid (C. Gilbert, & P. McGrath) Pain Coping Questionnaire 
Gary T. Reker 
Life Attitude Profile-Revised (LAP-R) 
Dennis Revicki 
PROMIS Adult Pain Behavior Bank 
Robin Richards, MD 
American Shoulder and Elbow Surgeons Shoulder Form (ASES) 
148 
 
 
J. Scott Richards 
UAB Pain Behavior Scale 
Tracey Riseborough 
Hospital Anxiety and Depression Scale (HADS) 
Kathryn Roach, PhD 
Shoulder Pain and Disability Index 
Damaris J. Rohsenow 
Smoking Effects Questionnaire 
Martin Roland, MA, MRCP 
Roland-Morris Low Back Pain and Disability Questionnaire 
Raymond Rosen and Jules Mitchell 
Brief Index of Sexual Functioning for Women Female Sexual Function Index 
Thomas Roth 
Global Sleep Assessment Questionnaire 
Daniel W. Russell UCLA Loneliness Scale 
Michael F. Scheier Life Engagement Test 
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Raf Schwarzer 
General Self-Efficacy Scale 
Debra Sciabarrasi Barthel Index 
William G. Shadel, PhD 
Smoker Self-concept and Abstainer Self-concept scales 
Cathy Sherbourne, Robert Brook, Brent Bradley Rand-36 Index of Vitality 
Saul Shiffman 
Nicotine Dependence Syndrome Scale 
Judith Siegel, PhD Multidimensional Anger Inventory 
Ann Skinner 
Sickness Impact Profile (SIP) 
C. R. Snyder (by B. Hoza) Children’s Hope Scale 
John Spertus, MD, MPH Seattle Angina Questionnaire 
Charles D. Spielberger, PhD 
State-Trait Anger Expression Inventory (STAXI) 
Barbara Starfield, MD, MPH 
Child Health and Illness Profile – Adolescent Edition (CHIP-AE) 
Michael Steger 
Meaning in Life Questionnaire – Expanded Version (MLQ-X) 
Kevin Stein 
Multidimensional Fatigue Symptom Inventory 
Mark Sullivan MD 
Cardiac Self-Efficacy Scale 
K.L. Syrjala 
Sexual Function Questionnaire 
Peter Tugwell, MD McMaster Toronto Arthritis 
David Tulsky, PhD SCI-QOL 
TBI-QOL 
James W. Varni, PhD 
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PedsQL™ Arthritis Module Version 3.0 Child Report (ages 8-12) PedsQL™ Asthma Module Version 3.0 
Child Report (ages 8-12) PedsQL™ Cerebral Palsy Module Version 3.0 Child Report (ages 8-12) 
PedsQL™ Multidimensional Fatigue Scale Standard Version Child Report (ages 8-12) PedsQL™ Pediatric 
Quality of Life Inventory Version 4.0 Child Report (ages 8-12) 
Wayne Velicer and James Prochaska 
The Self-Efficacy/Temptations Scale-Long Form Smoking: Decisional Balance Scale Transtheoretical 
Model Assessment 
Johan W. S. Vlaeyen 
Checklist for Interpersonal Pain Behavior 
14 
Lynn S. Walker 
Pain Response Inventory for Children 
John Ware, PhD PIQ-6 
SF-36 v2 
Medical Outcomes Study Sexual Functioning Scale 
David Watson 
Positive and Negative Affect Scale-Expanded form (PANAS-X) 
Terri E. Weaver 
Functional Outcomes of Sleep Questionnaire 
Wilse B. Webb 
Post-Sleep Inventory 
Nadine Weisscher 
AMC Linear Disability Score (ALDS) 
Nick Wetton 
Crown-Crisp Experiential Index 
Horng-Shiuann Wu, PhD 
Cancer-Related Fatigue Instrument  
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